Systems based analysis of gestric cancer myofibroblasts by Smith, Helen Louise
Systems Based Analysis of Gastric Cancer Myofibroblasts
Helen Louise Smith
Thesis submitted in accordance with the requirements of the University of 
Liverpool for the degree of Doctor in Philosophy
September 2012
Systems Based Analysis of Gastric Cancer Myofibroblasts
Helen Louise Smith
Abstract
The tissue microenvironment plays an important role in tumour development and 
the regulation of cancer cell migration. Tumours have been referred to as 'wounds 
that do not heal', as cancer cells exploit the normal wound response to aid tumour 
development and metastasis. During this process cancer cells secrete a range of 
factors that influence the function of cells within the surrounding tissue. 
Myofibroblasts are the predominant cell-type in the cancer microenvironment, 
where they surround the developing tumour. Cancer cells have the ability to re­
program these myofibroblasts in order to provide a range of factors that are 
required to promote the growth, proliferation and migration of cancer cells.
In this study a combination of bioinformatic and statistical approaches were used to 
define the range of genes and biological pathways that are differentially regulated 
in myofibroblasts derived from the immediate tumour microenvironment (CAMs) or 
from adjacent gastric tissue (ATMs). Comparison of gene expression profiles 
between CAMs, ATMs and normal gastric myofibroblasts (ANs) identified molecular 
signatures and biological processes that are changed in CAMs and/or ATMs. By 
correlating patient prognosis scores with CAM gene expression profiles it was 
possible to show that patient with poor prognosis segregate into two distinct 
populations with distinct gene expression profiles. Pathway enrichment and 
multivariate correspondence analysis, show that CAMs and ATMs both undergo 
metabolic reprogramming to induce a variation of the 'Reverse Warburg effect' in
which myofibroblasts exhibit increased levels of fatty acid (3-oxidation and 
enhanced production of acetyl-CoA and ketone body biosynthesis, along with the 
up-regulation of mono-carboxylate transporters that are required to facilitate the 
import of fatty acids and the export of ketone bodies. This data defines prognosis 
specific expression profiles, thereby providing new insight into the molecular 
processes that drive important paracrine communication networks during the 
development of gastric tumours. As such, this data provides a resource for future 
experimental studies and biomarker development.
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1 Chapter One: Introduction
1.1 The Aetiology of Gastric Cancer
According to Cancer Research UKs mortality statistics (2010) stomach cancer 
remains one of the top ten causes of cancer related deaths in the UK and incidence 
in far eastern countries (Japan and Korea) is higher (Jemal et alM 2010). 
Unfortunately, post diagnosis survival rates are very poor for patients with gastric 
cancer. This is primarily due to the fact that patients tend not to be symptomatic 
until the tumour is in an advanced stage of development, in many cases tumours 
may already have spread to lymph nodes and secondary tissues/organs before 
diagnosis (Matsukuma et al., 1996). For this reason we need to develop a better 
understanding of the molecular and functional changes that drive the development 
and spread of gastric tumours. Better insight into these processes could provide 
new options for developing better therapeutic strategies and the identification of 
possible diagnostic signatures or trends to improve detection or prognostic 
predictions. Risk factors relating to gastric cancer include smoking, poor diet, 
excessive alcohol consumption, helicobacter pylori (H.pylori) infection and a range 
of hereditary genetic factors (Fuchs and Mayer, 1995; Li et al., 2012; You et al., 
1998). H.pylori infection induces chronic inflammation leading to gastric atrophy 
and neoplasm, which may then lead to the development of an adenocarcinoma 
(Atherton, 2006; Kusters et at., 2006). A minority of gastric cancers may be 
lymphomas; cancer of the white blood cells (Parsonnet et al., 1994). Gastric atrophy 
can result from chronic inflammation of gastric tissues, which may lead to loss of 
acid producing parietal cells, which in turn increases gastrin production, thereby
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stimulating epithelial cell proliferation (Sipponen et al., 1985; Vannella et aL, 2012). 
Gland preservation is considered the key event to prevent a cancerous outcome 
(Correa et al., 2006). The constant regenerative response of chronic gastritis can 
lead to intestinal metaplasia, which is the change of a differentiated cell into 
another cell-type, in this case in response to gastritis the regenerative process 
replaces cells with columnar mucosa like intestinal cells. Intestinal metaplasia 
predisposes the patient to a much higher risk of developing gastric cancer if 
accompanied by dysplasia (You et al., 1998). Dysplasia is characterized by nuclear 
abnormalities, cytoplasmic abnormalities, and increased rate of cellular 
multiplication (LAUREN, 1965), it is a state of abnormal differentiation, which 
eventually leads to adenocarcinoma (Lauwers and Riddell, 1999; Oehlert et al., 
1979). Adenocarcinoma is the name of a malignant epithelial tumour, originating 
within glandular tissue. Histologically, adenocarcinoma can be separated into 
intestinal or diffuse types; intestinal adenocarcinoma resembles tubular type 
structures, whilst diffuse adenocarcinoma secretes mucus resulting in large pools of 
mucus/colloid. This histological classification of the stages of tumour development 
is commonly known as the Lauren classification (Shibata et al., 2001). A diagram of 
the multi-step gastric carcinogenesis pathway, which is believed to be initiated by 
H.pylori is shown in Figure 1.1.
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Figure 1.1 The multi-step gastric carcinogenesis pathway, believed to be initiated by H.pylori. COX- 
2, cyclo-oxygenase -2; EGFR, epidermal growth factor receptor; MSI, microsatellite instability; TGF, 
transforming growth factor. Figure adapted from (Leung et al 2002).
1.2 Inflammation and Cancer
Inflammation is caused by the body's response to infection or irritation, resulting in 
an increased repair response. However, long-term chronic inflammation can lead to 
initiation and development of cancer. The apparent synergy between these two 
processes may not be surprising, as both processes tend to suppress cell death 
(apoptosis) and increase cell growth and angiogenesis.
In general, inflammation increases the infiltration of inflammatory cells, resulting in 
increased local production of free radical species such as nitric oxide and super
3
oxides. Free radicals are produced to combat microbial infection, this process can
also damage DNA within host cells (Hussain et al., 2003; Rakoff-Nahoum, 2006). 
Leading to increased apoptosis, as cells attempt to protect the body against 
replication of potentially dangerous changes in DNA structure or sequence. The loss 
of cells leads to a need for tissue repair and regeneration, which is facilitated by 
further inflammation signals (Chen et al., 2003), including the secretion of pro- 
inflammatory interleukins (ILs) and cyclooxygenase-2 (COX-2) enzymes. An increase 
in IL-8 causes the release of IL-1(3 and Tumour Necrosis Factor alpha (TNF-a) from 
immune cells, stimulating the expression of COX enzymes, thereby stimulating 
production of prostaglandins, which further enhance the inflammatory response, 
leading to a further increase in nitric oxide production and a general increase in 
tissue acidity (Beales and Calam, 1998). Significantly, COX-inhibitors have been 
shown to decrease the tumour severity (Akre et al., 2001) and interference in pro- 
inflammatory responses remains an active area of anti-cancer research.
The importance of infection in initiating inflammation and tumour development 
was first demonstrated in 1985 using the Rous sarcoma virus (Dolberg et al., 1985). 
Currently it is estimated that around 15% of all cancers are initiated by microbial 
infection, with the prominent cause of gastric cancer being chronic infection with 
the bacterium Helicobacter pylori {H. pylori). H. pylori induces inflammation of the 
gastric mucosa. In most cases, inflammation remains superficial and does not 
develop into atrophic gastritis or gastric cancer. People most susceptible to atrophic 
gastritis are infected with the H. pylori cagA+ strain, which increases epithelial cell 
proliferation through gastrin secretion (Wang et al., 2000). In addition, H.pylori
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inhibits the p53 gene through AKT; as p53 roles include protecting the cell from
DNA damage this is a potential way H.pylori could increase the risk of gastric cancer 
(Wei et al.; 2010).
1.3 Common factors in cancer progression
Over the years, common hallmarks to all cancers have become apparent; these 
include proliferative signalling, replicative immortality, the avoidance of growth 
suppressors, resistance to cell death, angiogenesis, local invasion and metastasis 
(Figure 1.2) (Hanahan and Weinberg, 2011; Hanahan and Weinberg, 2000). Studies 
have been carried out to identify cell lineage-specific genes that are essential for 
cancer development (Luo et al., 2008). In general, genes may become differentially 
regulated due to acquisition of somatic mutations or alterations in epigenetic 
regulation.
Figure 1.2. Six Hallmarks of cancer. Figure adapted from (Hanahan and Weinberg, 2011).
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Gene mutations may occur naturally during cell duplication or they may be induced 
by exposure of oncogenic agents. Driver mutations occur in cancer cells and may 
provide the cell with a growth advantage, whereas passenger mutations are 
phenotypicaiiy neutral (Greenman et al„ 2007). A mutation may also be deleterious, 
were the expression of the gene is reduced or altered as a result of in-frame 
mutations that do not prevent gene expression. The exact position of an acquired 
mutation will have differential effects on gene expression, depending on its locality 
to the last splice site junction and the ability to trigger transcript degradation via the 
nonsense-mediated decay (NMD) pathway. The resulting level of expression of an 
in-frame mutation, determines the observed phenotype (Zhong et al., 2009). 
Somatic driver mutations have been shown to cause de-regulation of signalling 
pathways, avoidance of cell death and increased proliferation and invasion (Davies 
and Samuels, 2010). Reduced activity of the proto-oncogene KRas, leads to a 
reduction in the cyclin dependent inhibitor p21, which in turn increases the 
potential for metastasis (Alon et al., 1987).
Epigenetics is the regulation of gene expression though modifications in histone 
function, chromatin structure, DNA modification or the action of small non-coding 
microRNAs, rather than alteration in the genomic sequence. Tumour suppressors 
are often epigenetically regulated in cancers. For example, the tumour suppressor 
retinoblastoma (RB) protein is known to epigenetically regulate expression of the 
E2F family of transcription factors, thereby inhibiting DNA replication by recruiting 
histone deacetylases to promoter regions. Cyclin dependent kinases phosphorylate 
RB, thus preventing inhibition of gene transcription. In many cancers, mutations/
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loss of RB and cyclin dependent regulatory proteins, result in an over-expression of 
cyclin dependent kinases, resulting in a loss of senescence (Berdasco and Esteller, 
2010; Sherr and McCormick, 2002).
The Ras proteins is involved in increasing cell proliferation, differentiation and 
inhibition of apoptosis. As with p53, Ras GTPases are often mutated in many 
cancers, however, this does not appear to be the case in many gastric cancers, 
where RAS expression appears to be de-regulated by epigenetic effects. The RAS 
activator like-1 gene (GAP1 like) is hyper-methylated and its expression is reduced, 
consequently increasing the concentration of RAS, resulting in an increase in 
mitogen activated protein kinase and stimulating tumourogenesis. Also, Ras 
activator like-1 protein expression can be restored and proliferation reduced by 
inhibitors of histone-deacetylase (Seto et al., 2011). The promoter region of E- 
cadherin has also been shown to be hyper-methylated in many cancers, causing a 
decrease in E-cadherin expression and increased tumour invasion (Kanazawa et al., 
2002a).
1.3.1 Tumour suppressors and un-controlled cellular growth
Tumour suppressors are commonly de-regulated during cancer. The tumour 
suppressor p53 detects stress and promotes expression of cell-cycle inhibitors in 
order to induce senescence or apoptosis. Genetic mutations within the RB and p53 
pathways provide a proliferative advantage in the progression of cancer, up to 50% 
of cancers have mutations in the p53 gene, enabling cells to bypass senescence 
(Sherr and McCormick, 2002). In normal circumstances, cells experiencing constant 
stress, through lack of nutrients, or detection of DNA damage would undergo
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apoptosis. The BCL-2 family of proteins include pro and anti-apoptotic regulators 
which are often defective in tumours, therefore BCL-2 proteins and their binding 
partners are possible targets for cancer therapy (Adams and Cory, 2007).
Autophagy is a stress response that causes cells to recycle less essential intracellular 
components to aid cell survival. Tumour cells can take advantage of this process in 
order to remain in a low energy state when nutrients are sparse, or by suppressing 
the autophagy inducer Beclin-1 (Sinha and Levine, 2008; White and DiPaola, 2009).
1.3.2 Angiogenesis
Proliferating cells quickly use up nutrients within their immediate 
microenvironment; therefore they have evolved mechanisms of increasing local 
resources. Firstly, by inducing angiogenesis (Folkman et al., 1971) to obtain 
nutrients via increased blood supply and secondly by secreting factors that induce 
neighbouring cells to provide a selection of metabolic substrates (Mazure et al., 
1996). Importantly, angiogenesis has been detected in pre-malignant tumours 
therefore indicting it is an early change in cancer development and a possible target 
for therapeutic intervention (Raica et al., 2009).
Hypoxia has also been suggested to be the trigger for another trait associated with 
cancers, known as the Warburg effect (Warburg, 1956), or aerobic glycolysis is the 
process of cells converting glucose to lactate when oxygen is available in the micro­
environment (Pennacchietti et al., 2003). This process of converting pyruvate to 
lactate usually takes place under low oxygen conditions, however, in tumour cells 
this occurs in the presence of oxygen (Christofk et al., 2008). Therefore, Warburg 
suggested that the production of lactate in high oxygen conditions may be due to a
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defect in the mitochondria. In fact no such mitochondrial defect was found, instead 
cancer cells appear to produce high levels of lactate dehydrogenase and aerobic 
glycolysis can confer a selective growth advantage, in low oxygen conditions, as 
glucose is broken down aerobically to produce macromolecules and other essential 
factors that facilitate cell proliferation (Fantin et al., 2006).
1.3.3 Invasion and metastasis
Metastasis is one of the hallmarks of late-stage malignancy. Prior to migration, 
tumour cells induce degradation of the basement membrane, after which they can 
travel through the local tissue, before entering the circulatory system (intravasion). 
Extravasion occurs when circulating cells leave the vascular system and enter distal 
tissues, where they form new distal tumours (Hanahan and Weinberg, 2011). 
Formation of new tumours at metastatic sites is dependent on the 
microenvironment that exists in different organs (Pauli and Lee, 1988). In general, 
epithelial cells are very structured, uniformly aligned and have tight regular cell-cell 
adhesions, which inhibit cell movement (Lee et al., 2006). In order to become 
mobile and invasive, they have to be transformed from an epithelial to a 
mesenchymal phenotype. This epithelial-mesenchymal-transition (EMT) is a 
reversible morphological and physiological change that is seen when an epithelial 
cell invades the extracellular matrix. The reverse process is referred to as the 
mesenchymal epithelial transition (MET), which generally results in the formation of 
new colonies, either in the same tissue, or in distal organs.
During the EMT process, epithelial cells lose cellular polarity and adopt a 
characteristic spindle shape. In addition, cytoskeletal keratin is replaced with
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vimentin, expression of cell-cell adhesion molecules are reduced and cells display 
increased motility (Klymkowsky and Savagner, 2009; Lee et al., 2006). Initiation of 
EMT is thought to be stimulated through an array of pathways including, activation 
of tyrosine kinase receptors, which participate in the Transforming Growth Factor 
beta (TGF-(3), Epithelial Growth Factor (EGF), Fibroblast Growth Factor (FGF), 
Insulin-like Growth Factor (IGF), and the NFkB signalling pathway. Increased 
expression of E-cadherin directly inhibits EMT and metastatic behaviour in cancer 
(Kanazawa et al., 2002b). The important role of E-cadherins in gastric cancer was 
first confirmed by the identification of inactivating mutations and premature stop- 
codons in the E-cadherin gene, CDFI1 (Guilford et al., 1998). Since then E-cadherin 
transcriptional regulators Snail, SIP1 and Twist have all been shown to be frequently 
inhibited or down-regulated in gastric cancer (Rosivatz et al., 2002) and the E- 
cadherin promoter has also been shown to be methylated in gastric cancer 
(Kanazawa et al., 2002a). Interestingly, stromal myofibroblasts are believed to be 
the key cell type mediating the EMT transition (Trujillo et al., 2010).
1.4 The cancer microenvironment
There is now convincing evidence to show that the tissue microenvironment plays 
an important role in tumour development and the regulation of cancer cell 
migration. In 1988, Paget first proposed the seed and soil concept to explain the 
role that the tissue microenvironment plays in tumour development (Paget, 1989). 
in this analogy, Paget likens the relationship of a cancer cell and its 
microenvironment to that of a seed planted in different locations. Whether the 
seed or cancer cell grows depends on whether the environmental conditions are
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favourable or not. It is now clear that this analogy is a 'goocr reflection of events 
that regulate the initial stages of tumour development and determine preferential 
sites of metastasis for different tumours. We now know that cancer cells have the 
ability to re-program neighbouring cells within the surrounding tissue in order to 
provide a range of factors that are required to promote the growth, proliferation 
and subsequent migration of cancer cells (Witz, 2009).
Although all tissues are composed of a complex mix of different cell types, there are 
key factors that contribute to the development of tumours in several different 
tissues. These include factors that affect the integrity of the extracellular matrix, 
immune cell infiltration, and the role of stromal myofibroblasts. The extracellular 
matrix provides structural support and acts as a reservoir of nutrients, growth 
factors and other regulatory factors; it is comprised of a basement membrane, 
blood capillaries and matrix proteins including collagen, fibronectin and elastin, 
which are secreted by cells in the extracellular matrix including fibroblasts, 
adipocytes and immune cells (Bhowmicket al., 2004b; Dvorak, 1986). Dense growth 
of fibrotic and connective tissue is often seen surrounding tumour cells and this 
phenotype is referred to as desmoplasia (Willis R, 1961).
Tumours have been referred to as 'wounds that do not heal', as the normal wound 
response is exploited by cancer cells to aid tumour progression. Normally in 
response to injury, blood vessels are damaged and release fibrin and fibronectin, 
which cause an increase in the migration of inflammatory cells and fibroblasts, and 
promote the formation of new capillaries. Fibroblasts secrete extracellular materials 
to reconstruct the extracellular matrix. When the wound response is complete,
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fibroblasts migrate away from the wound and a scar is formed. Cancer cells exploit 
this response by secreting a vascular permeability factor, which causes the blood 
capillaries to become permeable, allowing fibrin and fibronectin to diffuse into the 
extracellular matrix. Cancer cells also secrete growth factors that increase fibroblast 
migration and proliferation. Increased levels of fibrin and fibronectin also promote 
angiogenesis and migration of fibroblasts and immune cells. However, in tumours, 
the concentration of fibronectin and fibrin does not decrease, as would normally 
happen in wound healing (Dvorak, 1986). Analysis of twenty solid malignant 
tumours showed that macrophages and lymphocytes where found mainly in stroma 
surrounding the tumour cells rather than within tumours. Interestingly, stomach 
cancer stroma was found to have one of the highest populations of macrophages 
and lymphocytes, which is believed to be due to the prevalence of a non-specific 
inflammatory response in this tissue (Svennevig and Svaar, 1979). While there is 
clear immune response in cancer (Vose et al., 1977) it has been shown that normal 
immune responses are suppressed within the tumour microenvironment (Vose and 
Moore, 1979). Also, although sub-population of lymphocytes have been shown to 
inhibit the cytotoxic response, identification of suppressor factors has proved 
problematic, with several groups proposing conflicting findings (Vose and Moore, 
1979; Yu et al., 1977). Significantly, treatment of peripheral lymphocytes from 
cancer patients, with a lethal macrophage agent carrageen was found to increase 
the cytotoxicity of the lymphocytes, indicating that macrophages may be the drivers 
of immune-suppression within the cancer microenvironment (Quan and Burtin, 
1978). However, the actual affect that immune infiltration may play in the
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orchestration of tumour development in different tissues or individual patients
remains to be defined.
1.4.1 Myofibroblasts
In general, fibroblasts are quiescent cells with low motility, which are found in all 
normal connective tissues. They are defined by a characteristic spindle-shaped 
appearance and expression of high levels of vimentin. Myofibroblasts were 
originally defined as a subset of fibroblasts that exhibited smooth muscle like 
features and expressed characteristic marker proteins in addition to vimentin: these 
include myosin (VM-type myofibroblasts), smooth muscle actin (a-SMA) (VA-type 
myofibroblasts) or a-SMA and desmin (VAD-type myofibroblasts). This study 
focuses on the role of VA-type myofibroblasts in the development of gastric 
tumours. It has been shown that myofibroblasts can form from the trans­
differentiation of conventional fibroblasts following stimulation with TGF-p, PDGF 
or the tumour niche. However, the actual origin of gastric myofibroblasts remains 
unclear and current evidence suggests that there may be different subclasses of 
myofibroblasts, possibly with different origins, however as yet no robust markers 
exist to define the subclasses, or the exact origins of myofibroblasts in different 
tissues. Interestingly, myofibroblasts, which are prominent in damaged, infected or 
cancerous tissue, can also be isolated from healthy gastric tissue, where they play a 
key role in trans-epithelial signalling, contribute to normal epithelial differentiation, 
enhance barrier function and modulate chloride secretion from intestinal epithelial 
cells (Beltinger et al., 1999; Powell et al., 1999).
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There is now strong evidence that myofibroblasts also play a major role in the 
development and spread of tumours. In many cases myofibroblasts have been 
found to be the dominant cell type in the cancer microenvironment (Tuxhorn et alv 
2002a), where they form 'nests' which surround the developing tumour (Samoszuk 
et al., 2005). Myofibroblasts were first identified in granulation tissue, which was 
recognized to play a key role in wound healing (Gabbiani et al., 1972; Majno, 1979). 
Under further investigation, it became apparent that this cell type also played a 
prominent role, in promoting proliferative conditions in neoplastic stroma (Zhi et 
al., 2010).
Although myofibroblasts have a characteristic morphology and express a-SMA 
there is still much that is unclear about these cells. It has been proposed that local 
conditions within a tumour or inflammatory niche may promote the trans- 
differentiation of myofibroblasts from normal fibroblasts, in response to stimulation 
by transforming growth factor (TGF)-p, endothelin-1 (ET-1) and IL-1 derived from 
epithelial cells (Chen et al., 2009; Phan, 2003; Ronnov-Jessen and Petersen, 1993; 
Ronnov-Jessen et al., 2002; Samoszuk et al., 2005; Tuxhorn et al., 2002a; 
Untergasser et al., 2005). Current theory suggests that fibroblasts firstly become 
'protomyofibroblasts', which express both {3 and y actins before completing the 
transition to active myofibroblasts, which then express a-SMA fibres (Micallef et al., 
2012a). The urokinase plasmingen activator receptor (uPAR) is an extracellular 
protease involved in cell migration, modification of the extracellular matrix and 
growth factor activation. Down-regulation of uPAR is required for the 
differentiation of fibroblasts into 'active' myofibroblasts. As such, the loss of uPAR
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is used as a marker for myofibroblast activation in some tissues (Bernstein et al.,
2007).
As there is heterogeneity within populations of fibroblasts, it may not be surprising 
that myofibroblasts derived from these cells, will also exhibit heterogeneity in 
marker expression (Chauhan et al., 2003a). In addition, there is now convincing 
evidence to suggest that other cells can also become "activated" and display 
myofibroblast like characteristics. In particular, epithelial cells, bone marrow 
derived mesenchymal stem cells (MSCs) (Guo et al., 2008; Micallef et al., 2012b; 
Mishra et al., 2008) and pericytes (Pietras et al., 2008; Skalli et al., 1989) have all 
been identified as potential sources of activated myofibroblasts. Also, the origin of 
activated myofibroblasts may be tissue specific. In the liver, myofibroblast type 
cells expressing ct-SMA are thought to be derived from both hepatic stellate cells 
and liver fibroblast cells.
Therefore, the origin of activated or even normal tissue myofibroblasts remains 
unresolved, and may well depend on the inflammatory status and the mix of 
stromal cells present in different tissues.
1.4.1.1 Identification of myofibroblasts
At present myofibroblasts are defined only by a characteristic spindle/stellate 
morphology and expression of a few relatively basic markers (a-SMA, vimentin, 
myosin or desmin). Although, myofibroblasts share a similar phenotype with 
smooth muscle cells in that they both have high levels of a-SMA, the two cell types
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can be clearly distinguished by the expression of additional myofibroblast markers
and unique global gene expression profiles (Gan et al.; 2007).
Myofibroblasts display heterogeneity between tissue and tumour type. However, 
some informative markers or trends in gene expression have been identified. In 
breast cancer associated myofibroblasts loss of expression of the transmembrane 
protein CD34 correlates with a more invasive phenotype. However, loss of this 
maker has not been detected in myofibroblasts from other types of cancer. 
Interestingly, CD34 was also down regulated in non-neoplastic fibroblasts 
surrounding epithelial tumours (Chauhan et al., 2003b). In this context it is 
significant to note that all myofibroblasts, whether derived from the site of a 
tumour (CAMs), adjacent histologically normal tissue (ATMs), or absolute normal 
myofibroblasts (ANM) express high levels of the marker a-SMA, thus raising the 
question of what is an 'activated' myofibroblast. Current markers for activated 
myofibroblasts permit distinctions from generic fibroblasts however; myofibroblasts 
tend to exhibit different functional properties, depending on their proximity to the 
developing tumour. As yet we do not have good markers to distinguish 'good' 'bad' 
or intermediate forms of myofibroblasts in tissues. As CAMs promote faster tumour 
growth, metastasis and have greater resistance to chemotherapy it is vital that we 
identify markers that distinguish the different forms of activated myofibroblasts. 
Equally, it has been suggested that ATMs are an intermediate between CAMs and 
ANMs (Hawsawi et al., 2008). However, we have no reliable marker to indicate 
when an ANM becomes an ATM or an ATM is about to become a far more 
dangerous CAM.
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In 1953, it was found that although tissue surrounding the site of a tumour
appeared benign, it had been changed or pre-conditioned to facilitate a high rate of 
reoccurrence. This phenotype was referred to as 'field cancerisation' (Slaughter et 
al., 1953). In one study, prostate cancer cells were combined with stromal cells from 
proximal or distant regions of the stroma in order to test if the 'field cancerisation' 
effect decreased with distance from the site of the primary tumour. Significantly, 
both tumour growth and angiogenesis decreased with distance (Barclay et al., 
2005). In addition, in colorectal cancer patients with a high abundance of a-SMA 
positive myofibroblasts in the reactive-stroma had a significantly reduced chance of 
survival. Thus showing that myofibroblasts abundance can be used as an indicator 
of patient prognosis (Tsujino et al., 2007).
It is apparent that to fully understand and identify a myofibroblast subpopulation 
of cells, the site of carcinogenesis (or inflammation), the composition of the tumour 
stroma and the relative gene expression profiles of CAMs and ATMs in that specific 
tissue must be defined, in order to better understand the molecular mechanisms 
that drive proximity dependant changes, and identify better markers for 
myofibroblast conversion from NTMs to ATMs and CAMs.
1.4.1.2 Myofibroblasts and Cancer
Reports of the role of myofibroblasts in carcinogenesis is varied; in some studies 
identification of myofibroblasts (by smooth muscle actin staining) has been used as 
a marker for patient prognosis (Fuyuhiro et al., 2010a; Fuyuhiro et al., 2010b), 
whilst in other studies myofibroblast recruitment/activation has been shown to 
correlate with increase tumour invasion, but not in the initiation of tumour growth
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{de-Assis et al., 2012). investigation into the role of myofibroblasts also varies
between tissues and their role is more characterised in prostate and breast than in 
other tissues. In the case of prostate cancer, the tumour microenvironment is 
known to play a role in tumour progression and metastasis (Barron and Rowley, 
2012; Bianchini et al., 2012; Giannoni et al., 2010; Shaw et al., 2009). To elucidate 
the mechanisms by which stromal cells drive cancer progression, Shaw et al (2009) 
examined the role of the sonic hedgehog pathway in paracrine signalling between 
the tumour and its microenvironment. Another, more recent study found that 
preventing the differentiation of prostate myofibroblast cells by using DHA, 
epithelial to mesenchymal transition (EMT) and tumour invasion (Bianchini et al., 
2012). Therefore, interfering with the role of the myofibroblast in the tumour 
microenvironment should reduce the proliferation and migration of cancer cells.
Studies in breast cancer indicate that the presence of myofibroblasts often 
correlates with increased invasiveness and poor prognosis. One study by Yazhou et 
al (2004) showed that loss of CD34 expression and increased expression of a-SMA 
in myofibroblasts was associated with carcinomas and not with normal breast tissue 
(Yazhou et al., 2004). Another study observed positive correlations between the 
presence of myofibroblasts in the tumour stroma and expression of the 
proliferation marker Ki67 and the proto-oncogene HER-2 in breast cancer cells in all 
patients tested (Surowiak et al., 2006). In lung adenocarcinoma, high myofibroblast 
signals were associated with increased lymph node metastasis, high stage tumour 
growth, vascular invasion and a shorter survival time (Shu and Li, 2012). However 
there is conflicting evidence among lung cancer studies; a report by Matsubara et al
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reported that sub-epithelial myofibroblasts identified by a-SMA expression in lung 
adenocarcinoma was actually a histological indicator of excellent prognosis in the 
patients they tested (Matsubara et al., 2009). These varying reports on the role of 
myofibroblasts in cancer progression demonstrate the continuing need for further 
research into the role that different forms of myofibroblasts may play in the 
development of different forms of tumour in different tissues.
As yet the role of the myofibroblasts in gastric cancer is not well documented; 
studies in scirrhous gastric cancer patients show that an increase in myofibroblast 
cells is correlated with a worse prognosis (Fuyuhiro et al., 2010c). Studies in mouse 
models of gastric cancer show that tumour associated myofibroblasts express 
VEGFA, which contributes to increased angiogenesis (Guo et al., 2008). In addition, 
a recent paper by Flolmberg et al (2012) showed that CAMs increased migration and 
proliferation of gastric cancer cells, when compared to either ATMs, or ANM. This 
study also showed that conditioned medium from gastric CAMs was sufficient to 
stimulate migration, invasion and proliferation of gastric cancer epithelial cells, 
when compared to media collected from ANMs cells. Also, proteomic analysis of 
the myofibroblast secretomes revealed a decrease in extracellular matrix adaptor 
protein like transforming growth factor induced gene-hB in the cancer 
myofibroblast. Significantly, this decrease was correlated with lymph node 
metastasis, worse prognosis and shorter patient survival (Holmberg et a!., 2012).
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1.4.1.3 Paracrine Communication between CAFs and cancer 
cells
Many studies have been carried out to elucidate the paracrine signalling that 
reciprocal changes in CAFs and cancer cells during tumour progression. This form of 
epithelial-mesenchymal crosstalk drives proliferation of both epithelial and stromal 
cells (Bhowmick et alv 2004b). Studies into the development of prostate cancer 
show that cancer progression was detected in genetically initiated epithelial cells 
but not in non-cancerous epithelial cells, thus indicating that CAFs stimulate 
progression of cancer but do not initiate cancer development. It is also interesting 
to note that CAFs changed the histology of the epithelial cells, but did not induce 
tumorigenesis (Olumi etal., 1999).
1.4.2 Cancer stroma models
1.4.2.1 In vitro/in vivo models of the cancer microenvironment
To investigate the molecular mechanisms of cross-talk between cancer ceils and 
CAFs, CAFs have been isolated from several different tissues before being studied in 
isolation, or in co-cultures with cancer cells. These co-culture methods allow specific 
phenotypes including migration, proliferation, and invasion to be systematically 
investigated. Some groups have developed self-renewing breast cancer models, 
consisting of cancer and stromal cells maintained in a constant 1:1 ratio (Piechocki, 
2008), while others have developed more elaborate co-culture systems which 
incorporate extracellular matrix and basement membrane components (Weaver et 
al., 1995). While these kind of in vitro models allow detailed dissection of the 
molecular mechanisms of crosstalk they are minimal models and may not fully
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reflect the complex cocktail of factors that balance paracrine effects in a more
complex tissue environment. For this reason, several in vivo animal models have 
been used to study the effect of normal and cancer derived fibroblasts on tumour 
development. As discussed in section 1.3.3.1, the most aggressive cancers with 
increased vascular systems were produced in mice when cancer cells were 
recombined cancer stroma rather than benign stroma (Barclay et al., 2005).
Genetically modified animals have also been used to deduce the in vivo effects that 
individual genes or sets of genes may have on tumour development. In transgenic 
mice, it has been shown that factors secreted from fibroblasts can directly increase 
the metastasis of tumours. Transgenic mice lacking the SLOOA4 protein are unable 
to metastasis, while co-injection of cancer (SL00A4 negative) cells with fibroblasts 
expressing the SL004A protein led to an increase in tumour metastasis. The SL004A 
gene is released from CAFs before being taken up by neighbouring cancer cells, 
where it increases cell motility by interacting with myosin (Grum-Schwensen et al., 
2005).
1.4.3 Gene expression in stroma
Both in vitro and in vivo models have been used to provide insight into the 
molecular processes that operate within the microenvironment of different types of 
tumour. With the increasing availability of high quality gene arrays microarray 
analysis has become a common method of studying global gene expression patterns 
in cancer stromal cell populations. As a result, it is now possible to use a list of only 
120 genes to classify breast carcinomas based purely on gene expression patterns 
observed in associated stromal cells (Symmans et al., 2003). Microarray analysis has
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also revealed the range of genes that are differentially expressed in CAFs compared 
to normal fibroblasts. These differences may provide new insight into the role that 
re-programmed CAFs play in driving tumour development. Comparison of similar 
profiles from different tumours or a greater range of patients will reveal the extent 
to which common mechanisms occur in different forms of cancer or different 
patients.
Gene expression studies performed on pancreatic cancer and fibroblast cell lines 
cultured in isolation or as mixed co-cultures show that the COX-2 gene was found to 
be over-expressed in both cell types and caused increased invasion when cancer 
cells were co-cultured with CAFs, as a result, COX inhibitors may provide a possible 
mechanism for therapeutic intervention (Sato et al., 2004). Using the FIG-U133A 
gene chip, fibroblasts derived from the site of a colon tumour or normal regions of 
the colon were compared. These results revealed that CAFs appeared to be more 
homogeneous than fibroblasts derived from a histologically normal region. 
Significantly, this study also showed that fibroblasts were able to stimulate cancer 
cell proliferation via soluble factors alone, PTGS2 (COX2) and TGF-(3, and that the 
proliferative effect was more intense in fibroblasts derived from tissue closer to the 
site of the tumour (Nakagawa et al., 2004). In prostate cancer, the MGC-1 gene chip 
was used to identify 20 genes whose expression profiles correlate with TGF-fJl 
induced trans-differentiation of fibroblasts into myofibroblasts (Untergasser et al., 
2005).
Several groups have used laser dissection methods to isolate samples of cancer cells 
and associated fibroblasts from a range of tumours, in order to provide insight into
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in situ gene expression profiles (Micke et al., 2007). As a result prognostic gene 
expression signatures have been defined for several types of cancer, including 
prostate cancer, where 44 genes were found to be consistently differentially 
expressed in the cancer stroma (Finak et al., 2008). Laser captured micro-dissection 
methods were also used to compare gene expression profiles in epithelia and 
stromal cells from patients with either pancreatic cancer or pancreatitis, thus 
providing a new way to distinguish between the two conditions (Fukushima et al., 
2004). In breast cancer, multi-variant analysis methods were used to define a 
stroma derived prognostic prediction (SDPP) signature. The multi-variant analysis 
displayed distinct clusters; representing distinct types of cancer. Patients with 
reduced re-occurrence had hits in a cluster of genes involved in the immune 
response, while patients with high levels of re-occurrence had hits in a cluster of 
genes involved in reduced wnt signalling, hypoxia and angiogenesis {Finak et al., 
2008).
1.4.4 Genetic mutations in stroma
It is well documented that cancer cells continue to acquire somatic mutations 
during tumour progression. These mutations can confer a selective advantage, 
which contribute to tumour growth, immune evasion and drug resistance 
(Komarova and Wodarz, 2005; Sumimoto et al., 2006). The occurrence of mutations 
in stromal cells is less well understood. A study investigating mutations in epithelial 
or stroma cells in breast neoplasia found that three genes (TP53, PTEN and WFDC1) 
showed loss of heterozygosity, in both epithelial and stromal compartments, 
leading to the suggestion that stromal cells were originally epithelial cells that
23
underwent epithelial-mesenchymal transition (Kurose et al., 2002). More recent 
studies suggest that stromal myofibroblasts are genetically more stable than 
associated cancer cells and do not show significant changes in chromosomal 
stability or rearrangement, as such CAFs may represent a more attractive 
therapeutic target as increased genetic stability means that these cells are less likely 
to evolve resistance to therapeutic drugs (Gururajan et al., 2012).
1.4.5 Paracrine signalling in the cancer micro-environment
Tumour development is clearly driven by a process of reciprocal paracrine signalling 
or cross-talk between cancer and stromal cells (Bhowmick et al., 2004a). Although 
paracrine signalling is a normal part of tissue homeostasis, it appears that changes 
in cancer cells modify signals sent to stromal cells. As a result, stromal cells become 
re-programmed to produce different factors, including a range of growth factors 
including FGF, IGF, EGF, hepatocyte growth factor (HGF), Platelet derived growth 
factor (PDGF), vascular endothelial growth factor (VEGF) and TGF-fJ, all of which, 
except TGF-P, stimulate epithelial cell proliferation (Bhowmick et al., 2004b; deJong 
et al., 1998a).
PDGF is released from many different cell types and its receptor is present on 
fibroblasts but not epithelial cells. Stimulation of the PDGF receptor (PDGFR) 
induces cell division, enhanced survival and migration of fibroblast to the site of 
injury/inflammation (Bonner, 2004). In cervical cancer, the PDGFR inhibitor Imatinib 
was used to demonstrate the role of PDGF in the cancer microenvironment. PDGF 
binds to its receptors on fibroblasts and pericytes, causing the expression of FGF-7, 
which induces epithelial cell proliferation and expression of FGF-2, which then
24
increases angiogenesis by binding to its receptors on endothelial cells (Pietras et alv
2008).
TGF-(3 is expressed by epithelial cells, and its receptors (TGF-PR) are expressed by 
fibroblasts. TGF-p produced by cancer cells was shown to induce trans­
differentiation of fibroblasts into myofibroblasts, thereby causing a reciprocal 
increase in cancer cell growth in co-culture studies. Interestingly the chloride 
channel CLIC4 was highly up-regulated (xl6) in activated fibroblast, CLIC4 inhibits 
myofibroblast leading to a stationary phenotype (Samoszuk et al., 2005); (Ronnov- 
Jessen et al., 2002). Equally, expression of a chloride channel in epithelial cells could 
inhibit breast cancer progression (Gruber and Pauli, 1999). In ovarian cancer, TGF- 
(3 induces fibroblasts to secrete fibroblast activation protein (FAP), which in turn 
increases cancer cell invasion, proliferation and migration (Chen et al., 2009). 
Similar findings in prostate cancer show that TGF-p increases myofibroblast 
numbers, angiogenesis and tumour growth (de Jong et al., 1998b; Tuxhorn et al., 
2002b). TGF-p is complex and has dual opposing roles, with dual time dependent 
autocrine effects on cancer cells. Firstly, inhibiting the DNA synthesis effects of EGF, 
FGF and PDGF produced by cancer cells. Then, after a 24 hours, TGFp itself 
stimulates DNA synthesis within cancer cells (Shipley et al., 1985). TGF-P also has 
opposing roles in cancer progression. In addition to increasing fibroblast 
proliferation, migration and invasion of cancer cells, TGF-p also demonstrates 
inhibitory effects on the growth and invasive properties of cancer cells. Knocking 
out the TGF-p receptor in fibroblasts resulted in a two-fold increase in tumour 
growth and invasion. TGF-p inactivation leads to an increase in expression of
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tumour growth factor alpha (TGF-a), macrophage stimulating protein (MSP) and
HGF from fibroblasts, which activate the ERB, RON and c-met receptors on epithelial 
cells, respectively (Cheng et al., 2005).
HGF expressed by fibroblasts acts to weaken cell-cell contacts and induce the 
degradation of the extracellular matrix thereby allowing increased migration of 
cancer cells. In low oxygen conditions, epithelial cells increase expression the HGF 
receptor (c-met), thereby increasing the sensitivity of cancer cells to HGF within the 
tumour microenvironment. Stimulation of the c-met receptor induces a distinct 
change in epithelial cell morphology, displaying a fibroblastic cell shape, which is 
characteristic of epithelial-mesenchymal transition and increased cell scattering. 
HGF expressed from fibroblasts is also known to act as an angiogenic factor, which 
acts through the c-met receptor on endothelial cells. However, HGF also promotes 
angiogenesis independently of the met receptor by causing blood vessels to branch 
(Michieli et al., 2004). Increased levels of HGF and HGF-receptor have been 
observed in the late stages of several tumours and this signature is clearly linked to 
'bad' patient prognosis (Aune et al., 2011). In addition, in mice truncation of HGF 
protects cells against radiotherapy, while truncation of the met receptor increased 
sensitivity to radiotherapy (Michieli et al., 2004). In gastric cancer, PGE2 and wnt 
signalling pathways are activated in epithelial cells, causing the release of an 
unknown soluble factor, which activates fibroblasts and recruitment of bone 
marrow derived mesenchymal stromal ceils (MSCs), which differentiate into 
myofibroblasts. Activated myofibroblasts then secrete high levels of VEGF, which 
increases angiogenesis (Guo et al., 2008).
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1.4.6 Extracellular matrix
The secretion of extracellular matrix proteins and extracellular proteases from 
fibroblasts aids tumour cell invasion. In breast cancer, media collected from CAFs 
treated with TGF-p, significantly increased the invasiveness of cancer cells by 
causing fibroblasts to secrete extracellular matrix proteins fibronectin and laminin 
(Casey et al., 2008). In general, extracellular matrix proteases allow degradation of 
the basement membrane to allow epithelial cells access to the stroma, whilst the 
secretion of extracellular matrix proteins allows fast migration of epithelial cancer 
cells along 'fibre roads', aiding travel through the stroma (Casey et ai., 2009).
Tight regulation of the secretion of proteases and protease inhibitors, is essential 
for normal physiological processes, however, during tumour development this 
balance is disrupted (Noel et al., 2008). Matrix metalloproteinases (MMPs) are 
expressed by fibroblasts, endothelial cells, macrophage-like cells and cancer cells. 
Tumour cells induce expression and secretion of MMPs, which degrade all 
extracellular matrix proteins facilitating tumour cell invasion. The cocktail of MMPs 
produced in the tumour microenvironment includes collagenases, which degrade 
fibrillar collagen; gelatinases, which degrade denatured colllagen and proteglycans 
or glycoprotein, such as laminin, fibronectin and gelatine (Heppner et al., 1996). 
MMPs facilitate EMT, by degrading connections between epithelial cells such as E- 
cadherin, therefore facilitating epithelial movement (Noe et al., 2001). MMP3 in 
particular has been shown to play a key role in EMT (Sternlicht et al., 1999).
Fibroblasts express all MMP family members apart from MMP7, which is uniquely 
expressed by epithelial cells (McCaig et al., 2006a). H. pylori infection increases
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MMP7 expression causing an increase in the proliferation and migration of stromal
myofibroblasts, through activation of PI3K signalling cascades (Hemers et al., 2005). 
In addition, insulin-like growth factor two (IGF-II) and insulin-like growth factor 
binding protein five (IGFBP5) are both expressed by fibroblasts. MMP7 cleaves 
IGFBP5 causing the release of IGF-II, which itself stimulates proliferation and 
migration of epithelial cells (McCaig et al., 2006b). Finally, MMP-9 is released from 
fibroblasts in many cancers in response to TGF-j3 stimulation (Stuelten et al., 2005).
Urokinase - type plasminogen activator (uPA) is a serine protease expressed by 
myofibroblasts and has a strong associations with cancer progression (Nielsen et al., 
1996; Smith and Marshall, 2010). uPA is activated upon binding to its receptor 
(uPAR) on epithelial cell, fibroblasts and macrophages (Dublin et al., 2000a). Once 
bound to its receptor, uPA converts inactive plasminogen into plasmin, a serine 
protease that degrades fibrin and activates MMPs (Carmeliet et at., 1997), leading 
to the degradation of the extracellular matrix and increased invasion and metastasis 
of cancer cells. Furthermore, expression of plasminogen activator inhibitors 1 and 2 
is decreased in many cancers, including gastric (Nakagawa et al., 2004; Norsett et 
al., 2010). As such, high levels of uPA and its receptor are indicative of poor 
prognosis in gastric cancer (Heiss et al., 1995).
1.4.7 Therapeutic interventions
In most cases, gastric cancer is only detected at late stages of tumour development 
-due to the lack of early stage symptoms. A combination of surgery, chemotherapy 
and immunotherapy are most commonly used to treat the tumour, however 5-year 
survival figures remain poor, with most combination therapies only increasing life
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expectancy of late stage gastric cancer patients by around six months (Vecchione et 
al., 2009). As such, there is a real need for less invasive stage-specific, or even 
patient specific, cancer drugs. Given the importance of epithelial mesenchymal 
cross talk in tumour progression, the microenvironment has become a focus for the 
development of new therapeutic strategies.
Due to the tumour promoting roles of PDGF, it seemed an attractive target for 
therapy, but as there are organ specific forms of PDGF receptor, development of 
specific drugs has proved problematic (Bonner, 2004). The drug Glivec (also known 
as imatinib or Gleevec) was the first tyrosine kinase receptor inhibitor approved as 
an anti-cancer drug, it has been developed to inhibit PDGF-a and (3 receptors. Glivec 
works in two ways, inhibiting the PDGFR on fibroblasts inhibits PDGFs mitogenic 
properties and inhibiting PDGFR on endothelial cells inhibits PDGF stimulated VEGF 
release. Glivec has also been shown to lower high intestinal fluid pressure (often 
associated with cancers) therefore increasing the amount of cancer drugs absorbed 
(Capdeville et al., 2002). Glivec also inhibits the effects of PDGF on fibroblasts, 
inhibiting the release of FGF-2 and FGF-7, therefore decreasing vascularisation and 
epithelial proliferation respectively (Pietras et al., 2008). Glivec is currently 
approved in several countries, for treatment of post-surgery gastro-intestinal 
stromal tumours.
Marimastat is an inhibitor of MMPs, which was trialled as a possible anti-cancer 
drug in several different organs. However, in each case mariamastat failed to have 
beneficial effects, with the exception of gastric cancer (Fielding.J, 2000). Drugs 
targeting the uPA receptor have also proved to be unsuccessful; this is thought to
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be due to off-target effects, such as increased cell invasion, proliferation and 
survival. Combined treatment with truncated of HGF and a truncated HGF receptor 
has been suggested for future cancer therapy. In addition, combining the truncated 
met receptor with radiotherapy may be another possible therapeutic strategy, as in 
mice this increased cancer cells sensitivity to radiotherapy (Michieli et al., 2004). 
New strategies that interfere with paracrine signalling or stroma/cancer metabolism 
may offer new hope for more effective intervention even in late stage tumours. 
However, in order to develop more rationally designed therapeutic strategies we 
need to develop a better understanding of the molecular processes and pathways 
that regulate paracrine effects in both cancer cells and associated stromal cells. 
Given the complexity of the systems involved, it is unlikely that answers to these 
questions will be provided by conventional reductionist approaches that focus on 
the mechanistic properties of individual cellular components.
1.5 Systems biology
Growing realisation of the need to understand the broader properties of biological 
systems has led to a shift away from classical reductionist methods towards more 
global or 'systems level' approaches, leading to a new field of network biology, and 
more recently network medicine. Unlike classical textbook representations, 
biological processes are inherently non-linear dynamic processes often involving 
multiple combinatorial or conditional steps or components. In this context, it is 
highly unlikely that one gene could be responsible for a specific phenotype. Even in 
situations such as cystic fibrosis where this is true, it is the combination of global 
gene expression profiles that determine the severity and rate of progression in
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different patients. Furthermore, even if defects are observed in a specific pathway 
component, this does not mean that the same component is a realistic therapeutic 
target. Better options may exist either up or downstream of the defective 
component however, rational selection of better therapeutic candidates requires 
insight into global network structure and an ability to predict potential effects on 
other important processes.
1.5.1 Protein interaction networks
Mathematicians have been applying graph theory since 1736, in this approach 
objects are plotted as 'nodes' and their relationships or interactions with one 
another as 'edges'. Use of graph theory to map biological functions, allows 
visualisation of the interconnectivity between different biological processes. Over 
the past decade graph theory has been applied to systematically map out all 
biological functions and evaluate topological features (Barabasi and Oltvai, 2004). in 
biological networks, nodes normally represent proteins, metabolites or enzymes, 
whilst edges between them represent interactions or chemical reactions. Biological 
networks can be un-directed, with edges being represented by lines, or directed, 
with edges being represented by arrows (Guimera and Nunes Amaral, 2005).
Many different topological measures are used throughout Network Biology to 
understand the control that a node, or a cluster of nodes, have over other network 
members. The degree of a node represents the number of interacting partners 
within the network, therefore nodes with a higher degrees have a greater ability to 
effect more members and/or a greater number of processes.
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1.5.1.1 Topological features
Unlike random mathematical networks, biological interaction networks tend to 
have a scale-free topology, with a few highly connected central proteins, and many 
less connected nodes. Removal of the less connected nodes has relatively little 
effect on network function, whereas highly connected nodes, called 'hubs/ tend to 
be essential. Removal or mutation of these nodes in yeast frequently led to network 
fragmentation, and lethality. In general, a scale-free topology offers protection 
against random mutations, which would most likely affect the least connected 
genes (Jeong et al., 2001; Li et al., 2008). In general, biological networks are not 
homogeneous, they contain areas of dense connectivity surround by areas with 
fewer connected nodes. These dense areas are termed modules. However, the 
biological significance of modules within protein interaction networks has been 
disputed; some believe that modules are just artefacts of network coverage, whilst 
others suggest modules are functional and represent an important level of cellular 
organisation.
In cancer research, modules within protein-protein interaction networks correctly 
identified GO biological function (Chuang et al., 2007). A functional module is a 
subset of molecules that are more connected or related to one another than other 
molecules due to their molecular/chemical specificity, cellular localisation or 
expression profile. This modular structure, allows changes within a module to occur 
without affecting the entire network. Similarly changes in connections between 
modules may affect multiple different processes. In this sense the modular nature 
of biological networks may facilitate functional evolution, which could not occur if
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molecules where un-structured, or non-modular {Hartwell et alv 1999). Many
software tools are now available to analyse the topological feature of networks. 
However, although each algorithm identifies clusters of proteins/genes rational 
evaluation is often required to evaluate the biological significance of the identified 
clusters (Hallinan, 2004). Netbox and MCODE both define modules based on 
network topology, Netbox is an online resource that allows users to map gene 
expression data onto a human interaction network in order to identify unique linker 
genes, network modules and perform comparisons with genes identified in previous 
cancer studies (Bader and Hogue, 2003; Cerami et al., 2010). This computational 
tool was initially developed to identify driver genes from passenger genes 
(Greenman et al., 2007) as identification of similar modules across a range of 
patients with a particular disease, may indicate new 'driver genes'. Interestingly, in 
different types of cancer, although overall the same modules were affected, 
different members were changed in different cancers. Therefore, knowledge of 
altered cancer related modules may help develop better intervention strategies 
(Cerami et al., 2010).
The importance of network biology in understanding cancer was highlighted by a 
study that used network-based analysis to identify genes involved in breast cancer 
metastasis. Gene expression arrays were mapped onto protein-protein interaction 
networks, producing sub-networks common to metastasis. One particular gene was 
not significantly changed but was found to be essential for inter-connecting a 
specific sub-graph, which was important in predicting whether a sample would be 
metastatic. The un-changed gene is similar to the linker genes identified in Netbox.
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Gene array analysis alone would not have identified the importance of these genes, 
but the combination with protein-protein interaction data highlights the future 
importance of this form of network biology in cancer research (Chuang et al.f 2007).
A number of studies have highlighted the importance of highly connected 'hub' 
proteins and their positioning either within or outside of network modules. In the 
yeast interactome, two types of hubs were observed, party hubs and date hubs. 
Party hubs displayed a similar pattern of co-expression with their interacting 
partners, and tended to share the same sub cellular localisations as their partners. 
In contrast, date hubs tend to exhibit lower levels of co-expression or co­
distribution with their interacting partners. As such, party hubs tend to occur within 
biological modules, while date hubs are important to the overall structure of the 
network and tend to occur between modules. Removal of party hubs did not affect 
the network connectivity, whilst the removal of date hubs resulted in smaller sub­
networks each with specific biological functions (Han et al., 2004).
Another study also assumes that the position of a node within a modular network 
may determine its role. In this study, nodes within modules were first categorised as 
a hub or non-hub, then using a participation co-efficient to determine how well- 
connected nodes are to other modules, hubs were divided into 3 categories and 
non-hubs into 4 categories. Results from this analysis suggest that although most 
modules are associated with one predominant function, several have multiple 
functions, indicating over-lapping central metabolic pathways. As predicted hubs 
have the lowest evolutionary loss rate compared to more peripheral nodes. The 
surprising finding is that non-hub connectors, genes that do not have a high degree
34
but are found between modules are significantly more conserved than hubs that 
are highly connected within a module. This may be because the removal of a hub 
within a module may be backed-up by redundant interactions, whilst the removal of 
a non-hub connector may be catastrophic to the communication through module- 
module connections in the network. Therefore, this study supports previous 
findings that show hubs to be more essential in the network, but also suggests that 
there may be other important non-hubs in the network which are better identified 
by global connectivity algorithms rather than simple degree (Guimera and Nunes 
Amaral, 2005).
To connect two nodes on a network, there may be a number of possible paths 
passing through different nodes, each being of variable lengths. The shortest path is 
defined as the shortest route that connects two nodes, and this is often used to 
calculate betweenness centrality values for nodes within a particular network (see 
below). Path-length is a quantitative measurement, and is calculated as the number 
of nodes that lie on the shortest path between two nodes. The clustering co­
efficient represents the tendency of a node to form groups, as shown in Figure 1.3, 
if A and B interact, and B and C interact, A and C may interact if they have a high 
clustering co-efficient. The clustering co-efficient of A is higher than the clustering 
co-efficient of node F, as 2 of node A's interaction partners interact, whilst none of 
node F's partners interact (Barabasi and Oltvai, 2004),
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Figure l.B Network representing the increased clustering co-efficient tendency of certain nodes.
Betweenness centrality is a measure of the amount of control that a node may have 
within a network. The concept of node centrality was first proposed by Bavelas et al 
in 1948 and is calculated by taking into account the number of shortest paths that 
pass through a node to connect two other nodes. A node that lies on a large 
number of shortest paths, is considered central and is thought to have more control 
over network function by inhibiting or increasing information flow to other parts of 
the network (Bavelas, 1948) (Freeman, 1977), with high betweenness nodes are 
known as 'bottleneck' nodes (Missiuro et al., 2009).
1.5.2 Disease networks
Human protein-protein interaction networks have been used to understand the 
complex biological interactions, occurring in different diseases. This understanding 
of networks is useful in drug-discovery, as understanding the entire network of 
possible circuits, allows the researcher to predict the consequences that targeting a 
single gene may have, including possible off-target effects or neutralising circuits 
(Zanzoni et al., 2009). In addition, the concept of pleiotrophy in disease is
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important; a single gene that has functions in different pathways can have multiple 
'pleiotropic' effects, in this context differences in function result from a single 
protein existing in different functional states or being part of multiple complexes 
involved in different cellular processes. Genes encoding this class of protein are 
thought to be genetically more stable than genes encoding proteins with roles in a 
single process, because a greater selection pressure will be imposed on a gene 
encoding proteins required for multiple processes. In this context, network biology 
has been useful in understanding the different disease phenotypes observed upon 
mutation of one gene. Different in-frame mutations do not always cause the 
'removal' of gene activity but may cause a loss of binding or activity with another 
specific gene or protein. Different in-frame mutations can represent the removal of 
edges from a network, rather than a node, therefore its activity is altered rather 
than removed (Zhong et al., 2009).
A set of human disease networks were produced to help identify groups of similar 
diseases based on their individual disease genes, at a network level. The networks 
consist of either, diseases that are connected to each other if they share common 
mutated genes, or genes that are connected to each other if they are related to 
similar diseases. Genes within distinct disease modules represented functional GO 
processes and interacted with each other more than random chance, which 
suggested the use of the network as a possible 'diseasome' for future studies. 
Interestingly in these studies hubs were shown to weakly correlate with disease 
genes. This is most likely due to the fact that disease genes can be split into 
essential and non-essential genes. Hubs are often essential genes (Jeong et al.,
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2001) and the majority of disease genes are shown to be non-essential. The reason 
the majority of germ line disease genes are non-essential could be explained using 
an evolutionary theory; if a disease gene was central it may lead to lethality, while 
peripheral disease genes are less likely to have such catastrophic effects and will be 
passed on through the generations (Goh et al., 2007).
1.5.3 Cancer networks
A complex relationship between genetics, epigenetics and environmental factors 
are thought to contribute to the progression of cancer. As outlined above, a systems 
level approach is required to deal with the inherent complexity of cancer networks. 
Currently available cancer drugs that target a specific receptors or growth factors 
have shown only small levels of success. In order to improve the success of 
chemotherapy we need to use new systems level approach, rather than the 'target 
and kill' strategy that has been applied to date. Also, systems based methods need 
to be used to investigate cancer in a stage specific manner, as cells and their 
environment operate in 'dynamic equilibrium' which changes throughout cancer 
progression (Knox, 2010).
Network of cancer genes is an on-line web resource, containing a collection of 736 
human genes that are mutated in some forms of cancer(Syed et al., 2010). Around 
half of these genes come from the Cancer Gene Census and the remaining set from 
high-throughput mutation cancer screenings. The resource supports a systems 
based approach, providing protein interaction information for each cancer related 
gene independent of their actual functions. 579 of the 736 cancer genes can be 
mapped onto the protein-protein interaction network, from which topological
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calculations of degree, clustering co-efficient and betweenness have been 
calculated.
1.5.3.1 Topological features of cancer networks
Many different studies have been carried out to identify topological features of 
proteins within cancer related networks, with the aim of identifying mutations that 
upon may have the biggest effect on tumour progression or prognosis.
As the scale-free topology of biological networks should protect against genetic 
mutation, alterations in epigenetic regulation could play an important role in cancer 
phenotypes. Interestingly, epigenetic alterations have been shown to have stronger 
association with cancer than genetic mutations. Also, diets that stabilise epigenetic 
proteins have been shown to have a positive protective effect over cancer 
progression (Knox, 2010). It appears that in general cancer related proteins are 
significantly more connected within interaction networks than would be expected 
by chance, with most having a high degrees in the network, suggesting that cancer 
proteins play a central role in the network function (Jonsson and Bates, 2006). 
However, many people worry that protein-protein interaction networks are bias 
towards cancer studies, and that the observed increase in connectivity involving 
cancer related proteins, may reflect study bias. In defence, Jonsson et al show 
cancer related proteins tend to contain significantly more promiscuous interaction 
domains in relation to non-cancerous proteins, with domain data retrieved from 
PFAM showing no bias towards cancer proteins (Jonsson and Bates, 2006).
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1.5.3.1.1 Cancer mutated genes and hubs
Some cancer related mutations clearly occur in germline cells such as p53 
mutations, as such these are conserved inheritable mutations (Jonsson and Bates, 
2006). However, many more cancer related mutations are somatic, occurring in 
differentiated cells and these are rarely inherited (Zanzoni et al., 2009).
The fact that most cancer genes are not conserved through evolution would explain 
the high number of cancer related hub proteins. While 5% of nodes in a random 
network would be expected to be hub proteins, over 13% of hubs in the current 
human interactome are cancer genes, therefore demonstrating an enrichment of 
hubs in cancer related genes {Syed et ai., 2010). In addition, cancer related genes 
tend to be associated with signalling hubs (Awan et al., 2007; Cui et al., 2007). This 
work has led to the establishment of an oncogenic signalling map and identification 
of 'oncogenic super-highways, which are often mutated in cancer.
1.5.3.2 Crosstalk in biological networks
Superimposing canonical pathways onto protein-protein interaction networks 
demonstrates a large amount of potential cross-talk between pathways (Wu et al., 
2010). One particular study used protein-protein interaction data to investigate 
crosstalk between different significantly changed biological pathways. They 
produced a pathway crosstalk network in which clusters of pathways were shown to 
share similar biological functions, with signalling related pathways generally 
producing the largest cluster. They concentrated on identifying pathways that had 
low numbers of cross-talk between them, in order to identify cross-talk between
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less similar processes and state the networks could be used as a framework for 
datasets to be mapped onto (Li et al., 2008).
Currently, tools such as NetBox are available which allow the identification of 
modules within networks, a prediction is then made of the range of possible 
biological pathways that individual modules could be involved in. Alternative tools, 
such as Metacore™, allow the identification of over-represented pathways within 
given datasets but do not provide information on connectivity between pathways. 
There is currently no tool available that allows the user to map differentially 
regulated genes on to pathways, identify over-represented pathways, and identify 
the entire range of pathway crosstalk within an interaction network.
1.5.3.2.1 Personalised medicine
In the future, individual patient genome sequence information will be more 
affordable, by combining this information with interactome and expression data, it 
will be possible to use network biology methods to provide new insights into 
personalised or stratified medicine and optimal strategies for cancer treatment 
(Zanzoni et al., 2009). In the meantime, patient prognosis scores have been used to 
try and predict the stage and type of cancer, in order to administer the appropriate 
treatment. In gastric cancer, one group devised a method for scoring patients into 
prognostic groups. cDNA samples from cancer and normal regions were screened 
for five conventional pathological factors; tumour size, depth of invasion, 
histological growth pattern, lymph node metastasis and liver metastasis. Applying a 
t-test to each pathological factor, they show that patients could be divided into 
'good' and 'bad' prognosis groups, with the scoring system successfully
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differentiating, previously hard to predict patients, which are at high risk (Inoue et 
al., 2002). Similar pathological factors were utilised by an alternative group, who 
defined a prognostic scores for gastric cancer (PSGC) using a ten-variable staging 
multivariate technique (Kologlu et al., 2000). Our patient samples have associated 
prognosis scores assigned based on a similar list of staging variables, which we aim 
to devise an appropriate method to deduce outcome. To conclude, although there 
is a large number of cancer interaction networks currently published, the important 
relationship between the cancer and stromal cells is evident, and the current 
requirement for improved stromal/cancer networks is clear. In addition, the 
combination of patient prognosis data, used together with techniques enabling 
differentially regulated genes to be mapped to over-represented pathways, within 
cross talk visualising, protein-protein interaction networks, may provide us with the 
best approach to be able to understand the complex processes occurring within the 
cancer micro-environment, within different tumour stages.
The first two results chapters within this thesis apply a range of canonical pathway 
and statistical tools to compare the gene expression profiles between cancer- 
associated, adjacent and absolute normal myofibroblasts. Key molecular signatures 
and biological processes were identified, such as the differential regulation of genes 
involved in cell adhesion, glycan metabolism, DNA repair and metabolic pathways 
including fatty acid p-oxidation, ketone body synthesis and cholesterol biosynthesis. 
Upon receiving additional patient prognosis information, and access to additional 
gene expression analysis software, several patients were clear outliers and were 
consequently removed. Chapter five consists of analysis of the refined dataset,
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canonical pathway analysis and refined multivariate techniques which confirm the 
molecular signatures and biological processes identified within the first two 
chapters; and are expanded to define a system whereby cancer cells undergo 
metabolic reprogramming to induce a variation of the reverse Warburg effect. 
Finally, utilisation of the patient prognosis scores are utilised to define prognosis 
specific expression profiles, thereby providing new insight into the molecular 
processes that drive important paracrine communication networks during the 
development of gastric tumours.
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2 Chapter Two: Methods 
2.1 Data processing
Biopsies were dissected from patients with gastric cancer in Szeged Hospital, 
Hungary. Samples were taken from 14 patients with gastric cancer; samples taken 
directly from the region of the tumour are referred to as cancer samples or Cancer 
Associated Myofibroblasts (CAMs). In 12 of the 14 cancer patients, biopsies were 
also taken from tissue adjacent to the site of the tumour, these are known as 
Adjacent Tumour Myofibroblasts (ATMs). For comparison, absolute normal 
reference samples were obtained from 12 post-mortem organ donors who had no 
known underlying medical conditions, which are referred to Absolute normal 
samples (ANs). All samples are shown in Table 2.1.
Gastric cancer patient foliow-up scoring details and related patient details are 
provided in Table 2.2 and Table 2.3 respectively. Patient prognosis scores are 
determined using the semi-quantitative scoring system. This scoring system takes 
into account degree of anaemia, BMI loss, the stage of the tumour (grade, type, 
lymphatic vessel invasion, vascular invasion and positive margins of resection), 
tumour marker elevation (serological), re-occurrence of the tumour, whether the 
tumour was a synchronous or metachronous, metastasis and the mortality of the 
patients. Based on these measures histologists in Hungry then assigned patient 
prognosis scores (Table 2.4) from 0-14, with scores of 0 relating to no difference 
from a healthy subject and 14 representing a very progressive stage of gastric 
cancer. Patient sample details associated with absolute normal patients are 
provided within Table 2.5.
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Label Sample Sample type
1-CAM Sz42/1 P5 Cancer
1-ATM Sz42/2 P5 Adjacent
2-CAM Sz45/1 P5 Cancer
2-ATMA Sz45/2 P5 Adjacent 1
2-ATMB Sz45/22 P7 Adjacent 2
3-CAM Sz190/1 P4 Cancer
3-ATM Sz190/2 P4 Adjacent
4-CAM Szl92/1 P5 Cancer
4-ATM Szl92/2 P5 Adjacent
5-CAM Sz194/1 P5 Cancer
5-ATM Sz194/2 PS Adjacent
6-CAM Szl95/1 PS Cancer
6-ATM Szl95/2 PS Adjacent
7-CAM Sz198/1 PS Cancer
7-ATM Szl98/2 PS Adjacent
8-CAM SZ268/1 PS Cancer
8-ATMA Sz268/2 PS Adjacent 1
8-ATMB Sz268/22 PS Adjacent 2
9-CAM Sz271/1 PS Cancer
9-ATM Sz271/2 PS Adjacent
10-CAM Sz294/1 P4 Cancer
10-ATMA Sz294/2 PS Adjacent 1
10-ATMB Sz294/22 P4 Adjacent 2
11-CAM Sz305/1 PS Cancer
11-ATM B Sz305/22 PS Adjacent 1
11-ATM A Sz305/2 PS Adjacent 2
12-CAM Sz308/1 PS Cancer
12-ATM Sz308/22 P6 Adjacent
13-CAM Szl87/1 P8 Cancer
14-CAM Szl97/1 PS Cancer
15-CAM Sz389/1 P7 Cancer
15-ATM Sz389/2 P7 Adjacent
21-ANMA Szl96/2 PS Absolute normal
22-ANMA Sz241/2 P6 Absolute normal
22-ANMB Sz241/22 P6 Absolute normal
23-ANMA Sz246/2 P6 Absolute normal
23-ANMB Sz246/22 P6 Absolute normal
24-ANMA Sz261/2 P6 Absolute normal
24-ANMB Sz261/22 P6 Absolute normal
25-ANMA Sz279/22 P4 Absolute normal
26-ANMA Sz334/2 PS Absolute normal
26-ANMB Sz334/22 PS Absolute normal
27-ANMA Sz351/2 PS Absolute normal
27-ANMB Sz351/22 PS Absolute normal
28-ANMB 845P7 Absolute normal
Table 2.1. All cancer, adjacent and absolute normal samples. Table shows the labels used throughout 
analysis, which correspond to a patient sample ID, and the type of sample. Patient samples shown in 
red were removed, but are shown to explain the gaps in patient numbering.
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Patient No. Origin Age Gender
Szl96/2 gastric corpus 67 M
Sz279/22 gastric antrum 60 M
Sz334/2 gastric corpus 52 F
Sz334/22 gastric antrum 52 F
Sz351/2 gastric corpus 41 M
Sz351/22 gastric, antrum 41 M
Sz241/2 gastric, corpus 44 F
Sz241/22 gastric, antrum 44 F
Sz246/2 gastric, corpus 45 M
Sz246/22 gastric antrum 45 M
Sz261/2 gastric, corpus 52 F
Sz261/22 gastric antrum 52 F
Table 2.5. Absolute normal (AN) patient details obtained from 12 post-mortem organ donors who 
had no known underlying medical conditions.
2.1.1 Myofibroblast cell culture generation
Myofibroblasts were isolated from tissue samples and cultured by Peter Hegyi, 
(Department of Medicine, University of Szeged, Hungary), as previously described 
(McCaig et al., 2006b). Primary myofibroblasts were cultured by Dr I. Steele and Dr 
C. Holmberg, (University of Liverpool, UK) in a Dulbecco's modified eagles medium 
(DMEM) (Sigma, Poole, Dorset, UK) supplemented with 10% Fetal Bovine Serum 
(FBS) (Perbio, Cheshire, UK), 2% Antibiotic-Antimytotic (Sigma, Poole, Dorset, UK), 
1% Penicillin-Streptomycin Solution (Sigma, Poole, Dorset, UK), and 1% non- 
essential amino acid solution (Sigma, Poole, Dorset, UK). Cells were maintained at 
37°C and 5% C02 and media was changed every 46-60 hours. Confluent cells were 
split by adding 0.25% typsin (Sigma, Poole, Dorset, UK) for 10-15 minutes. Cells 
passages were recorded and only cells from passages 4-12 were used for further 
analysis, as generally after passage 12, their morphology changes and they become 
senescent.
49
2.1.2 Gene expression array and normalisation
Cells were cultured and RNA extracted using the RNeasy Kit (Qiagen) by Dr 1. Steele. 
Gene expression analysis was conducted on ail samples using the GeneChip Human 
Genome U1S3 Plus 2.0 Array (Affymetrix, SantaClara, CA, USA), at the Liverpool 
Genome Research Facility by Dr Lucille Rainbow. The Human Genome U133 plus 2.0 
Array, allows analyses 38,700 gene transcripts 11 pairs of probes are used to 
measure the level of expression of a single gene. These consist of perfect and mis­
match probes, plus a selection of normalisation probes, which consist of a range of 
human maintenance genes, which have constant levels of expression and are 
therefore used to normalise signals across multiple arrays. The GeneChip® Scanner 
3000 was used to image arrays, and quality control was performed using Affymetrix 
microarray 5 Q.C metrics. Gene-arrays were analysed for their quality using the 
Array Quality Metrics package, which is explained in detail within section 2.5.1.1. 
Statistical analysis of gene expression profiles was performed in GeneSpring GX.10 
(Agilent) with baseline transformation and experiments were normalised using the 
Mas5 method. This process also flags the data with P (present), M (marginal) and A 
(absent) flags. For an oligonucleotide to be classed as detected in this study it had 
to have been assigned a 'present' flag for all patients within one of two comparison 
groups. This gene list was then analysed for differential regulation as explained in 
section 2.1.3.2 below.
However, to understand the effect a particular normalisation technique may have 
on the results, gene expression profiles were also normalised using the increasing 
popular Robust Multi-array Average (RMA) technique. The RMA derived 
differentially regulated gene lists were not used within any downstream analysis.
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yet we believe it is important to make this comparison for the confidence of the 
reader. The RMA normalisation was completed using Partek®, and is therefore 
discussed in detail in section 2.1.3.4.
2.1.3 Statistical analysis
To compare changes in gene expression profiles in different myofibroblasts 
populations, three datasets were compiled for analysis, CAM vs. AMN, CAM vs. ATM 
and ATM vs. AMN.
2.1.3.1 Background oligonucleotides
As a specific cell type may not produce every single known protein, we first 
compiled lists of genes that were expressed in each cell-type. Within this study, all 
genes found to be expressed at a baseline level were pooled to define the list of 
expressed genes for each of the myofibroblast populations. For these studies an 
oligonucleotide was only classified as being detected, if a P flag was present in 100% 
of patients from either or both of the comparison groups.
2.1.3.2 Differentially regulated oligonucleotide lists.
Microarray data was processed through GeneSpring GX.10 software (Agilent). As 
myofibroblasts were prepared from paired cancer and adjacent samples, a paired T- 
test was conducted on data from these samples. As patient's sz45, sz268, sz294 and 
sz305 had a single CAM sample but two ATM samples, two independent paired T- 
tests were performed using the same CAM sample with each of the two ATM 
samples. Therefore, in total 15-paired t-tests were performed. No genes passed a p- 
value <0.05 Benjamini-Hochberg false discovery rate FDR correction, this may be 
due to the samples being paired and therefore very similar. Therefore, in each case
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oligonucleotides with un-corrected p-values <0.05 were considered to be 
differentially expressed. Un-paired T-tests were performed on array data derived 
from CAM vs. ANM and ATM vs. ANM comparisons. In each case P-values were 
corrected for false discoveries in accordance to the Benjamini-Hochberg false 
discovery rate (FDR) algorithm. FDR corrected p-values <0.05 were considered 
differentially expressed. To determine if genes were over or under-expressed, the 
log fold change was calculated for each oligonucleotide and the geometric mean 
was calculated for oligonucleotide intensities within each sample group, i.e. CAM, 
ATM or ANM. For each differentially expressed oligonucleotide in the CAM vs. ATM, 
CAM vs. ANM and ATM vs. ANM studies a log base 2 transformation was applied to 
ensure that the relative changes in the data are proportionate, with changes around 
negative, or small intensities being comparable to changes around large intensities.
2.1.3.3 Patient prognosis groups
'Good' and 'bad' patient prognosis groups were compiled from the four best and 
four worst prognosis scores respectively, with the intention of identifying changes 
in myofibroblasts derived from patients with a worse or better prognosis score. In 
addition to sub-grouping patients into 'good' and 'bad' prognosis groups, we also 
wanted to isolate changes that occur in myofibroblasts derived from the cancer or 
adjacent regions, in order to highlight the stage (CAM or ATM) that changes 
occurred during tumour development.
2.1.3.3.1 'Good' patient prognosis
'Good' patient prognosis scores are classed as those below 9, therefore the four 
patients with the best prognosis scores were sz42, szl94, szl98 and sz389, which
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relate to samples 1, 5, 7 and 15, respectively. Un-paired T-tests were conducted on 
the 4 'good' CAM samples vs. all 12 ANM samples, or the 4 'good' ATM samples vs. 
all 12 ANM samples (Table 2.6). In each case, P-values were corrected for false 
discoveries using the Benjamini-Hochberg correction algorithm. Corrected p-values 
<0.05 were considered to be differentially expressed and the log2 fold-change was 
calculated for each oligonucleotide.
'good' patient prognosis groups
CAM vs. ANM
1-CAM
All 12 Absolute normal samples
5-CAM
7-CAM
15-CAM
ATM vs. ANM
1-ATM
All 12 Absolute normal samples
5-AMN
7-ATM
15-AMN
Table 2.6 'good' patient subgroups, CAM vs. ANM and ATM vs. ANM.
2.1.3.3.2 'Bad'patient prognosis
Patients with prognosis scores above 9 were classified as having 'bad' prognosis, 
therefore the four patients with the worst prognosis score were szl90, szl92, sz271 
and sz308, which relate to samples 3, 4, 9 and 12, respectively. Un-paired T-tests 
were conducted on the 4 'bad' cancer samples vs. all 12 absolute normal samples 
and the 4 'bad' adjacent samples vs. all 12 absolute normal samples (Table 2.7). P- 
values were again corrected for false discoveries using the Benjamini-Hochberg 
correction algorithm described in section 1.1.4.2. All corrected p-values <0.05 were 
considered to be differentially expressed and log2 fold change values were 
calculated for each oligonucleotide.
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'Bad' patient prognosis group
CAM vs. ANM
3-CAM
All 12 absolute normal samples
4-CAM
9-CAM
12-CAM
ATM vs. ANM
3-ATM
All 12 absolute normal samples
4-ATM
8-AMN
12-ATM
Table 2.7 'Good' patient subgroups, CAM vs. ANM and ATM vs. ANM.
2.1.3.4 Partek®
The Partek® Genomics suite, version 6.6 beta Copyright © 2008 (Partek® Inc., St. 
Louis, MO, USA) became available to us towards the latter part of this project. 
Throughout the study, data was normalised using MasS, as described in section 
2.1.2, however due to the increasing popularity of an alternative normalisation 
technique, Robust Multi-array (RMA), it seemed sensible to compare the two. 
Affymetrix CEL files were uploaded into Partek® and normalised using the RMA 
algorithm. In brief; background correction on the PM values, quantile normalisation 
across all chips on experiment, Log2 transformation and a median polish 
summarisation. The resulting RMA normalised expressions were exported from 
Partek and differentially resulted gene lists and their associated fold changes 
calculated as described in section 2.1.3.2.
Partek® was also used to assess the quality of the data and ensure correct fold 
changes were applied. Briefly, the data was transposed and patient IDs were 
identified as categorical factors and oligonucleotide expression levels as double
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response factors. Then additional information was added manually; Individual 
patient samples were annotated based on their sample type (cancer, adjacent or 
normal), any patient pair information for cancer and adjacent samples and batch 
processing information were taken into account.
Principal component analysis (PCA) was performed on un-corrected data, data 
corrected based on microarray analysis dates, and data corrected on patient pair 
information. In each case, results were visualised as 2 and 3 dimensional plots. Data 
corrected based on microarray analysis dates takes into account any systematic 
variation that may be associated with sample preparation, whilst correction based 
on patient pair samples, takes into account variation between individuals. Also 
within Partek®, differentially expressed gene lists for each comparative dataset 
were identified using the ANOVA method. Factors within the ANOVA included 
sample type and for the CAM vs. ATM dataset, patient pair information. Ranges of 
differentially regulated gene lists were compiled based on different stringencies as 
stated below. Differentially regulated genes had to have a p-value <0.05 and have 
fold changes greater than 2, 1.8, 1.6, 1.4, 1.2 or 1 fold change. As before, p-values 
were corrected using the Benjamini-Hochberg false discovery rate for the CAM vs.. 
ANM and the ATM vs. ANM dataset, but not for the CAM vs. ATM dataset. 
Differentially expressed gene lists were visualised using hierarchical clustering 
analysis (HCA) within Partek® at each of the fold change thresholds, thereby 
allowing the best fold-change cut-off to be selected.
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2.2 Metacore™
Metacore™ (GeneGo Inc) is a commercial integrated software suite for network and 
pathway analysis. Metacore™ allows different data-types to be uploaded, visualised 
and analysed with the use of its manually curetted knowledge database of protein- 
protein interactions, transcription factors, drug targets, metabolic pathways and 
signalling pathways.
2.2.1 Conversion of oligonucleotide probe IDs to Genes
For each dataset, text files of Affymetrix oligonucleotide associated log fold-changes 
and p-values were imported into Metacore™. For each oligonucleotide, associated 
Entrez gene Ids were exported from Metacore™. For genes that are represented by 
multiple oligonucleotide probes, Metacore™ selects the highest probe expression 
value.
2.2.2 GeneGo Pathway analysis
For each data set, significantly changed Entrez gene IDs and their associated 
background detection list were uploaded into Metacore™. Individually, a 
significantly changed gene list was activated and the appropriate background list set 
as the 'universe7. The Enrichment ontology's - GeneGo pathway function was then 
applied to identify over-represented pathways by calculating if there are 
statistically, more significantly changed genes present in a particular pathway than 
would be expected by random chance. Pathways are also given a False Discovery 
Rate (FDR) corrected p-value. The FDR correction takes into account the large 
number of Fisher tests applied to the datasets and calculates the chance of 
incorrectly rejecting the null hypothesis.
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2.2.3 Retrieval of assigned gene lists
Lists of significantly changed genes mapped to a Metacore™ GeneGo pathways was 
obtained through 'File > properties > on maps'. This displays the number and which 
significantly changed genes are mapped to a pathway within Metacore™. Retrieving 
lists of significantly changed genes mapped to significantly over-represented 
pathways was more problematic, as pathway member information for a select 
group of pathways cannot be exported from within enrichment ontology's - GeneGo 
pathway results.
Using 'View > GeneGo maps' (completed during 2010, this function has currently 
expired), all pathways that had at least 1 significantly changed gene hit are listed 
and groups of pathways exportable, however no associated pathway over­
representation p-values are displayed. Therefore, this list had to be cross- 
referenced with the over-represented p-values obtained from enrichment 
ontology's - GeneGo pathway results. Pathways within 'View>GeneGo maps', were 
only selected if their over-represented p-value <0.05.
2.2.4 Transcription factor analysis
Metacore™ was used to identify transcription factors within differentially expressed 
gene lists. Two lists of differentially regulated transcription factors were compiled 
for each dataset, those with a p-value <0.05 and those with a p-value <0.05 and a 
1.6 fold change cut-off. These two lists of transcription factors were then identified 
in the differentially expressed gene lists in Partek® and transcription factor 
heatmaps generated for the CAM vs. ANM, CAM vs. ATM and ATM vs. ANM 
datasets.
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2.3 DAVID
The Database for Annotation, Visualization and Integrated Discovery (DAVID) was 
used to assess over-represented KEGG and BioCarta pathways within the datasets 
(Athippozhy et al., 2011; Huang et al., 2009; Huang et al., 2008). Individually, lists of 
significantly changed Entrez gene IDs and their associated background Entrez IDs 
were uploaded into the DAVID bioinformatics resource. Numbers of genes mapped 
within the DAVID database were recorded. The functional annotation chart tool 
within DAVID allows significantly changed genes to be mapped onto related 
biological pathways, specifically KEGG and BioCarta. Datasets were processed 
through the functional annotation tool: In this study, ail pre-defined defaults were 
cleared, KEGG and BioCarta Pathways were selected and a functional annotation 
chart analysis was performed on the data. Functional annotation chart results 
provide all related biological KEGG and BioCarta pathways, with associated over­
representation pathway p-values and Bonferroni- Hochberg FDR corrected p-values. 
Pathways with FDR corrected p-values <0.05 were considered over-represented in 
the significantly changed gene-list.
2.3.1 Retrieval of assigned gene lists
To retrieve the total number of significantly changed genes that were mapped to 
KEGG and BioCarta pathways in DAVID, genes that were not mapped to pathways 
were downloaded via the functional annotation chart before being deducted from 
our total significantly changed gene list. Retrieval of significantly changed genes 
mapped to significantly over-represented pathways (p< 0.05) was obtained by
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selecting and downloading the 'genes' column in the functional annotation chart 
results for each significantly over-represented pathway.
2.4 Ingenuity®
IPA 7 is part of Ingenuity® systems (Ingenuity® Systems, www.lngenuity.com), a 
commercial web-based software database. IPA 7 allows the analysis of microarray, 
micro-RNA and proteomics data, which can be used to study gene, protein and drug 
information. Ingenuity's knowledge database is manually curated by PhD level 
scientists reading full-text articles. Datasets are mapped onto the Ingenuity® 
knowledge database of canonical metabolic and signalling pathways, derived from 
papers, reviews, textbooks and the KEGG database. Ingenuity® allows users to 
either upload their own reference set or apply the Ingenuity® knowledge database 
as a reference set. A combined list of background and significantly changed genes 
along with their associated p-values were uploaded into Ingenuity®. If p-values had 
not been calculated for background genes, a standard p-value of 0.99 was assigned. 
Once uploaded the following filters and settings were assigned: The background 
was set as 'user defined' (this is the entire list of background and significantly 
changed genes uploaded), direct and in-direct relationships, all species, all tissues 
and all data sources were selected. To select for significantly changed genes a cut­
off p-value of 0.05 was applied. Lists of significantly changed genes, that were 
mapped to different Ingenuity® categories, were exported as: mapped to 
Ingenuity®, mapped to canonical pathways, mapped to networks, and not mapped. 
The pathway analysis was set to run; Exported canonical pathway results display: 
pathways, -log (p-value), p-value (un-corrected or corrected), ratio and significantly
59
changed genes hitting a specific pathway. The ratio is a calculation of the number of 
significantly changed genes in a pathway divided by the total number of genes in a 
pathway. This provides information about which pathways have the most 
significantly changed genes in them and therefore may be most affected by 
differentially expressed genes. P-values are calculated using the Fisher exact test 
and P-values were displayed as -logio values, therefore -log values > 1.3 are 
equivalent to p-values < 0.05. Pathways with p-values < 0.05 were considered to be 
over-represented. FDR corrected p-values for over-represented pathways were 
obtained. Settings were also altered to display FDR corrected over-represented p- 
values based on Benjamini Hochberg FDR algorithm. JPEG images and lists of over­
represented canonical pathway results were exported for un-corrected and FDR 
corrected p-values separately.
2.4.1 Retrieval of assigned gene lists
The list of genes mapped to Ingenuity® pathways shows the input Entrez IDs and 
their associated gene symbols within the Ingenuity® knowledge database. All other 
lists of genes exported from Ingenuity® are in the form of official gene symbols 
rather than Entrez gene IDs. Therefore, the 'mapped to Ingenuity®' gene-list 
conversions together with the VLOOKUP function in excel was used to convert all 
gene symbols exported from Ingenuity®, to the required Entrez gene IDs. Lists of 
significantly changed genes mapped to statistically over-represented pathways 
were compiled by merging significantly changed genes mapped to all pathways with 
p-values < 0.05, within the canonical pathway results table. Lists of significantly 
changed genes mapped to any canonical pathway within Ingenuity® was obtained
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by merging all significantly changed genes mapped to all pathways from the 
canonical pathway results table. The canonical pathway results table only includes 
pathways with p-values large enough to visualise on chart {as depicted by blue bars 
on the canonical pathway charts). Therefore, to obtain a complete list of genes 
hitting all pathways regardless of resultant pathway over-representation p-value, 
additional pathways need to be individually selected and significantly changed 
genes that are mapped to it exported.
2.5 Reactome
Reactome is an online open-resource interaction, reaction and pathway database 
(Matthews et al., 2009; Vastrik et al., 2007). Its database is manually curated and 
peer.reviewed, from NCB1, PubMed, Uniprot, Entrez gene ID, ensemble, KEGG and 
Gene Ontology. The Reactome database is freely available to download and 
Reactome data model consists of individual reactions being grouped into networks, 
of which entities interact, to form larger biological pathways. Reactome Skypainter 
(Feb 2010) allows users to upload experimental data, and through the application of 
a one-tailed Fisher exact test, determine which pathways are statistically over­
represented in the dataset. However, Reactome Skypainter does not allow the 
application of a custom background, therefore applies the entire Reactome 
database as the background for statistical pathway over-representation 
calculations. Neither does Reactome apply a false discovery rate correction for the 
large amount of Fisher exact tests being carried out.
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2.5.1 R computing language
The R computing language is a statistical and graphical computing software 
environment based on the S programming language, created by John Chambers and 
Bell Labs. Bioconductor provides a range of tools, which can be integrated with Rfor 
the statistical analysis of genome-wide studies (Gentleman et al., 2004). The 
Bioconductor package BioMart (Durinck et al., 2005) was used to access the 
Reactome pathway database for statistical analysis in R. Full details of R script can 
be found in Supplementary script 1.
2.5.1.1 Array Quality Metrics
The Bioconductor package ArraydualityMetrics was used to assess the relative 
quality of the different gene arrays within the dataset. Identification of variance and 
noise due to technical causes such as the platform, lab, experimentalist, RNA 
extraction, amplification, hybridisation, labelling and sampling need to be assessed 
to ensure biological effects are visualised and statistical power is not reduced. 
ArrayQualityMetrics was applied before normalisation, to all 39 raw Affymetrix CEL 
files. The ArrayQualityMetrics report can be subdivided into the following sections: 
individual array quality; comparison of homogeneity between arrays; variance mean 
dependency and Affymetrix specific plots. Full details of R script can be found in 
Supplementary script 2.
2.5.1.2 Pathway analysis and BioMart assigned gene lists
The format of the output results from the Reactome over-representation pathway 
script, are Reactome unique pathway IDs. I wrote an R script to extract Reactome 
unique pathway IDs and their related Pathway names from the Bioconducter
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software BioMart. Reactome unique pathways were converted to pathway names 
to aid biological interpretation of the pathway results. Full details provided in 
Supplementary script 3.
2.6 Cytoscape
Cytoscape is an open source software platform for the integration and visualisation 
of molecular interaction networks (Cline et al., 2007). It was created at the institute 
of systems biology, in Seattle in 2002. Either version 2.7 or 2.8 have been used to 
generate protein-protein interaction network figures, proteins are represented by 
nodes and interactions represented by edges.
2.6.1 Human protein interaction network
In December 2008, Dr. R. Hyde (Sanderson Lab, University of Liverpool) constructed 
a human and interolog protein-protein interaction network, as previously published 
(Markson et al., 2009). This was based on the collation of many different human 
and interolog protein interaction databases, as yet a database containing all known 
human protein interactions does not exist. The databases are comprised of manual 
literature curation by expert biologists and direct user submissions, all are freely 
downloadable. An interolog is a predicated conserved interaction between two 
proteins that have orthologs that interact in another species. These predicted 
interactions may provide insight into the function of currently un-characterised 
human proteins.
Four human databases were used to collate the human protein interaction data; 
Molecular INTeraction Database (MINT) (Ceol et al., 2010), The Human Protein 
Reference Database (HPRD) (Keshava Prasad et al., 2009), BioGrid (Breitkreutz et al.,
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2008) and IntAct (Kerrien et al., 2007). Interoiog interaction data was collated for 
Drosophila melanogaster {D. mei), Caenorhabditis elegans (C e/e), Mas musculus 
(M. mus) and Saccharomyces cerevisiae (S. cerevisae) from MINT, BioGrid, IntAct 
with orthology calls from the NCBI tool-homologene {Sayers et al., 2009) and 
inParanoid (O'Brien et al., 2005). Combining all mined data resulted in a human and 
interoiog protein-protein interaction network with 13,101 nodes (proteins) and 
143,179 edges (interactions). All gene identifiers were converted to Entrez Gene Ids 
for standardisation throughout the analysis.
2.6.2 Myofibroblast expression networks
As all genes are not expressed in all cell types, it was important to generate a 
myofibroblast specific gene expression network, which contained all genes detected 
in this specific cell-type at a baseline level. To generate this network, an attribute 
file was produced containing a union of genes detected at baseline level 
(background) in CAM vs. ANM, CAM vs. ATM and ATM vs. ANM datasets. Attribute 
files were assembled for each experimental group, CAM vs. ATM, ATM vs. ANM and 
CAM vs. AN. Attribute files contained either differentially expressed Entrez gene IDs 
and Log fold changes or differentially expressed Entrez gene IDs and p-values. P- 
values are un-corrected for the CAM vs. ATM dataset, and FDR corrected for the 
CAM vs. ANM and ATM vs. ANM. The myofibroblast network was opened in 
Cytoscape, attribute files for each comparison group were imported and selected 
using 'old filters'. New networks of differentially expressed genes were then 
generated for each comparison group, with nodes being assigned colours according 
to the direction of log-fold change.
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2.6.2.1 'Good' and 'bad' myofibroblast expression network
As the 'good' and 'bad' patient sub-groups represent data from 4 cancer and 4 
adjacent samples, rather than the full 12, a specific gene expression network was 
also generated for this sub-set of myofibroblasts. The resulting 'good' and 'bad' 
gene expression network was produced by first compiling an attribute file 
containing a union of genes detected at a baseline level (background) of all the 
'good' and 'bad' patient prognosis backgrounds, for the CAM vs. ANM and the ATM 
vs. ANM datasets. The 'good' and 'bad' gene expression network was then 
produced exactly as the standard myofibroblast gene expression network, 
described in section 2.62. Attribute files were assembled for each experimental 
group, CAM vs. ANM, 'good' and 'bad' and ATM vs. ANM 'good' and 'bad'. Attribute 
files contained either differentially expressed Entrez gene IDs and Log fold-changes, 
or differentially expressed Entrez gene IDs and p-values. Subsequent analysis using 
Netbox required 'good' and 'bad' attribute files to be set up using official gene 
names, therefore extra attribute files were generated, containing either 
differentially expressed official gene names and log fold-changes, or differentially 
expressed official gene names and p-values. All p-values used for 'good' and 'bad' 
attribute files were FDR corrected. The myofibroblast network was opened in 
Cytoscape and attribute files for each comparison group were imported, selected 
uses 'old filters'. New networks of differentially expressed genes were generated for 
each comparison group, with nodes being colour coded according to the direction 
of Log fold change.
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2.6.3 Hypernode
Hypernode is a Cytoscape plugin designed by Dr. Russell Hyde (University of 
Liverpool). Utilising the KEGG pathway database, all human pathways and gene 
members were downloaded and utilised within the hypernode plugin. It is able to 
condense pathway genes on to 'hypernodes' if they are present in a single pathway, 
genes which are present in >1 pathway appear as nodes connecting multiple 
'hypernodes'. Datasets were uploaded into Cytoscape and visualised using the 
plugin, allowing the complex connectivity between pathways and highlighting genes 
providing the crosstalk to be visualised.
2.6.4 BiNGO
The Biological Network Gene ontology tool BiNGO™ (Maere et al., 2005) is a 
Cytoscape plugin that allows networks to be analysed for the over-representation of 
Gene Ontology (GO) annotations. Lists of genes or networks can be analysed, and 
visualised within Cytoscape as a map of hierarchical GO annotations. BiNGO™ 
results also contain a GO annotation text file, with details of input genes linked to 
over-represented GO annotations. To calculate which GO terms were over­
represented in the differentially expressed gene set, BiNGO™ requires a background 
gene list to be set. For this purpose background gene lists from individual datasets 
were assembled and uploaded into Cytoscape, enabling differentially expressed 
genes to be identified from relevant background networks prior to performing 
BiNGO™ analyses. The hypergeometric test was used to look for over­
representation of GO annotations, in differentially expressed gene sets compared to 
their individual backgrounds. For each dataset the analysis was run twice, firstly to
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visualise all GO annotations with un-corrected p-values <0.05 and then for the
visualisation of GO annotations with Benjamini-Hochberg FDR corrected p-values 
<0.05. Individually, gene lists were compiled of Entrez gene IDs falling within Go 
annotations with p-values <0.05 and GO annotations with FDR corrected p-values 
<0.05 for further analysis.
2.7 Comparison of canonical pathway analysis tools.
As initial pathway analysis was conducted in Metacore™, for each dataset, lists of 
differentially regulated genes un-mapped to pathways in Metacore™ were 
assembled. Analysis of these Metacore™ unmapped genes was then performed 
using DAVID, Reactome and Ingenuity® to provide an indication of the distinct 
advantages that each analysis tool may provide. There was a selection of genes that 
could not be mapped to a canonical pathway by any of the four toots. BiNGO's GO 
annotations, was finally used to try to provide further insight into the biological 
roles of these genes.
2.8 Epigenetics
A list of chromatin remodelling factors was manually curated from the Human 
Epigenetic Chromatin Remodelling factors RT2 Profiler™ PCR Array (SABiosciences, 
QIAGEN, Frederick, USA). These genes were combined with a list of epigenetic 
modification enzymes extracted from the Human Epigenetic Chromatin 
Modification Enzymes RT2 Profiler™ PCR Array (SABiosciences, QIAGEN, Frederick, 
USA) and a list of proteins involved in epi-microRNAs, epigenetic genes which are 
regulated by microRNAS (lorio et al., 2010). Gene names were converted into Entrez 
gene IDs using the DAVID bioinformatic gene ID conversion tool. From this,
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epigenetic attribute files were uploaded into Cytoscape and selected from the
entire Human interactome with interologs, resulting in an epigenetic network, 
allowing for the mapping of experimental data and clear visualisation of epigenetic 
changes.
2.8.1.1 'Good' and 'bad' prognosis epigenetic networks
Entrez gene ID attribute files compiled in section 2.6.2.1 for 'good' and 'bad' 
patient's differentially regulated genes were mapped onto both epigenetic 
networks. Colours of nodes represent the direction of the fold change. Within each 
experimental group, CAM vs. ANM and ATM vs. ANM, epigenetic changes seen in 
the 'good' and 'bad' patients were exported from Cytoscape and unique and 
common epigenetic changes for the 'good' and 'bad' patient prognosis groups was 
recorded.
2.9 Multivariate analysis
Multivariate analysis (MVA) was carried out with the help of statistician (Richard 
Jackson, University of Liverpool) using the R computing language environment. Full 
details of Fisher tests, matrix formation and MVA similarities based on genes or 
based on pathways, and correspondence analysis are provided in Supplementary 
scripts 4-8 respectively.
2.9.1 Pathway over-representation tests
Previously mentioned pathway analysis tools use the Fisher exact test to determine 
whether a pathway is statistically over-represented within a significantly changed 
gene set. In this study three different techniques were used to detect over­
represented pathways, or processes, within a given gene list. These include the
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Fisher exact test, and Chi-Squared tests. Below is an example of the 3x2 contingency 
table formed to carry out such statistical tests. In contrast, a 2x2 contingency table 
was formed using only a, b, d and e, not taking into account genes not in the 
background set.
Pathway
Yes No
Diff. Expressed a d
Background b e
Not in background c f
The odds ratio was thought to be a more appropriate scoring system to apply to 
define over-represented pathways;
a*e
odds ratio =------
b*d
The odds ratio takes into account the proportion of differentially expressed genes in 
a pathway to the number of non-differentially expressed (background) genes in a 
pathway. Therefore, if an odds ratio is greater than 1 the proportion of differentially 
expressed genes in a pathway is greater than the proportion of background genes in 
a pathway.
2.9.2 Matrix formation
Multivariate analysis uses a dissimilarity matrix of l's and 0's; in our case, the 
numbers identify which genes are present in which pathways. Within R, Reactome
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pathway mappings from pathway ID to Entrez gene ID was extracted from BioMart, 
though the Bioconductor website. Significantly changed gene lists and background 
gene lists were read into R; and only those genes and associated pathways 
extracted from Reactome with genes in our background lists were used in the 
analysis. The matrix was then calculated, pathways form the matrix columns and 
genes the rows, the script cycles through each gene, placing a T if the gene is 
present in the given pathway and '0' if it is absent.
2.9.3 Multivariate analysis - similarities of genes
Similarity of genes, calculates the similarities of genes based on the pathways in 
which they are present. The genes/pathways matrix includes all background and 
significantly changed genes. To reduce the amount of noise the matrix was trimmed 
to remove all genes that were present in less than two pathways and all pathways 
that had less than two significantly changed genes were also removed. Using a 
binary method, the trimmed matrix was then converted into a matrix of distances, 
based on how different the genes are to one another. A value of zero represents no 
difference between two genes and a value of 1 represents two genes which are 
identical to each other (with regards to the pathways they appear in). Hierarchal 
cluster analysis (HCA) was then conducted using the average link algorithm on the 
dissimilarity matrix. The method initially tries grouping the most similar genes into 
pairs, after which its groups the next pair of similar genes and so on until all genes 
are connected in a tree-like dendrogram. Tight clusters of genes represent a similar 
pathway representation.
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Multidimensional scaling (MDS) also uses the dissimilarity matrix, the MDS object is
created which provides a set of MDS co-ordinates to be plotted in a 2 or 3- 
dimensional space. Points on the plot represent genes, while geometrical distances 
provide a measure of dissimilarity between one another. Red points represent 
significantly changed genes and black nodes represent background genes. 
Significantly changed genes in clusters or with similar geographical positions, were 
grouped and exported from R for further analysis. Reactome pathway information 
for each group of genes was exported from the BioMart website.
2.9.4 Multivariate analysis - similarities of pathways
Similarity of pathways, calculates the similarities of pathways based on the genes 
that they include. The genes/pathways matrix only includes significantly changed 
genes. To reduce the amount of noise and identify real groups of pathways within 
the data the matrix was trimmed to remove all pathways that contain less than two 
significantly changed genes and ail genes present in less than two pathways. Using a 
binary method, the trimmed matrix was converted into a matrix of distances, based 
on how different pathways are to one another. A value of zero represents no 
difference between two pathways and a value of 1 represents two pathways, which 
are identical to each other (with regards to the genes they contain). Hierarchal 
cluster analysis (HCA) was conducted using the average link algorithm on the 
dissimilarity matrix. HCA groups pathways using the same method described in 
'similarity based on genes'. Tight clusters represent pathways with a similar gene 
makeup.
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Multidimensional scaling (MDS) also uses the dissimilarity matrix, the MDS object is
created which provides a set of MDS co-ordinates to be plotted in a 3-dimensional 
space. Points on the plot represent pathways and their geometrical distances will 
represent a measure of dissimilarity between one and other. Red points on the plot 
represent pathways with an odds ratio of 2 or greater, which are classed as over­
represented and black nodes represent pathways with an odds ratio less than 2. 
Over-represented pathways that form clusters/have a similar geographical position 
were identified and exported from R for further analysis. Entrez gene ID information 
relating to each group of pathways was then obtained from the BioMart website.
2.9.5 Correspondence analysis
Correspondence analysis is a multi-variant analysis technique, which is similar to 
multi-dimensional scaling, in that they both plot the difference between 
observation in a point in space. The difference is, multi-dimensional scaling plots 
genes or pathways, whereas, correspondence analysis allows Genes and Pathways 
to be considered at the same time and plots them both on the same set of axis. In 
this approach, clusters not only identify interesting genes but also associated 
pathways.
As previously described in MVA analysis section 2.10.1, correspondence analysis 
uses an odds ratio to define which pathways are over-represented and the 
compilation of a pathway and gene matrix. The genes/pathways matrix includes all 
background and significantly changed genes. To reduce the amount of noise the 
matrix was trimmed to remove all genes that were present in less than two 
pathways and remove all pathways that had less than two significantly changed
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genes in them. Correspondence analysis provides a set of co-ordinates to be plotted 
in a 3-dimensional space, points on the plot represent genes (red) and pathways 
(black) and their geometrical distances provides a measure of dissimilarity between 
one another. Central dense clusters were exported from R for further analysis, as 
points of potential high connectivity or cross-talk.
2.10 Netbox
Netbox is a java-based online resource, which allows the input of data onto a 
human interaction network, and use of methods to identify unique linker genes, 
network modules and the generation of random modules to statistically analyse 
global and local module connectivity (Cerami et al., 2010). They produced a human 
interaction network, curated from literature resources only. The human interaction 
network includes protein-protein interactions and signalling pathways from four 
databases, HPRD (Keshava Prasad et al., 2009), Reactome (Matthews et al., 2009), 
HCI-Nature pathway interactome database (P1D) (Schaefer et al., 2009) and MSKCC 
cancer cell map.
Linker genes are genes that themselves are not differentially expressed but which 
link two differentially expressed genes together. Statistically significant linker genes 
were identified by their global degree and their hypergeometric distribution, also 
known as the one-tailed Fisher exact test. The Benjamini Hochberg FDR correction is 
applied and those passing a P-value < 0.05 are considered statistically significant. 
The edge betweenness algorithm (Girvan and Newman, 2002) was used to detect 
modules within the network. The betweenness algorithm was first introduced in 
1977 (Freeman, 1977), as a measure of information flow through a network; an
73
edge lying on a large number of shortest paths has a large control over the
information flow of a network. This process is used to detect communities within 
networks, an edge with a high betweenness value may lie on a large number of 
shortest paths but have a low degree and therefore it may connect two areas of 
highly connected nodes or modules. The edges betweenness algorithm used here 
removes edges with a large betweenness value from the network successively. 
Modules are assigned a modularity score, using an assertive mixing algorithm 
(Newman, 2003). If the number of edges within the module is no better than 
expected by random chance then the modularity score will approach 0, while a 
modularity score of 1 indicates a highly modular network.
To assess the statistical significance of the networks modularity score, random 
simulations are run on a network of the same size, same number of nodes and 
degree distribution but a random selection of interaction partners. The time (0) the 
algorithm takes to run is based on the formula: 0 (mn) (Newman, 2001), were m is 
the number of edges and n is the number of nodes in the network. The algorithm 
needs to be re-run after every edge is removed, so a worst time of 0 (m2n) is 
predicted. As this algorithm is immensely time consuming, the need to produce 
1000 random simulations becomes impractical, instead 100 random simulations are 
run. The modularity score of the network is then altered to take into account the 
random re-wired network and a scaled modularity score given, known as the z 
score. The z score is calculated by taking the modularity score for the actual 
network, deducting the modularity score for the random network and then dividing
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by the standard deviation of the random re-wired network. (Wang and Zhang,
2007).
2.10.1 Settings and command script
Netbox was downloaded from http://cbio.mskcc.org/tools/netbox.html. unzipped 
and added as an environment variable to the Netbox directory. Configuration files 
were set up for CAM vs. ANM, CAM vs. ATM, ATM vs. ANM, CAM vs. ANM ('good' 
and 'bad' separately), and ATM vs. ANM ('good' and 'bad' separately). Within 
configuration files, the shortest path threshold was set as 2, thus allowing 
differentially regulated genes to be indirectly connected by statistically significant 
linker genes. The p-value threshold for linker genes to be added to the network was 
<0.05.
The following code was run in the computers command prompt:
C;\> cd netbox 
C:\netbox> cd gbm_data
C:\netbox\gbm_data C:\Python27\pytbon.exe c:\netbox\bin\netAnaiyze.py 'name 
of configuration file' -i
The -i allows the linker p-value to be varied within the configuration file, before 
producing a network. Network sif files were uploaded into Cytoscape, modules 
were genes categorised into a certain module are identified using modulues.txt 
attribute files and linker nodes distinguishable from differentiated genes by 
uploading the node_type.txt attribute files.
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2.11 Identification of previous un-assigned genes
After pathway analysis, in Metacore™, DAVID, Reactome, and Ingenuity® many 
differentially regulated genes are still unassigned to canonical pathways. As there is 
no pathway information for these unmapped genes, we wanted to try to 
understand what these genes are involved in, and how they relate to the 
significantly over-represented pathways. Although unmapped genes are not 
mapped to canonical pathways we screened the NetBox network to see if any 
unmapped genes had been assigned to modules or connect modules by interacting 
with members of multiple modules. This is important to our understanding of the 
roles the differentiated unmapped genes may play, as modules are believed to 
represent functional modules/biological organisation within the cell (Hartwell et al., 
1999).
2.12 Correlation analysis
Through collaboration with statistician Richard Jackson (University of Liverpool), we 
were able to perform correlation analyses to look at the relationship between the 
fold change of genes and patient prognosis scores. Outside of R, for the un-paired 
datasets, CAM vs. ANM and ATM vs. ANM, the arithmetic mean of all absolute 
normal samples was calculated and this value was used to calculate individual 
patient log fold changes. Within R, correlation analysis was performed using 
Supplementary scripts 9-11, a separate script for each of the datasets. CAM vs. AN, 
ATM vs. ANM and CAM vs. ATM datasets of individual patient logged intensities 
were opened in R. Individual patient log fold-changes were calculated for each 
Entrez gene ID. As multiple probes map to a single gene, there are a select number
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of duplicate genes in the dataset, the average log FC was then taken for such genes. 
Patient prognosis scores are read into R and two different types of correlation 
analysis was calculated. Spearman's correlation uses the ranked prognosis scores 
and Pearson's correlation uses the actual prognosis scores. Genes that are highly 
correlated with prognosis have values close to +/-1, which represent genes that are 
either positively or negatively correlated with prognosis. In this analysis, a positive 
correlation represents a gene with a larger fold change in patients with worse 
prognosis scores, whilst a negative correlation represents a gene with a smaller fold 
change in patients with worse prognosis scores. Data was visualised as heapmaps 
generated in R. A series of different correlation analysis thresholds were applied to 
select the optimum correlation threshold for each dataset. In addition, a box plot 
was generated for each dataset within R, in order to display the variance of the log 
fold-changes for each gene for individual patients and a plot of prognosis score vs. 
log fold change for every gene and patient.
2.13 T-Test
Through collaboration with statistician Richard Jackson (University of Liverpool), 
genes that have statistically significant difference in expression levels between 
'good' and 'bad' patient sub-groups were identified. Outside of R, as the 'good' and 
'bad' sets are generated from the un-paired CAM vs. ANM dataset, as before, the 
arithmetic mean of all absolute normal samples was calculated and this value was 
used to calculate each individual patient log fold-change.
Within R, a t-test was performed to test the statistical difference between the 
'good' and 'bad' log fold-changes for each gene was applied using the script
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provided in Supplementary script 12. The logged intensity values of all cancer 
samples for the 'good' and 'bad' sets and absolute normal patient arithmetic means 
were opened in R. Individual patient log fold-changes were calculated for each 
Entrez gene ID. As multiple probes map to a single gene, there are a select number 
of duplicate genes in the dataset, the average log fold-change was then taken for 
such genes. The individual patient samples were annotated as 'good' or 'bad' and a 
T-Test was run to identify genes with statistically different fold change in expression 
in the 'bad' and 'good' sets. Lists of genes with statistically different expression 
profiles were assembled at three different p-value thresholds, p<0.05, p<0.01 and 
p<0.005 and visualised using heat maps.
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3 Chapter Three: Comparative gene expression profiling
3.1 Introduction
The primary aim of this study was to develop a better understanding of how 
myofibroblasts derived from the site of gastric tumours or adjacent tissue may be 
changed relative to normal gastric myofibroblasts. By defining changes in gene 
expression patterns for myofibroblasts derived from a range of patients with 
varying prognostic scores we aimed to identify gene signatures, which may relate to 
different stages of tumour development and/or 'good' vs. 'bad' patient prognostic 
groups. In addition, we wished to use pathway enrichment methods to provide 
insight into the molecular processes that are changed in CAMs as opposed to ANMs.
3.2 Isolation and characterisation of primary 
myofibroblast cell lines
Details of the isolation and characterization of primary human gastric 
myofibroblasts that were used to generate microarray data for this study are 
described in Holmberg et al. (2012). In brief, human primary myofibroblasts were 
isolated from resected gastric tumours (CAMs) or matched adjacent tissue (ATMs) 
by Dr Peter Hegyi, (Department of Medicine, University of Szeged, Hungary), 
following protocols described by (Wu et al., 1999). Absolute Normal Myofibroblasts 
(ANMs) were isolated from deceased transplant donors with normal gastric 
morphology. Figure 3.1 (taken from Holmberg et al 2012) shows examples of 
changes in myofibroblast numbers and tissue architecture in tissues from which 
CAMs, ATMs or ANMs were derived. To ensure that all tissues from which CAM, 
ATM and ANM samples were purified had expected and consistent tissue profiles
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myofibroblast morphology, abundance and tissue architecture were quantified 
(Figure 3.ID).
Figure 3.1 Representative images of tissues from which ANMs (A), CAMs (B) or ATMs (C) were 
isolated. Brown stain shows localization and relative abundance of myofibroblasts in each 
tissue. D) Quantification of myofibroblast morphology, architecture and number in cancer, 
adjacent and normal tissues. * ANOVA, p<0.05 CAM vs. ATM, CAM vs. ANM. From Holmberg 
et. al. Carcinogenesis 33:1553 (2012)
All tissue samples were scored for myofibroblast morphology (0 = normal, 1 = mildly 
distorted or 2 = severely distorted) and tissue architecture (0 = myofibroblasts 
restricted to periglandular or subepithelial localisation, 1 = myofibroblasts located 
in periglandular and sub-epithelial regions and elsewhere in the interstitium or 2 = 
severe architectural damage with meshwork-like appearance). In addition, 
myofibroblast numbers were also scored as 0: similar to normal tissue, 1: mild to 
moderately increased or 2: substantially increased.
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To confirm that isolated primary human gastric myofibroblasts retained
characteristic morphology, markers and function of each cell line was tested to 
confirm the presence of a spindle/stellate morphology and strong co-expression of 
the two canonical myofibroblast markers, vimentin and aSMA (Figure 3.2). In 
addition, all CAMs were tested to ensure that they retain the ability to induce the 
migration and proliferation of the AGS gastric cancer cell line (Figure 3.3). Data 
from these studies confirm that at the time at which RNA was prepared from 
primary gastric myofibroblasts they maintained all of the hallmarks that have been 
used to define this cell type in other tissues.
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Figure 3.2 Fluorescence images showing strong coexpression of the 
myofibroblast markers vimentin and a-SMA in isolated primary human CAMs, 
ATMs and normal tissue myofibroblasts NTMs. From Holmberg et. al. 
Carcinogenesis 33:1553 (2012)
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Figure 3.3 Isolated human gastric CAM cell lines retain an ability to induce migration and 
proliferation of AGS gastric cancer cells. (A) Increased migration of CAMs compared with ATMs 
and NTMs (left) in Boyden chambers, and individual pair-wise comparisons of CAMs versus their 
corresponding ATMs (right). (B) Individual pair-wise comparison of BrdU labeling and cleaved 
caspase-3 staining in CAMs versus their corresponding ATMs. Data taken from Holberg et. al 
Carcinogenesis 33:1553 (2012).
Following isolation, myofibroblasts were cultured as described previously (McCaig 
et al.2006), before being processed for transcriptional profiling always less than 
passage 7. In each case cells were grown to 80% confluence before being harvested 
and processed for RNA isolation. Due to the number of samples being investigated 
myofibroblasts were processed for microarray analysis in batches as indicated in the
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Table 3.1.
CAM Label Sample Batch date ATM Label Sample Batch date
1-CAM Sz42/1 P5 09/04/2008 1-ATM Sz42/2 PS 04/09/2008
2-CAM Sz45/1 P5 27/11/2007 2-ATMA Sz45/2 PS 29/11/2007
2-ATMB Sz45/22 PS 11/07/2008
3-CAM Sz190/1 P4 09/04/2008 3-ATM SZ190/2 P4 27/11/2007
4-CAM Szl92/1 PS 27/11/2007 4-ATM Sz192/2 P5 18/12/2007
5-CAM SZ194/1 P5 29/11/2007 5-ATM Sz194/2 P5 04/09/2008
7-CAM Sz198/1 P5 29/11/2007 7-ATM Sz198/2 PS 20/02/2008
8-CAM SZ268/1 P5 18/12/2007 8-ATMA Sz268/2 PS 15/04/2008
8-ATMB Sz268/22 P5 15/04/2008
9-CAM SZ271/1 P5 18/12/2007 9-ATM Sz271/2 PS 15/04/2008
10-CAM Sz294/1 P4 09/04/2008 10-ATMA Sz294/2 PS 02/05/2008
10-ATMB Sz294/22 P4 02/05/2008
11-CAM Sz305/1 P5 20/02/2008 11-ATM B SZ305/22 PS 20/05/2008
12-CAM Sz308/1 P5 09/04/2008 12-ATM Sz308/22 P6 20/05/2008
13-CAM Szl87/1 P8 20/02/2008
14-CAM Sz197/1 P5 20/02/2008
15-CAM SZ389/1 P7 15/04/2008 15-ATM Sz389/2 P7 12/04/2009
AN Label Sample Batch date AN Label Sample Batch date
21-ANMA Szl96/2 09/04/2008
22-ANMB Sz241/22 P6 20/06/2008
23-ANMA Sz246/2 P6 20/06/2008
23-ANMB Sz246/22 P6 20/06/2008
24-ANMA Sz261/2 P6 20/06/2008
24-ANMB Sz261/22 P6 20/06/2008
25-ANMA Sz279/22 P4 20/06/2008
26-ANMA Sz334/2 P5 10/07/2008
26-ANMB Sz334/22 P5 10/07/2008
27-ANMA Sz351/2 P5 10/07/2008
27-ANMB SZ351/22 PS 10/07/2008
28-ANM 845 P7 10/07/2008
TableS.l Cancer Associated Myofibroblasts (CAM), Adjacent Tumour Myofibroblast (ATM) and 
Absolute Normal Myofibroblasts (ANM) displaying associated Affymetrix batch dates.
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3.3 Data analysis
3.3.1 Preliminary assessment of data quality
Affymetrix arrays were run and initially assessed for technical quality within the 
Liverpool Genome Research Centre (GRC) by Dr Lucille Rainbow. These arrays 
included spike-in hybridisation controls, which are used to assess the quality of the 
hybridisation process. Within the GRC BioB, BioC, BioD and CreX probes are used as 
internal controls to assess consistency and efficiency of hybridisation across 
Affymetrix arrays. Significantly, no array data is released from the GRC unless these 
quality controls are met. ANM example of the consistency of probe intensities 
across a selection of arrays is shown in Figure 3.4
Hybridisation control probes
Figure 3.4 Data from quality control tests suggest good quality hybridisation across all 
experiments. The normalised signal intensities of hybridisation control oligonucleotides for 
each microarray, shown as a red line, were comparable across all experiments. Data 
generated in the Varro lab (University of Liverpool).
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3.3,2 Further detailed analysis of data quality
A range of quality control procedures are commonly used to identify, or exclude 
variability arising from sample preparation, processing, technical errors or extreme 
biological outliers. Experimental or batch variation may result from slight 
differences in technical procedures including RNA extraction, amplification, RNA 
degradation, probe-labelling, hybridization etc. In contrast, biological outliers may 
be indicative of contamination, incorrect sample labelling or unexpected 
abnormalities in the sample being studied. Determining the quality of the data is an 
essential first step, which is routinely performed prior to normalisation. Several 
methods of normalising Affymetrix microarray data have been widely used in the 
literature. Common examples include the RMA and Mas5 (Hubbell et al., 2002; 
Irizarry et al., 2003b; Pepper et al., 2007). In the RMA normalisation method data is 
quantile normalised (Irizarry et al., 2003c). This involves taking the average 
intensities of all probes across all chips, therefore a poor array would potentially 
skew the whole dataset, if it were not identified and removed. In contrast, in the 
MasS normalisation method each chip is independently and sequentially analysed 
and linear regression methods are then used to re-scale each chip to its total 
intensity (Hubbell et al., 2002). Although in the MasS method data from good 
quality arrays would not be directly affected by one or more poor quality arrays, 
normalisation without prior removal of poor quality arrays could result in artificial 
differential gene expression profiles.
To facilitate the identification and removal of poor quality array data, several 
different packages have been developed, including the open access Bioconductor
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package, which utilises the R computing language to perform Array Quality Metrics 
(AQM) analyses. The AQM output report provides a range of different quality 
metrics, which together provide an assessment of the quality, intensity 
distributions, variance of the mean dependency, together with a range of 
Affymetrix specific plots (Kauffmann et al., 2009; Kauffmann and Huber, 2010), 
which enable the quality of data from individual arrays to be assessed and 
compared. To assess the quality of data from microarrays used in this study un­
normalised CEL file data for all 39 samples, from cancer, adjacent or absolute 
normal myofibroblasts were analysed using the AQM package. The AQM package 
labels the arrays from 1-39 as shown in Tables.2.
Array Patient Label Array Patient Label
1 3-CAM 21 12-CAM
2 4-CAM 22 12-ATM
3 4-ATM 23 11-CAM
4 7-CAM 24 11-ATMB
5 7-ATM 25 . 2-CAM
6 1-CAM 26 22-AIMMB
7 13-CAM 27 23-ANMA
8 14-CAM 28 23-ANMB
9 1-ATM 29 24-ANMA
10 3-ATM 30 24-ANMB
11 5-CAM 31 25-ANMA
12 5-ATM 32 26-ANMA
13 9-CAM 33 26-ANMB
14 9-ATM 34 27-ANMA
15 8-CAM 35 2-ATMA
16 8-ATMA 36 27-ANMB
17 8-ATMB 37 28-ANM
18 10-CAM 38 15-CAM
19 10-ATMA 39 15-ATM
20 10-ATMB
Table 3.2. AQM re-labeiling of patient samples 1-39, to be used in combination with subsequent 
quality metric plots.
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3.3.2.1 Individual array quality
A common method for visualizing the distribution of data on an array is to generate 
an MA plot of the data, where (M) is a ratio of the probe intensity divided by the 
average intensity across all arrays and (A) represents the average log intensities 
across arrays. The purpose of an MA plot is to investigate intensity bias, ideally we 
would expect the majority of intensities (plotted along the M=0 axis) to be 
distributed at the lower end of A. If the majority of points were distributed above or 
below 0, this could represent a problem with data quality. MA plots of the four best 
and worst arrays are displayed in Figure 3.5. Arrays were numbered from 1-39 for 
the AQM report, therefore array numbers represent the following patients; array 29 
(24 ANA), array 26 (22 ANB), array 27 (23 ANA), array 4 (7 CAM), array 12 (5 ANA), 
array 18 (5 ANA), array21 (12 CAM), array6 (1 CAM). Across the worst arrays, there 
are slight banana shape trend across M (e.g. arrays 27 and 4), indicating the need 
for further normalisation. Generally, arrays with intensities above zero may 
represent increased background noise.
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Figure 3.5 MA plots of the four worst (upper panels) and four best plots. M (y-axis) is computed by 
dividing the intensity by the median intensity of the same probe across all arrays and the A (x-axis) 
represents the mean of their logarithms. Arrays were numbered from 1-39 for the AQM report, 
representing the following patients; array 29 (24 ANA), array 26(22 ANB), array 27(23 ANA), array 4(7 
CAM), array 12(5 ANA), array 18(5 ANA), array21 (12 CAM), array 6 (1 CAM).
Arrays can also be visualised using spatial distributions of feature intensities (Figure 
3.6). Again Spatial representations of the four best and four worst arrays are 
displayed, with arrays numbered from 1-39 within the AQM report, where array 
numbers represent the following patients; array 8 (14 CAM), array 3 (4 ATM), array 
9 (1 ATM), array 2 (4 CAM), array 30 (24 ANMB), array 37 (28 ANM), array38 (15 
CAM) and array35 (2 ANMA). This type of visualisation allows the easy identification 
of spatial effects such as air bubbles or printing problems, an obvious example of 
which is shown in Figure 3.7. Although array 8 (14CAM) was determined as an 
outlier, visually the array does not display any obvious spatial defects compared to 
other high-quality arrays.
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Figure 3.6 Spatial representations of the four worst (upper panels) and four best arrays. Arrays 
shown above show results obtained from analysis of the following biological samples; array 8 (14 
CAM), array 3 (4 ATM), array 9 (1 ATM), array 2 (4 CAM), array 30 (24 ANMB), array 37 (28 ANM), 
array38 (15 CAM) and array35 (2 ANA). Based on the distribution of the values across all arrays, an 
outlier threshold of 0.0851 was determined, which array 8 (14 CAM) exceeded.
Figure 3.7 An example of the kind of spatial defects that can occur due to the presence of an air 
bubble during processing. This image is not taken from an array utilized in this study.
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3.3.2.2 Array Intensity Distributions
To assess consistency of probe intensity levels between arrays, boxplots and density 
plots were analysed. Boxplots for all 39 arrays are displayed in Figure 3.8A. In these 
plots boxes represent the interquartile range (lower quartile, median (centre line) 
and the upper quartile), while the whiskers represent the minimum and maximum 
intensities not considered to be outliers (Mcgill et al., 1978). Arrays that show 
consistency should have similar width and position along the x-axis, arrays with 
shifted positions or elongated widths may represent outliers or poor quality data. 
The Kolmogorov-statistic method was performed to identify statistical outliers 
(Figure 3.8B), Using this approach to analyses data from all arrays, a threshold of 
1.65 was deemed to be the value that indicated an outlier. None of the arrays 
exceeded this threshold and therefore, none of the arrays analysed were 
considered to be statistically significant outliers.
Density plots are smoothed histograms, in which the majority of intensities are 
expected to be clustered around the smaller range, tailing off towards larger values. 
In this analysis, background noise would be seen as a shift in the distribution of the 
histogram towards the right, whereas small humps in the right-hand-side tail would 
represent saturation effects. Neither of these effects was observed in any of the 
plots from the 39 arrays used in this study (Figure 3.8C). Therefore, this data 
together with data from boxplot analysis indicate that there are no obvious outlying 
arrays.
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[Figure 3.8 A) Displays intensity distribution boxplots of all 39 arrays analysed in this study. B) Bar 
chart representing the Kolmogorov-statistic analysis for outlier detection. (Ka) Based on all the 
arrays, a threshold of 1.65 was deemed the value indicating an outlier. None of the arrays analysed 
in this study exceeded this threshold. C) Density plots (smoothed histograms) for all 39 arrays.
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3.3.2.S Between Array Comparisons
Hierarchical clustering and principal component analysis (PCA) methods are 
routinely used to identify arrays; or samples that are significantly different from one 
another. The Heatmap shown in Figure 3.9A represents the similarity between ail 
39 arrays analysed in this study, this analysis identifies two arrays (array 38 = 15 
CAM and 39 = 15 ATM) as outliers. In addition, principal component analysis (Figure 
3.9C) of this data identifies arrays 38 (15 CAM) and 39 (15 ATM) as being distinct 
from the remaining 36 arrays. These samples represent cancer and adjacent 
samples from the same patient (15). Although these samples have different batch 
dates (Table 3.1), these two microarray were carried out a year later than the other 
samples, therefore batch effects cannot be ruled out.
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AFigure 3.9 A) A false colour heat-map showing the similarity between all 39 arrays. The colour scale 
on the left hand side represents the relative similarity with blue representing similar arrays whilst 
yellow represents least similar arrays. Outliers are identified by an asterisk. B) Bar chart representing 
the absolute mean distance between all arrays (Sa), computed by calculating the mean difference 
between every set of probes between two arrays. Arrays 38 (15 CAM) and 39 (15 ATM) were defined 
as outliers, as their sum of distances to all arrays is exceptionally large with bars exceeding the 
vertical black threshold. These samples are highlighted via an asterisk in (A). C) First two dimensions 
of principle component analysis visualising the similarity between arrays. Previous outlying arrays 
are outlined by dashed circles; array 38 (15 CAM) in red and array 39 (15 ATM) in purple.
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3.3.2.4 Variance Mean Dependency
In variance mean dependency analyses the variance of intensities is plotted against
the ranked mean of intensities (Figure 3.10). In this type of analysis, larger
variations are often associated with larger intensities; therefore, a slight increasing
trend in the line is expected, however the smaller the trend the greater the
probability that normalisation may correct for any variability in data quality. As the
trend is not strong even before normalisation, we are confident that there is no
inherent bias towards intensities at either end of the spectrum in primary data used
in this study.
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Figure 3.10 Standard deviation for each feature on the array plotted against the mean of intensities, 
ranked from low to high. Red points represent the medium of the standard deviations.
3.3.2.5 Aflymetrix Specific Plots
The final part of the AQM analysis provides a range of Affymetrix specific plots, 
showing relative log expression, normalised un-scaled standard error, RNA 
degradation and Perfect-match (PM) / Miss-match (MM) density distribution.
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Logging data allows an easier comparison to be made between arrays. The relative 
log expression for each of the 39 arrays is displayed in Figure 3.11A. Generally, the 
boxes should have a similar spread and be centred around zero. However, array 8 
(14 CAM), 38 {15 CAM) and 39 (15 ATM) exceeded the Kolmogorov-statistic 
threshold in this analysis and therefore appear to be outliers. Feature intensities as 
shown in Figure 3.11B also identified array 8 (14 CAM) as an outlier, although the 
array didn't display any obvious spatial effects. In combination with these feature 
intensities the variation in array intensities do not seem to be related to 
experimental errors. As these samples are derived from different individuals, and 
different gastric regions, we may expect to see a reasonable amount of biological 
variation between these samples. The scaled un-normalised standard errors (NUSE) 
for every array are shown in Figure 3.11C. The NUSE visualises the standard error of 
each probe sets MM>PM rate. In particular, arrays are normalised to account for 
the variability between chips and are adjusted so that the medians centre around 
one. Therefore, the greater the deviation from one the lower the array quality. In 
this analysis arrays 7 (13 CAM), 8 (14 CAM), 38 (13CAM) and 39 (13ATM) are 
defined as outliers. Therefore apart from array 7 (13 CAM), reassuringly the results 
obtained from the relative log expression and the normalised un-scaled standard 
error plots all agree with each other. Array 7(13 CAM) has performed well and has 
not been defined as an outlier within any of the other analytical techniques within 
the array quality control report. Furthermore, it is the least dramatic outlier within 
the NUSE plot. Therefore this sample was not excluded from subsequent analysis.
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Figure 3.11 Relative log expression for each of the 39 arrays. (A) Boxplots of individual arrays, boxes' 
represent the inter-quartile range, while whiskers represent the minimum and maximum intensities 
in each case. Arrays marked with an asterisk are considered outliers. (B) Bar chart representing the 
Kolmogorov-statistic for outlier detection. Based on all the arrays, a threshold of 0.0895 was deemed 
the value indicating an outlier. Arrays 8 (14 CAM), 38 (15 CAM) and 39 (15 ATM) exceeded this 
threshold and were considered outliers. (C) Normalised un-scaled standard errors represents the 
standard error of each probe sets MM>PM rate. Standard errors are normalised by adjusting the 
medians to centre around one. Arrays highlighted with an asterisk are considered outliers. (D) 
Outlier detection was computed using the 75th quantile of standard error. Based on the distribution 
of all of the arrays, a threshold of 1.1 was determined and arrays 8, 38 and 39 were considered 
outliers.
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3.3.Z.6 RNA Degradation and PM/MM Analysis
RNA degradation analysis plots the ordered probe sets by location relative to the 5' 
end of the target molecule against the mean intensity, based on probe location. As 
RNA is more often degraded from the 5' end (Dublin et al., 2000b), reduced 
intensities are often reported for the 5; end rather than the 3' end. This is 
identifiable as an increasing slope, with steeper slopes indicating a greater degree 
of degradation. All of the 39 arrays show encouragingly similar patterns/amounts of 
RNA degradation, array 38 (15CAM) and 39 (15ATM), as highlighted by the upper 
two lines, show slightly more, but not statistically more RNA degradation (Figure 
3.12). Therefore, RNA degradation does not seem to be a significant problem in the 
samples used in this study.
Perfect-match (PM) and mismatch (MM) density distribution plots are shown in 
Figure 3.13. As expected, the density estimates of the PM intensities are shifted to 
the right, reflecting a greater degree of hybridisation, in comparison to MM probes, 
which are designed to detect non-specific binding. As the expected hybridisations 
have resulted from the appropriate probe type, we are confident that the probe 
sets are correctly detecting appropriate sequences. Together, the RNA degradation 
plot and the PM/MM density distribution plot display trends that are associated 
with good hybridisation/RNA quality.
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Figure 3.12 RNA degradation plots for all 39 arrays, with each line reflecting a single chip. Probe sets 
are ordered by location relative to the 5' end of the target molecule (X axis) while mean intensity 
values of probe sets within a given location on the chip (Y axis). The two top slopes (highlighted with 
stars) represent array 38 (15 CAM) and 39 (15 ATM).
log(lntensity)
Figure 3.13 PM/MM density distribution plot (smoothed histogram). Density estimate of intensities 
of PM probes are shown in blue and density estimate of intensities of MM probes are shown in grey. 
MM probes are expected to have poorer hybridisation than the PM probes and therefore shifted to 
the right.
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3.3.3 Preliminary Principal Component Analysis
The Partek® informatics software was used to perform principal component analysis 
(PCA) in order to compare global gene expression signatures for all cancer (CAM), 
adjacent (ATM) and absolute normal (ANM) myofibroblast cell lines (Figure 3.14). In 
all PCAs performed in this study, cancer samples are shown in RED, adjacent 
myofibroblasts in BLUE and absolute normal samples in GREEN.
Before batch correction two samples did not cluster with their respective 
myofibroblast types, as indicated by dashed circles in Figure 3.14. Absolute normal 
sample Sz241/2, fell within the cancer and adjacent myofibroblast samples, whilst 
the adjacent sample Sz45/22 was closely associated with absolute normal samples. 
Following batch correction each of these samples was found to distribute with their 
appropriate myofibroblast groups (Figure 3.14B). However, as microarray data was 
generated on >3 different dates (Table 3.1), it was recommended (Dr J. Puthen, 
Cancer Biostatistics unit, UoL) that patient correction rather than batch correction 
methods would be more appropriate for this particular analysis. Regardless of the 
two outliers highlighted in Figure 3.14A, PCA of corrected data shows clear 
separation between ATM, CAM and ANMs (Figure 3.14B).
99
Figure 3.14 Principal component analysis of all CAM (RED), ATM (BLUE) and ANM (GREEN) patient 
samples. (A) Un-corrected (B) Batch corrected. Two clear outliers are indicated by dashed circles. 
Also, samples labelled 15 CAM and 15 ATM were identified as outliers by Array Quality Metrics,
Samples identified as potential outliers by AQM analysis [38 (15CAM) and 39 (15 
ATM)] do appear to be different from other CAM or ATM cell lines, yet both still 
segregate with the correct myofibroblast subgroup (samples outlined in Figure 
3.14). While these differences were noted these samples were not removed as they 
still show distinct similarity to the correct myofibroblast populations. As global gene 
expression profiles for CAMs and ATM cells appeared to be very similar, a separate 
round of RCA was conducted on just CAM and ATM samples. Figure 5.15A, B & C 
show uncorrected RCA results, with cage ellipsoids showing sub-group boundaries, 
with an x-axis rotation being shown in Figure 3.15C. Similar to previous RCA analysis 
there is little distinction between CAMs and ATMs. Although, it is interesting to note 
that CAMs always distribute near to their associated adjacent samples (Figure 
3.16A), indicating that patient specific gene expression profiles are more similar 
than myofibroblast sub-type expression profiles.
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X-axis rotation of the PCA plot shown in Figure 3.16B shows that sample Sz45/22 
does not segregate close to its CAM or other ATM sample. This evidence supports 
the previous PCA analysis performed on all CAM, ATM and ANM samples in which 
sz45/22 clustered with ANM samples, rather than with other ATM samples. 
Therefore, ANM sample Sz241/2 and ATM Sz45/22 were removed before 
performing further analysis so as not to impair identification of robust subtype 
specific gene expression signatures.
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Figure 3.16 Principal component analysis of CAM (RED) and ATM (BLUE) samples. Plots represent 
zoomed and annotated versions of PCA plots from Figure 5.2A. (A) Patient pairs identified (B) 
Rotation on the x-axis reveals position of patient label 2, 2A and 2B, relating to samples Sz45/1, 
Sz45/2 and Sz45/22.
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3.3.4 Secondary Principal Component analysis
Figure 3.17 shows RCA analysis of CAM vs. ANM samples and ATM vs. ANM samples 
(following removal of normal sample Sz241/2 and adjacent sample Sz45/22), before 
and after batch correction. Without batch correction, CAM and ATM gene 
expression profiles are clearly distinguishable from ANM gene expression profiles. 
Although global gene expression profiles of CAM and ATM samples are more similar 
(Figure 3.18A&B), patient pairs correction improves separation of the two types of 
myofibroblast (Figure 3.18C&D).
Figure 3.17 Principal component analysis of (A) Un-corrected CAM (red) and ANM (green) samples. 
(B) Batch corrected CAM (red) and ANM samples (green) (C) Un-corrected ATM (blue) and ANM 
(green) samples (D) Batch corrected ATM (blue) and ANM (green) samples.
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Figure 3.18 Principal component analysis of CAM (red) and ATM (blue) samples. Panels A and B show 
un-corrected data while panels C and D show patient-pair corrected data. Cages represent ellipsoids, 
which depicts the spread of the data based on the centre of origin.
3.3.5 Comparison of gene expression profiles in different
myofibroblast populations following Mas5 normalisation of 
microarray data
To compare changes occurring in CAM and ATMs, three datasets were normalised 
by the Mas5 method before being compiled for pairwise comparisons: CAM vs. 
ANM (Table 3.3A), CAM vs. ATM (Table 3.3B) and ATM vs. ANM (Table 3.3C).
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A
CAM vs. ANM
Cancer Absolute normal
Label Sample Label Sample
1-CAM Sz42/1 P5 22-ANA Sz241/2 P6
2-CAM Sz45/1 P5 22-ANB Sz241/22 P6
3-CAM Szl90/1 P4 23-ANA Sz246/2 P6
4-CAM Szl92/1 P5 23-ANB SZ246/22 P6
5-CAM Sz194/1 P5 24-ANA SZ261/2 P6
7-CAM Sz198/1 P5 24-ANB SZ261/22 P6
8-CAM Sz268/1 P5 25-ANA SZ279/22 P4
9-CAM Sz271/1 P5 26-ANA Sz334/2 P5
10-CAM Sz294/1 P4 26-ANB Sz334/22 P5
11-CAM Sz305/1 P5 27-ANA Sz351/2 P5
12-CAM Sz308/1 P5 27-ANB Sz351/22 P5
13-CAM Szl87/1 P8 28-AN 845 P7
14-CAM Szl97/1 P5
15-CAM Sz389/1 P7
B
CAM vs. ATM
Cancer Adjacent
Label Sample Label Sample
1-CAM Sz42/1 P5 1-ATM Sz42/2 P5
2-CAM Sz45/1 P5 2-ATMA Sz45/2 P5
3-CAM Sz190/1 P4 2-ATMB Sz45/22 P7
4-CAM Sz192/1 P5 3-ATM SZ190/2 P4
5-CAM Sz194/1 P5 4-ATM Szl92/2 P5
7-CAM Szl98/1 P5 5-ATM Szl94/2 P5
8-CAM Sz268/1 P5 7-ATM Szl98/2 P5
9-CAM SZ271/1 P5 8-ATMA Sz268/2 P5
10-CAM Sz294/1 P4 8-ATMB Sz268/22 P5
11-CAM Sz305/1 P5 9-ATM Sz271/2 P5
12-CAM Sz308/1 P5 10-ATMA Sz294/2 P5
15-CAM Sz389/1 P7 10-ATMB Sz294/22 P4
11-ATMB Sz305/22 P5
12-ATM Sz308/22 P6
15-ATM Sz389/2 P7
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c
ATM vs. AN
Adjacent Absolute normal
Label Sample Label Sample
l-ATM Sz42/2 P5 22-ANMA Sz241/2 P6
2-ATMA Sz45/2 P5 22-ANMB Sz241/22 P6
2-ATMB Sz45/22 P7 23-ANMA Sz246/2 P6
3-ATM Sz190/2 P4 23-ANMB Sz246/22 P6
4-ATM Sz192/2 PS 24-ANMA Sz261/2 P6
5-ATM Sz194/2 PS 24-ANMB Sz261/22 P6
7-ATM Szl98/2 PS 25-ANMA Sz279/22 P4
8-ATM A Sz268/2 PS 26-ANMA Sz334/2 PS
8-ATMB Sz268/22 PS 26-ANMB Sz334/22 PS
9-ATM Sz271/2 PS 27-ANMA Sz351/2 PS
10-ATMA Sz294/2 PS 27-ANMB Sz351/22 PS
10-ATMB Sz294/22 P4 28-ANM 845 P7
ll-ATMB Sz305/22 PS
12-ATM Sz308/22 P6
15-ATM Sz389/2 P7
Table 3.3 (A) CAM vs. ANM dataset. (B) CAM vs. ATM dataset, Patient samples sz45/l, sz268/l and 
sz294/l, were used twice for statistical analysis. (C) ATM vs. ANM dataset.
3.3.5.1 Compiling background and differentially expressed gene 
lists
For this study background oligonucleotides were defined as all probes detected at 
or above baseline levels. Therefore, for oligonucleotides to be defined as present in 
our datasets a 'P' flag must be present in 100% of patients from either or both of 
the comparison groups. Numbers of oligonucleotides identified as background 
oligonucleotide probe IDs for each dataset are listed in Table 3.4. Student T-Tests 
were used to define background oligonucleotides that were differentially expressed 
in each comparison. For the CAM vs. ANM dataset, an unpaired student T-test was 
performed on 14 cancer samples vs. 12 absolute normal samples (Table 3.3A). For 
the ATM vs. ANM dataset, an un-paired student T-Test was performed on 15
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adjacent samples and 12 absolute normal samples (Table 3.3C). For the CAM vs. 
ATM dataset, as patients sz45, sz268 and sz294, had a single CAM but two ATM 
samples, CAM sample was used twice for statistical analysis and a paired student T- 
Test was performed on the 15 CAM and 15 ATM samples (Table 3.3B).
CAM vs. ANM Affymetrix IDs Entrez gene IDs
Background detected 19,251 10667
Significantly changed P-value<=(0.05) 2958 2277
Significantly changed P<=(0.05) and >2FC 325 246
CAM vs. ATM Affymetrix IDs Entrez gene Ids
Background detected 18,994 10,723
Significantly changed P-value<=(0.05) 2364 1850
Significantly changed P<={0.05) and >2FC 67 48
ATM vs. ANM Affymetrix IDs Entrez gene IDs
Background detected 19,452 10,765
Significantly changed P-value<=(0.05) 5357 3830
Significantly changed P<=(0.05) and >2FC 600 431
Table 3.4 Background and differentially regulated gene lists for each dataset showing efficiency of 
conversion of Affymetrix IDs to Entrez gene IDs,
Within the CAM vs. ANM and ATM vs. ANM datasets, oligonucleotides with 
Benjamini-Hochberg FDR corrected p-values < 0.05 were considered to be 
differentially expressed. Whist for the CAM vs. ATM datasets, un-corrected p-values 
<0.05 were considered to be differentially expressed. Finally, the log fold-change 
was calculated to determine whether differentially expressed oligonucleotides were 
over or under-expressed. Oligonucleotides were classified as differentially 
expressed if they had a p-value < 0.05. Initially no fold change cut-off was applied 
in order to assess the potential effect that multiple small but significant changes in
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gene expression may have on pathway perturbation and pathological load within
the system. Affymetrix IDs were first converted to Entrez gene IDs in order to link 
expression profiles to a unique gene locus.
3.3.6 Detection of myofibroblast markers
To validate that samples are in fact myofibroblast cell lines, the gene expression 
profiles were screened for the expression of the two main myofibroblast markers, 
aSMA and vimentin (VIM) (Tuxhorn et al., 2002a). As expected, both aSMA and 
VIM were expressed in all CAMs, ATMs and ANMs at a background level, as 
depicted by 'Present' flags for these genes in all samples. Histograms of normalised 
'natural scale1 expression values across all individual samples for aSMA and VIM 
are shown in Figure 3.19.
a-Smooth Muscle Actln Expression Levels
7 -i
Vimentin Expression Levels
Figure3.19 Histograms of A) alpha-smooth muscle actin (a-SMA) and B) Vimentin (VIM) Mas5 
normalised 'natural scale1 average probe expression values across all individual samples included in 
the analysis.
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3.3.7 Results of pairwise gene expression analyses
3.3.7.1 Comparing gene expression profiles between different 
forms of gastric myofibroblast
Following Mas5 normalisation a high degree of similarity was observed between 
genes that were differentially expressed in CAM vs. ANM and ATM vs. ANM 
comparisons. Significantly, 98.5% (1920/1948) of differentially expressed genes 
(P<0.05, no fold change cut-off) were found to be changed in the same direction in 
both myofibroblast populations, with 901 genes being over-expressed and 1019 
genes being under-expressed in both cases. In addition, 43% of genes were found 
to exhibit 'progressive changes' in gene expression with larger directional changes 
being observed in CAMs compared to ATMs. This pattern of gene expression would 
be consistent with a model of proximity dependant reprogramming via secreted 
tumour derived factors. Genes exhibiting progressive changes are discussed in more 
detail throughout Chapter 5.
3.3.7.2 Pathway and Go annotation analysis of differentially 
regulated genes following Mas 5 normalisation
Initially, differentially expressed genes were mapped onto pathways using the
commercial Metacore™ GeneGo pathway enrichment tool. However, as
approximately 70% of these genes could not be mapped to biological pathways in
Metacore™ a selection of alternative bioinformatics tools including Ingenuity,
Reactome, DAVID and BiNGO™ were used to provide greater insight into the range
of processes that are changed in different myofibroblast populations. A comparison
of the coverage provided by each tool is shown in Figure 3.20 and Table 3.5.
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Figure 3.20 Comparison of pathway enrichment tool coverage of CAM vs. ATM differentially 
regulated genes. Black numbers within rectangles represent shared differentially regulated genes. 
Red numbers represent total numbers of differentially regulated genes associated with each tool.
CAM vs. ATM
Metacore™ un-mapped genes 1469 % coverage
DAVID 94 8.506787
Ingenuity 45 4.072398
Reactome 81 7.330317
Table 3.5 The numbers and percentage of CAM vs. ATM differentially regulated genes (p<0.05) that 
were un-mapped to Metacore™ canonical pathways, but are mapped to pathways within DAVID, 
Ingenuity or Reactome.
This process enabled a further 307 genes to be assigned to pathways/processes. 
This variability may be due to differences in the range of pathways available in each 
tool, or to differences in the compositions of pathways in different tools. Lists of 
significantly enriched pathways identified by each tool for the CAM vs. ATM dataset
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are provided in Supplementary fiies 3.1-3.4, however a summary of the combined 
changes observed for each myofibroblast population is outlined below and key 
processes are discussed further in Chapter 5.
3.3.7.3 CAM related changes
Pathways found to be uniquely over-represented in CAMs include, TGF-(3 induced 
epithelial-mesenchyme transition (EMT). In the apoptosis and survival pathway 
anti-apoptotic TNFs/NF-kB/Bcl-2 and RelA transcription factors are increased, which 
may lead to a reduction in apoptosis via activation of BCL proteins. A decrease in 
integrin expression was also seen suggesting decreased cell-extracellular matrix 
contact. Also, three 3/4 Junction Adhesion Molecules (JAM) A, B and C were all 
down-regulated. This may be an important change as studies in breast cancer show 
that JAM A is a negative regulator of cell migration and invasion (Naik et al., 2008). 
Interestingly, our data also shows that cholesterol synthesis is significantly altered 
in CAMs. This may be important as cholesterol synthesis is up-regulated in cancer 
cells and the mevolanate pathway has been identified as a target for anti-cancer 
therapy, since Lovastatin (an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme-A 
reductase) was shown to reduce tumour size and has been proposed for use in 
phase II trials (Thibault et al., 1996).
Significantly, 3-hydroxy-3-methylglutaryl-coenzyme A reductase, already appears to 
be down regulated in CAMs. The potential significance of this observation is 
discussed further in Chapter 5. Also, 3 members of the Oligo-Saccharyl-Transferase 
(OST) membrane protein complex that are required for N-glycan synthesis, were
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found to be up-regulated in CAMs; suggesting a role for N-glycan synthesis in gastric 
tumour progression.
Using the DAVID KEGG and BioCarta tools, N-glycan biosynthesis, epithelial cell 
signalling in Helicobacter pylori infection, leukocyte transendothelial migration, TACI 
and BCMA stimulation of B cell immune responses and steroid biosynthesis were 
found to be significantly altered in CAMs. As changes in EGF receptor glycosylation 
induce sensitivity to extracellular EGF (Matsumoto et al., 2008), observed changes 
in CAM expression profiles could explain enhanced proliferation and migration 
phenotypes observed in these cells. Interesting the pathway signature relating to H. 
pylori infection is unique to CAMs and was not detected in ATMs. Using the 
Ingenuity tool, NF-kB signalling was found to be altered in CAMs, with a number of 
genes being up-regulated, including Rel-A, which may increase inflammation, cell 
proliferation and survival. Clathrin-mediated endocytosis was also altered in CAMs, 
which may well effect growth factor signalling in these cells. The SLC16A3 and 
SLC7A7 monocarboxylate transporters which are responsible for the import and 
export of metabolites including lactate and pyruvate, which play a key role in 
stroma mediated tumour growth were both found to be up regulated in CAMs. The 
ingenuity tool also identified significant changes in the CD40 signalling pathway 
thus linking ER stress to increased inflammation and release of soluble factors 
causing the release of cytokines and subsequent T-cell activation (Hasnain et al., 
2012).
A group of over-lapping pathways involved in signal transduction through the
insulin receptor including PKB mediated events, mTOR signalling and AMPK
activation by LKB1 all contained a large number of down regulated genes. PKB
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mediated events include mTOR signalling, which conveys signals on the availability 
of growth factors and nutrients at the cell surface thereby controlling the rate of 
cell growth and proliferation. Also, an inhibitor of the mTOR complexl raptor was 
up-regulated in CAMs, implying a potential decrease in mTOR mediated cell growth 
and proliferation in these cells.
AMPK is a key regulator of energy homeostasis, and is activated under high levels of 
cellular stress, or low glucose levels. AMPK inhibits glycogen and fatty acid synthesis 
and stimulates glycolysis and fatty acid oxidation (Steinberg and Kemp, 2009). 
Together these signatures provide the first insight into differential mechanisms of 
energy metabolism in gastric CAMs.
Tool Pathways/processes Potential effects
Metacore™ TGF-beta induced EMT
Cholesterol synthesis
Increased motility
Increased cholesterol
DAVID H.pylori infection Inflammation triggering pathway?
Ingenuity PBS MARK signalling pathway Decreased transcription and 
translation
Reactome
HIV infection
Monocarboxylate transport
Regulation of AMPK via LKB1
Cytoskeletal proteins
Increased pyruvate/lactate 
transport
Inhibit storage/stimulate 
metabolism
Decreased mobility
Metacore™ and DAVID N-glycan biosynthesis Increased glycans
Meta core™ and 
Reactome ER stress response/anti-apoptotic Mixed apoptotic signals
Ingenuity and
Reactome
CD40 signalling, Un-folded 
protein response Increased inflammation
Metacore™, Reactome 
and Bingo
JAM adhesion molecules/ 
integrins/cell-cell adhesion
Decreased adhesion/increased 
motility?
Table 3.6 Summary of over-represented CAM pathways. Along with the tools used to identify 
specific over-represented pathways or gene ontology process and potential cellular effects.
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3.3.7.4 Changes in gene expression observed in ATMs
Lists of significantly enriched pathways identified by each tool for the ATM vs. ANM 
dataset are provided in Supplementary files 3.9-3.12. Initial pathway enrichment 
analysis in Metacore™ revealed a significant increase in the expression of genes 
involved in: smooth muscle contraction, cytoskeletal remodelling and a range of 
metabolic pathways, including amino acid and ketone body metabolism and 
biosynthesis pathways which were highly up-regulated in ATMs. Together with 
expression of HADHB mitochondrial protein subunits, which catalyse the last steps 
of ketone body biosynthesis (Figure 3.21). We also observed a significant decrease 
in the expression of genes involved in calcium signalling pathways, and a strong 
over-all decrease in genes involved in DNA mismatch repair and gene expression. 
Significantly, Thioredoxin (TXN) and its oxidation catalyst peroxiredoxinl (PRDX1) 
were up-regulated in ATMs (Figure 3.21), where they may play a key role in 
responding to oxidative stress within the tumour microenvironment. TXN is a redox 
signalling protein that can act as a messenger, in stress related signalling cascades, 
while also acting as an anti-oxidant reducing agent. Interestingly, the glutathione 
metabolism pathway was also enriched in ATMs. Glutathione acts in a similar way 
to thioredoxin as both play a role in orchestrating cellular responses to oxidative 
stress. (Lushchak, 2012). Normally cellular levels of GSH are high and GSSG are low, 
but under high oxidative stress this is reversed (Pompella et al., 2003). As all of the 
enzymes facilitating the reduction of oxidised species are up-regulated and the 
enzyme converting GSSG back into GSH is also increased, there is a strong 
indication that ATMs may be programmed to operate under conditions of oxidative 
stress, or exhibit unique metabolic properties to ATMs.
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In this context it is interesting to note that Reactome analysis also identified 
increases in the expression of genes involved in the pentose phosphate pathway, 
including glucose-6-phosphate dehydrogenase (G6PD), phosphogluconate 
dehydrogenase (PGD) and transaldolase 1 (TALDOl). This pathway is an alternative 
to glycolysis, or the TCA cycle. Therefore, it is possible that ATMs have become 
programmed to utilise the non-oxidative pentose phosphate pathway to generate 
energy for themselves, whilst allowing pyruvate to be transferred to neighbouring 
cancer cells as proposed by the "Reverse Warburg effect". Alternatively, over­
representation of the pentose phosphate shunts may be linked to levels of 
oxidative stress and inflammation as the end product of the pentose phosphate 
shunt (NADPH) also links into Glutathione metabolism.
In total 28 human solute carriers were found to be differentially regulated in ATMs. 
Half being up-regulated, including the pyruvate/lactate transporter SLC16A (MCT4) 
and half are down regulated.
Finally, downstream components of the ROCK signalling pathway are all down 
regulated in ATMs, suggesting that these cells have a decreased potential for 
migration and angiogenesis, trend supported by results recently published by 
Holmberg et al. (2012).
117
Tool Pathways/processes Effects
Metacore™ Smooth muscle contraction 
DNA mis-match repair
Increased motility
Decreased DNA repair
DAVID Primary acid biosynthesis Increased primary bile acids
Ingenuity EIF2 signalling pathway Unclear effect on protein translation
Reactome
Solute carrier transport Altered membrane transport
Pentose phosphate shunt Increased NADPH production
Cell cycle Decreased proliferation
Cell junction organisation Decreased cadherin/ cell-cell inter
Reactome and Ingenuity Cellular apoptosis Increased apoptosis
Ingenuity and Reactome Thioredoxin and Glutathione Increased oxidative stress protection
Metacore™ and Reactome Ketone body metabolism Increased Ketone bodies
Met, DAVID and Ingenuity Amino acid metabolism
Amino acid degradation
Increased Amino acids
Increased Acetyl coA and ketone bodies
Table 3.7 Summary of over-represented unique ATM pathways, together with the tools used to 
identify over-represented pathway or gene ontology process and the potential cellular effects.
S.3.7.5 Common changes observed in both CAMs and ATMs
Complete lists of all over-represented Metacore™ GeneGo pathways, for CAM vs. 
ANM and ATM vs. ANM comparisons are provided in Supplementary Files 3.5 and 
3.9. N-cadherin was found to be commonly down-regulated in CAMs and ATMs, 
along with its intracellular downstream effectors a-catenin and actin. Significantly, 
N-cadherin was found to be more down-regulated in CAM vs. ANM indicating a 
progressive change in cell-cell adhesion. A striking observation in this analysis is the 
fact that exactly same pathway components are frequently altered in both CAMs 
and ATMs, with the vast majority of changes occurring in the same direction (Figure 
3.23). This potentially provides support for a model in which certain myofibroblast 
pathways may have been re-programmed by common insults, such as prolonged 
chronic inflammation, prior to the additional local reprogramming of CAMs by 
tumour derived factors. A comparison of the coverage provided by each tool is 
shown in Figure 3.24 and Table 3.8.
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Figure 3.24 Comparison of numbers of differentially regulated genes assigned to pathways in 
different informatics pathway enrichment tools (A) CAM vs. ANM. (B) ATM vs. ANM. Black numbers 
within rectangles represent shared differentially regulated genes and red numbers represent total 
numbers of differentially regulated genes associated with each individual tool.
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CAN vs. AN
Metacore™ un-assigned genes 1105 % coverage
DAVID 47 4.253394
Ingenuity 59 5.339367
Reactome 76 6.877828
ATM vs. AN
Metacore™ un-mapped genes 1405 % coverage
DAVID 72 6.515837
Ingenuity 82 7.420814
Reactome 79 7.149321
Table 3.6 Numbers and percentages of CAM vs. ANM and ATM vs. ANM differentially regulated 
genes (p<0.05), which were un-mapped to Metacore™ canonical pathways, but can be mapped to 
canonical pathways within DAVID, Ingenuity and Reactome.
A list of complete and statistically significant pathways (p<0.05) identified by DAVID 
KEGG and BioCarta, for the CAM vs. ANM and the ATM vs. ANM datasets, are 
provided in Supplementary Files 3.6 and 3.10 respectively. The glycosaminoglycan 
degradation pathway was significantly altered in both CAMs and ATMs, with several 
pathway components being consistently up-regulated in both cell types. 
Deregulation of genes involved in the glycosaminoglycan degradation pathway has 
previously been shown to be important in the progression of cancer (Yip et al., 
2006), however the role of this process in cancer associated fibroblasts has not yet 
been explored. Potentially these changes could affect the biosynthesis of keratin- 
sulphate and heparin sulphate, which effect cell proliferation and angiogenesis 
(Bernfield et al., 1999), by acting as docking sites for angiogenic factors such as 
VEGF, FGF and MMP7, which enhance endothelial cell migration (Yu and Woessner, 
Jr., 2000).
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Pathways found to be statistically over-represented in Ingenuity following CAM vs.
ANM and ATM vs. ANM comparisons along with the complete lists are included in 
Supplementary File 3.7 and 3.11 respectively. Interestingly the top over­
represented pathway in both the CAMs and ATMs was the synthesis and 
degradation of ketone bodies, with all differentially regulated genes showing an 
increase in expression. Ketone bodies are a by-product formed when fatty-acids are 
broken down to release energy, suggesting that CAMs and ATMs may both use fatty 
acids as an alternative form of energy to the preferred glucose. This phenomenon is 
discussed in more detail in Chapters 5 &6.
Pathways found to be overrepresented by Reactome analysis are included in 
Supplementary File 3.8 and 3.12.
Metacore™ Cell-adhesion_cadherins Decreased cell adhesion
DAVID Glycosaminoglycan degradation Increased angiogenesis
Ingenuity
Synthesis and degradation of ketone bodies
Amino acid synthesis
Increased ketone synthesis
Increased amino acids
Reactome Influenza infection Increased infection
Metacore™ and 
Ingenuity
DNA damage_cell cycle control Decreased DNA repair
Metacore™ and
Reactome
Cell-cycle Decreased proliferation
Metacore™,
Reactome, Ingenuity 
and Bingo
Translation initiation, elongation factor 
signalling and silencing due to infection
Increased translations, 
decreased if infected.
Table 3.7: Summarisation of the common over-represented CAM and ATM pathways, along with the 
tools able to identify the specific over-represented pathway or gene ontology process and the 
potential cellular effects.
3.3.7.6 BiNGO™ Analysis
Even after using multiple pathway enrichment tools, a large percentage (around 
65%) of genes with altered expression patterns were still unassigned to any
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biological process. Therefore, BINGO was used to investigate the potential function 
of genes within this subset of unassigned genes. For the CAM vs. ATM dataset, 678 
out of 1162 differentially regulated genes were able to be assigned GO annotation 
terms in BiNGO™ (Supplementary File 3.13). Revealing 103 biological processes that 
are over-represented at the <0.05 level and 4 over-represented at the FDR 
corrected < 0.05 level. Processes over-represented in the CAM vs. ATM dataset 
represent unique cancer changes. FDR corrected over-represented biological 
processes include; biological adhesion, cell adhesion, cell-cell adhesion and 
homeophilic cell adhesion.
For the CAM vs. ANM and the ATM vs. ANM dataset, 445 of the 818 and 564 out of 
1049 differentially regulated genes were able to be assigned GO annotation terms 
in BiNGO™ respectively. BiNGO™ analysis of the CAM vs. ANM, revealed 169 
biological processes over-represented at the <0.05 level and 6 over-represented at 
the FDR corrected <0.05 level (Supplementary file 3.14). BiNGO™ analysis of the 
ATM vs. ANM dataset, revealed 200 biological processes that were over­
represented at the <0.05 level and 3 over-represented at the FDR corrected <0.05 
level (Supplementary file 3.15). Processes over-represented in both the CAM vs. 
ANM and ATM vs. ANM datasets represent common biological processes. Very 
similar changes were again seen within CAMs and ATMs, with ATMs displaying a 
larger number of differentially regulated genes. Therefore allowing significantly 
more altered genes to be analysed however, findings from BiNGO™ analyses tend to 
agree with data obtained by all four canonical pathway tools.
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3.3.7.7 Comparative analysis
3.3.7.7.1 Genes assigned to pathways / Go annotations
The ability of each tool to map the most significantly changed genes to a pathway or 
process was assessed. Figure 3.25 displays the number of statistically significant 
genes (p<0.05) that were mapped onto canonical pathways, within Metacore™, 
Ingenuity, Reactome and DAVID, or gene ontology's within BiNGO™.
Figure 3.25. Percentage of differentially regulated genes (p<0.05), within the CAM vs. ANM (Blue), 
ATM vs. ANM (red) and the CAM vs. ATM (green), able to be mapped to canonical pathway analysis 
tools (Metacore, Ingenuity, DAVID, Reactome) and GO annotations (BinGo™).
Excluding BiNGO™, canonical pathway enrichment tools were able to map around 
30% of all differentially regulated genes, across all datasets. DAVID mapped slightly 
more and Reactome slightly less. BiNGO™ mapped the highest number of 
differentially regulated genes to GO ontology terms, but as shown within BiNGO™ 
section 3.3.6, interpretation of the exact roles that these gene products may play 
within CAMs or ATMs is hard to define.
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The apparent differences observed between data from different tools may be due
to differences in the range of pathways available in each tools, or variability 
between the compositions of pathways in different tools. Overall, gene coverage 
within the different tools seems to lead to specific subsets of pathways being 
highlighted in each tool, with signalling pathways being predominantly highlighted 
in Ingenuity and DAVID, whilst coverage in Reactome appears to be more bias 
towards the cell cycle or transcription and translation and transcription related 
pathways.
3.3.7.8 Retrospective comparison of MasS and RMA
normalisation methods
RMA is an increasingly popular method for pre-processing array data, which 
includes background correction, normalisation and summarisation (Irizarry et al., 
2003). There are several differences between the MasS and RMA methods. MasS 
normalises each array independently and uses the perfect-match (PM) and mis­
match (MM) probes to assign present (P), marginal (M) and absent (A) flags 
alongside the normalised expressions. In contrast, RMA uses a multi-chip model, 
based on the theory that MM probes sometimes have higher intensity values than 
PM probes, resulting in negative expression values, which may cause noise at low 
intensity levels. Therefore, the RMA method does not consider MM probes and 
does not produce flagged data (Irizarry et al., 2003a).
A comparative study was performed to assess the effect that normalisation by RMA 
rather than MasS may have on the number of genes found to be significantly 
changed, or the range of affected biological pathways. To perform this comparison 
Affymetrix CEL files were uploaded into Partek® and normalised using RMA as
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described in section 2.I.3.4. RMA and Mas5 normalised probes were converted into 
Entrez gene IDs using Metacore.
Using Mas5, only probes with a P flag in 100% of samples within a comparison 
group were considered for statistical analysis. In the RMA method these filters are 
not set, therefore all 54,000 probes on the array are considered for statistical 
analysis. As a result many more genes appear to be statistically changed using RMA 
compared to Mas5 normalisation (Supplementary files 3.16-3.18). For purposes of 
comparison a p-value of 0.05 and a threshold of 2-fold change were initially used to 
identify differentially regulated genes by both methods of normalisation.
Importantly, the CAM vs. ANM and ATM vs. ANM differentially regulated genes are 
defined by a Benjamini-Hochberg corrected p-value of <0.05 and a 2 fold change in 
intensity, whilst the CAM vs. ATM dataset is defined by an uncorrected p<0.05 and a 
2 fold change. The Benjamini-Hochberg FDR correction cannot be applied to the 
CAM vs. ATM dataset as the samples are paired and too similar, therefore no genes 
passed an FDR corrected p-value <0.05.
Using these criteria, the number of differentially regulated genes in each dataset, 
was determined using both normalisation techniques (Table 3.8). The similarity of 
the gene lists defined as differentially regulated using each normalisation technique 
are shown in Figure 3.26 Within the CAM vs. ANM dataset, 72% of Mas5 and 89% of 
RMA defined differentially regulated genes were identical between the two 
normalisation techniques. Similar percentages were also observed for the ATM vs. 
ANM dataset, with 72% of Mas5 and 91% of RMA defined genes being identified by 
both methods.
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Data Set MasS RMA
CAM vs. ANM 246 208
ATM vs. ANM 431 342
CAM vs. ATM 48 46
Table 3.8 Comparison of numbers of differentially regulated genes identified by Mas5 or RMA 
normalisation methods when comparing CAM vs. ANM, ATM vs. ANM or CAM vs. ATM datasets. For 
CAM vs. ANM and ATM vs. ANM differentially regulated genes were defined using a Benjamini- 
Hochberg corrected p<0.05 and 2 fold change, whilst the CAM vs. ATM dataset is defined using an 
uncorrected p<0.05 and a 2 fold change.
Figure 3.26 Similarity between differentially regulated gene lists derived from Mas5 and RMA 
normalisation. (A) CAM vs. ANM, (B) ATM vs. ANM, (C) CAM vs. ATM. The CAM vs. ANM and ATM vs. 
ANM differentially regulated genes are defined using a Benjamini-Hochberg corrected p<0.05 and 2 
fold change, whilst the CAM vs. ATM dataset is defined by an uncorrected p<0.05 and a 2 fold 
change. Numbers within the circles represent genes defined as uniquely differentially regulated or 
commonly differentially regulated following Mas5 or RMA normalisation. Numbers in brackets 
indicate total numbers of differentially regulated genes identified by each normalisation algorithm.
When using these stringent thresholds (p-value<0.05 and 2 fold change), Mas5 
identifies a greater number of changed genes, and RMA generated a smaller 
percentage of unique changed genes.
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To investigate the effect that the observed 20-30% differences in changed genes 
may have on the range of biological processes that may be affected, the top over­
represented biological pathways from a Metacore GeneGo pathway analysis were 
compared for gene lists generated by both normalisation methods, in each case 
using the entire complement of Affymetrix chip genes as a background gene list to 
identify biological pathways associated with the differentially regulated gene lists 
from both normalisation techniques.
Results from this analysis show that, although only 50% of pathways defined as 
statistically over-represented (p<0.05) are identical when comparing Mas5 to RMA 
(CAM vs. ANM and ATM vs. ANM datasets), similar biological processes are over­
represented in each case (Supplementary files 3.19-3.21). For example, in the CAM 
vs. ANM dataset, both techniques identified regulation of the cell cycle, DNA 
damage repair pathways, specifically relating to the cancer related BRCA genes, 
immune response, and VEGF signalling as top ranking changed processes. The only 
process uniquely identified by RMA generated data was hormone biosynthesis. 
With respect to the ATM vs. ANM dataset, both normalisation techniques again 
identified similar biological processes such as control of cell cycle, DNA damage 
repair, extracellular-matrix remodelling, transcriptional control of cholesterol 
biosynthesis, cholesterol, hormone and bile acid biosynthesis. Flowever, in this 
analysis RMA normalised data uniquely identified EMT transition as a significantly 
changed process. Clearly this is a highly relevant process in terms of the cancer 
microenvironment, which would have been missed through the application of Mas5 
normalisation, under these stringent conditions.
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Analysis of CAM vs. ATM data normalised by Mas5 or RMA produced very similar 
pathway profiles, with 5/6 pathways being defined as over-represented by both 
normalisation techniques including developmental pathways involving epithelial 
mesenchymal transition and bile acid biosynthesis. The only pathway that was 
uniquely identified by either normalisation technique was the WNT signalling 
pathway identified by the Mas5 method and an immune response pathway that 
was only identified by RMA normalised data.
Overall, strikingly similar biologically processes were identified for Mas5 or RMA 
derived gene lists, despite the observed 20-30% difference in numbers of changed 
genes. This suggests that the 20-30% of genes that are different must either be 
involved in similar processes or be highly dispersed among many different pathways 
in such a way that these changes would not be highlighted by statistical pathway 
enrichment methods. Therefore, at this level of stringency, Mas5 and RMA 
normalisation methods result in different numbers of significantly changed genes, 
however (at least with respect to our data), the vast majority of biological processes 
found to be significantly affected is very similar. As the RMA method is not based on 
the use of flags to identify genes present in all samples, this method inevitably leads 
to the identification of significantly larger numbers of changed genes. As such, it is 
possible that analysis of less stringently filtered data from both normalisation 
methods would reveal far greater differences in both numbers of changed genes 
identified and the spectrum of biological processes that are changed. Data 
presented in Table 3.9 shows that this is the case. Using a p-value<0.05 with no fold 
change cut off, the similarity of gene lists identified using Mas5 and RMA are shown 
in Figure3.27. Within the CAM vs. ANM and ATM vs. ANM dataset, similar
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percentages of genes were defined as identically differentially regulated, around 
74% and 81% respectively. However, a smaller percentage of identically 
differentially regulated genes (55%) were observed for the CAM vs. ATM dataset.
Data Set MasS RMA
CAM vs. ANM 2277 2563
ATM vs. ANM 3830 4264
CAM vs. ATM 1850 2531
Table 3.9 Comparison of the number of differentially regulated genes identified by Mas5 or RMA 
normalisation methods when comparing CAM vs. ANM, ATM vs. ANM or CAM vs. ATM datasets. For 
CAM vs. ANM and ATM vs. ANM differentially regulated genes were defined using a Benjamini- 
Hochberg corrected p<0.05, whilst the CAM vs. ATM dataset is defined using an uncorrected p<0.05.
C2563) n*s5 (3630)
WW (2531)
Figure 3.27 Similarity between differentially regulated gene lists derived from MasS and RMA 
normalisation. (A) CAM vs. ANM (B) ATM vs. ANM (C) CAM vs. ATM. The CAM vs. ANM and ATM vs. 
ANM differentially regulated genes are defined using a Benjamini-Hochberg corrected p<0.05, whilst 
the CAM vs. ATM dataset is defined by an uncorrected p<0.05. Numbers within the circles represent 
genes defined as uniquely differentially regulated or commonly differentially regulated following 
MasS or RMA normalisation. Numbers in brackets indicate total numbers of differentially regulated 
genes identified by each normalisation algorithm.
Comparative pathway enrichment analysis of these differential genes lists in 
comparison to the p-value<0.05 and 2FC, within 2/3 datasets lead to more 
pathways being identified within RMA than MasS (Supplementary files 3.22-3.24).
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Upon reducing the stringency to just a p-value threshold, within the CAM vs. ANM 
dataset both normalisation techniques revealed the over-representation of fatty 
acid metabolism pathways, which we propose are important for the CAM 
phenotype (Chapter 5). Interestingly data from the RMA normalisation method 
uniquely identified K-RAS signalling and the IGF signalling pathways, both know to 
play important roles in cancer progression. With respect to the ATM vs. ANM 
dataset, both normalisation techniques revealed over-representation of a large 
number of lipid biosynthesis pathways and related intracellular cholesterol 
transport pathways, apoptosis related signalling pathways, TGF and insulin-like 
growth factor signalling as being significantly perturbed. The differentially regulated 
gene list derived from RMA normalisation revealed a number of important cancer 
related signalling pathways, including vascular endothelial growth factor, hedgehog, 
epithelial growth factor and wnt signalling.
The less stringent RMA and Mas5 derived CAM vs. ATM dataset both revealed a 
large set of TGF induced EMT pathways specifically in relation to cancer cells, 
apoptosis signalling, cell adhesion, cholesterol biosynthesis and cholesterol 
transport. Flowever, RMA again uniquely revealed some biologically relevant 
pathways including; platelet derived growth factors in cell migration, N-Glycan 
biosynthesis and transforming growth factor induced cell proliferation.
Subsequent experimental work in the Sanderson lab has confirmed trends and 
conclusions derived from our Mas5 normalised data (Chapters 5 and 6), further 
experiments will now be performed to investigate potentially interesting new leads 
that have emerged from this retrospective reanalysis of data by the RMA method.
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3.4 Discussion
The aim of the work described in this chapter was to establish if isolated primary 
human CAMs and ATMs exhibit distinct gene expression profiles, which may provide 
insights into the range of biological processes that are altered in comparison to 
gastric myofibroblasts isolated form histologicaly normal tissue. To achieve this aim 
several important criteria had to be satisfied, in order to be confident in predictions 
arising from the comparative analysis of complex gene expression profiles. Firstly, it 
was important to establish that isolated CAMs and ATMs retained characteristic 
markers and properties, which have been described for CAMs, ATMs or ANs in other 
tissues. Analysis of comparable low passage (p4-p7) CAM, ATM and ANM performed 
in the Varro lab (University of Liverpool) showed that all isolated primary human 
myofibroblasts retained strong co-expression of the classic myofibroblast markers 
vimentin and a-SMA (Figure S.2). In addition, functional analysis of each 
myofibroblast cell line showed that all isolated CAMs retained the ability to enhance 
the migration and proliferation of AGS gastric cancer cells (Figure 3.3). Analysis of 
data from microarray studies also confirmed that both vimentin and a-SMA 
expression was detected in all of the isolated primary myofibroblast samples (Figure 
3.19). Therefore, this data demonstrates that at the time that samples were 
prepared for microarray analysis, isolated primary human gastric myofibroblasts 
exhibited appropriate myofibroblast morphology, markers and functional 
properties.
Other criteria that needed to be addressed were the quality of the primary array 
data and the degree of variability that may arise from batch processing. In a 
retrospective analysis we also assessed the relative merits of using RMA rather than
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Mas5 to normalise microarray data. As all arrays were run by the Liverpool Genome 
Research Facility spike-in hybridisation controls were automatically run to assess 
consistency across all experiments. However, the Bioconductor 
'ArrayQualitylVIetrics' (AQM) package was also used to assess the consistency and 
quality of data across all 39 CAM, ATM and ANM un-normalised microarray 
CEL.files. This analysis showed that, Array 8 (14 CAM), 38 (15 CAM), and 39 (15 
ATM) were detected as outliers due to observed variations in feature intensities 
(array 8 only), the relative log expression values and the observed degree of scaled 
un-normalised standard error. The combinations of these observations suggest that 
these arrays should possibly have been removed from subsequent analysis to avoid 
skewing results. However, it is significant to note that these two arrays were not 
derived from the same batches (Table 3.1). Also, following normalisation of data by 
either batch or patient correction methods these samples correctly segregated with 
appropriate myofibroblast subsets (CAMs & ATMs respectively) and neither sample 
was an outlier within its subtype cluster.
Considering the results of this analysis, overall the quality of the array data appears 
satisfactory, with the exception of 2 arrays. In retrospect it would have been 
preferable for samples to be processed in fewer batches, thereby making batch 
correction simpler and potentially more efficient. However, despite the large 
numbers of batch processing dates normalisation and batch/patient correction does 
largely correct for observed outliers in primary data. Therefore, although fewer 
batches would have led to less variation between samples within each 
myofibroblast subgroup (CAM, ATM or ANM) differences observed in gene
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expression between myofibroblast subgroups appear valid, as PCA analysis shows
segregation of CAM, ATM and ANM samples.
It is likely that fewer batch numbers may have reduced observed variability 
between samples within each myofibroblast subgroup, thereby improving our 
ability to identify gene expression profiles that correlate with prognostic trends, 
(see Chapter 5). However, in this context it is important to note that there is no 
obvious correlation between batch processing dates and our ability to segregate 
prognosis subgroups, based on differential trends in gene expression profiles. This 
point is discussed in more detail in Chapters 5 and 6.
Considering the consequences of using Mas5 or RMA normalisation methods. Using 
stringent thresholds for data from each normalisation method (FDR corrected 
pValue<0.05 and 2 fold change) generated relatively simitar gene lists which when 
used for pathway enrichment analysis also identified very similar lists of significantly 
affected process. However, comparison of post normalisation gene lists generated 
using a FDR corrected pValue<0.05 only shows that a far greater number of altered 
genes were retained after normalisation. In this case RMA normalised data also 
identified a greater range of changed pathways, which were not identified by Mas5 
normalised data. Given the larger number of genes retained following RMA 
normalisation it is highly likely that this dataset would also be more valuable that 
Mas5 data when performing correlation and correspondence studies described in 
chapters 4 and 5. Although Mas5 normalisation generates significantly smaller post 
normalisation gene lists it is likely that trends or signatures are correct, although
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quite possibly incomplete. This possibility will be explored as part of on-going 
studies in the Sanderson lab.
In this study a range of pathway enrichment tools were used to provide insight into 
biological processes that are altered in CAMs and/or ATMs relative to ANMs. As a 
result three classes of altered processes where identified: (1) Those that are change 
in both CAMs and ATMs, (2) Those which show progressive changes from ATMs to 
CAMs and (3) those that are unique to either CAMs or ATMs. These differences are 
explored further in Chapter 5, however in brief: Changes seen in both CAMs and 
ATMs may reflect historical programming of gastric tissue myofibroblasts resulting 
from chronic tissue inflammation, which may have occurred prior to tumour 
development. In contrast, progressive changes seen between ATMs and CAMs may 
reflect distance related gradation in tumour mediated myofibroblast 
reprogramming. Finally, processes that appear to be uniquely altered in CAMs or 
ATMs may reflect the balance between dominance of tumour-induced changes or 
the suppressive effects of normal tissue stroma.
Potentially important trends were highlighted by this analysis, several of which are 
developed further in Chapter 5. In brief: A wide range of metabolic and 
inflammatory processes were altered in both CAMs and ATMs. These observations 
would be consistent with a reverse Warburg type system in which tumours program 
stromal myofibroblasts to provide nutrients for tumour growth. One potentially 
interesting finding was the fact that the TGF-p induced EMT pathway was uniquely 
over-represented in CAMs. Interestingly, expression of TGF-P2 itself was also
increased in CAMs. As TGF-(3 has been shown to 'activate7 fibroblasts (Untergasser
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et al., 2005) it is possible that CAMs may play a role in inducing ANM to ATM or 
ATM to CAM conversion. CAMs also showed a very clear Helicobacter pylori induced 
signalling response that was not seen in ATMs. Also, glycogen/fatty acid synthesis 
appears to be inhibited in CAMs while glycolysis and fatty acid oxidation is increased 
(Steinberg and Kemp, 2009). This observation may provide a new way of 
differentiating CAMs and ATMs in vivo. As the l\l-glycan pathways are significantly 
over-represented in CAM vs. ANM and CAM vs. ATM, but not in ATM vs. ANM 
comparisons, it is possible that N-glycan biosynthesis may be an important feature 
of tumour 'conditioned' CAMs.
4 Chapter Four: Network and multivariate analysis of cancer 
related gene expression signatures.
4.1 Introduction
Canonical pathways are well-established biological processes, containing defined 
gene members. However, it is now clear that pathways do not operating in 
isolation. Also, changes in different isoforms of genes, such as adenylate cyclase, 
can elicit different stimuli, which are all transformed through a common point 
among multiple signalling pathways (Jordan et al., 2000) (Figure 4.1).
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Figure 4.1. Many isoforms of adenylate cyclase act through PKC to produce a range of different 
intracellular downstream effects (Jordan et al., 2000).
Therefore, it is now clear that many genes may operate as components of multiple
pathways (Figure 4.2). However, conventional pathway enrichment algorithms do
not reflect the potential impact that a change in expression of a single pathway
component could have on multiple pathways; or if it represents an essential part of
a single pathway, or the junction or hub point between multiple pathways. The aim
of the work described in this chapter is to go beyond the use of basic pathway
enrichment methods, to investigate the concept of load and hub perturbation
effects on processes within integrated biological networks. It is clear from analysis
of any interactome network that crosstalk between pathways must be both
extensive and regulated. In addition, most studies to date have not addressed the
potential issue of load, or accumulative burden within particular biological
processes. For example use of fold change thresholds to identify 'significant'
changes may mask the accumulative effects of small apparently less-significant
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changes in multiple components of the same pathway. This concept can be 
extended to ask what would be the added effects of multiple changes in proteins 
not annotated as conventional pathway members but which interact with one or 
more pathway components? Could changes in these components also contribute to 
phenotypic cause effect relationships? Here the human protein-protein interactome 
is used to increase coverage of differentially regulated genes, which may affect one 
or more known biological processes. In addition, statistical techniques have been 
applied to try to detect affected proteins that participate in multiple over­
represented processes.
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4.2 Results
4.2.1 Preliminary network analysis findings
Network analysis was performed on the available dataset, which was later refined in 
accordance with new patient information, however the underlying principles, and 
observed trends provide evidence to support the idea that this form of network 
analysis may provide additional insight into the potential significance of the large 
number of significantly changed genes that are not assigned to pathways by 
conventional pathway enrichment methods.
Genes mapped to Metacore™ pathways were mapped onto the human 
interactome, this revealed a high level of connectivity between proteins relating to 
genes with altered gene expression profiles (Figure 4.3A). Although the genes fall 
into clear pathways when utilizing pathway enrichment tools such as Metacore, 
there is no distinction of pathways when significantly changed genes are mapped 
into the human interactome. This trend was investigated using an in-house network 
analysis tool called 'Hypernode' (Figure 4.3B). In essence, the Hypernode algorithm 
condenses all genes within a certain pathway onto a single node. Therefore, 
connections between nodes represent connections between genes present within 
different pathways. This demonstrates that although we tend to think of pathways 
as having linear order, they are obviously not working in isolation. They are highly 
connected processes often sharing multiple components. As such, disruption of 
shared components can potentially have more dramatic effects on multiple 
pathways and the system as a whole.
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In addition, it is clear that genes that were not mapped to Metacore pathways, form 
highly connected networks (Figure 4.3C). Such genes would have been ignored 
using standard canonical pathway tools, but are clearly highly connected. Therefore, 
it is important to investigate which genes they may be interacting with and what 
pathways their differential expression could potentially effect.
Figure 4.3. Protein-protein interaction networks A) Nodes represent differentially regulated genes 
mapped to Metacore pathways and connections represent the interactions between them B) Nodes 
represent differentially regulated genes unable to be mapped to Metacore pathways and 
connections represent the interactions between them. Within A) and B) red nodes represent up 
regulated genes and green nodes represent down regulated genes. C) Hypernode network, nodes 
represent pathways and the connections between pathways represent interactions between genes, 
red coloured nodes do not represent direction of fold change.
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Visualisation of pathway cross-talk/connectivity via the human interactome 
demonstrates the complex nature of connectivity and potential cross-talk between 
pathways, and the need for new techniques that can highlight multi­
functional/connecter genes. In theory, the identification of genes that play a role in 
many pathways, is important, as the differential regulation of a small number of 
promiscuous genes could alter cause/effect relationships across a wide range of 
canonical pathways.
4.2.2 Assembling a Myofibroblast specific protein interaction 
network
As all genes are not be expressed in all cell types, it was important to first generate 
a myofibroblast specific gene expression network, in which all genes that were 
detected at a baseline level in microarray studies are included (Figure 4.4A). The 
resulting network consists of 10,959 nodes and 80,095 edges. As explained in 
methods section 2.6.1, this network also contains interologs, which are binary 
protein interactions that are predicted to be conserved between homologous 
proteins in another species.
From this myofibroblast network, individual sub-networks were then created for 
each dataset. The CAM vs. ANM network consists of 10,667 proteins, connected by 
78,615 interactions, the ATM vs. ANM normal network consists of 10,768 proteins 
connected by 78,974 interactions and the CAM vs. ATM normal network consists of 
10,722 proteins connected by 77,584 interactions (Figure 4.4A-C). For each dataset, 
there are clearly a large number of significantly changed genes, which are highly 
connected in the network, representing a high degree of communication.
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Therefore, as the level of cross-talk within individual datasets is high, we aim to 
identify the differentially regulated processes/pathways and identify the sites of 
cross-talk, within these highly connected networks.
In addition, we wished to gain insight into the pathways that may be affected by the 
large numbers of differentially regulated genes, which themselves are not known to 
be core members of canonical pathways. Therefore, differentially regulated genes 
mapped to Metacore™ pathways were mapped into the interactome, and 1-step 
networks were produced, which contains all proteins that interact with 
differentially regulated genes. Differentially regulated genes within the one step 
shell were then identified. Next, we assessed whether differentially regulated genes 
from the one-step shell would have been assigned to canonical pathways using 
other pathways analysis tools, such as DAVID, Ingenuity and Reactome. For the CAM 
vs. ANM dataset, an additional 230 differentially regulated genes which directly 
interacted with differentially regulated genes mapped to Metacore pathways. 
Similar results were found for the other two datasets; with 292 and 174 genes in 
the CAM vs. ATM and ATM vs. ANM datasets respectively. Analysis of significantly 
changed genes within the context of binary protein-protein interaction network, 
have highlighted the large amount gene expression information that is lost when 
using canonical pathway analysis tools in isolation.
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Extending this principle we wished to identify all differentially regulated genes that
interact not just with differentially regulated genes assigned to canonical pathways 
but to any member of canonical pathways that contain differentially regulated 
proteins. This type of information is extremely hard to access from Metacore, as the 
software does not allow large-scale export of individually annotated GeneGo 
pathway information. Individual pathways can however be selected and all genes 
within that pathway exported, one pathway at a time. Therefore exporting all 
members of all pathways would be extremely time-consuming, as our average 
dataset hits around 500 different pathways.
4.2.3 Multi-variant analyses
Unlike the hypothesis driven tests explained above multi-variant analysis techniques 
are exploratory, providing data from which hypothesises can then be derived. 
Multi-dimensional scaling is used to form groups within the data, where a group 
represents a sub-section of data that is more similar to each other.
4.2.3.1 Multi-dimensional scaling
For this sub-section, all of the analysis presented was performed for each dataset, 
but as the results from each were so similar, only example figures from the CAM vs. 
ATM dataset are shown as an example. Figure 4.5, shows different techniques 
commonly applied to detect over-represented pathways or processes within a given 
gene list: the Fisher exact test, the 2x2 Chi-Squared test and combined 3x2 and the 
Chi-Squared test. Each Reactome pathway is plotted against its over-representation 
p-value for each given test and a dotted line is placed at a p-value of 0.05, therefore
145
any pathways plotted below this threshold are classed as statistically over­
represented. It is apparent that each statistical test gives a completely different 
pattern of pathway over-representation, with a very different number of pathways 
being classed as over-represented. The application of the 3x2 Chi-squared test 
rather than the 2x2 Chi-squared test also dramatically alters the interpretation of 
the results. Below is an example of the 3x2 contingency table formed to carry out 
such statistical tests:
Pathway
Yes No
Diff. Expressed a d
Background b e
Not in background c f
The decision of which test to use is complicated, a 2x2 contingency table is formed 
using only a, b, d and e, not taking into account genes not in the background set. 
The inclusion or exclusion of genes not in the background dramatically affects the 
results (Figure 4.5). In this analysis we are looking for differences between 
differentially and non-differentialiy expressed genes, not those genes 'not in 
background'. Therefore, this extra category could mean that you get a very 
significant P-value, but not for the difference you are looking for. The Fisher test is 
exact, and is used when the data distribution is known, it is very powerful when the 
distribution is assumed correctly but is harder to compute than the Chi-sq. The chi- 
squared test makes a distribution assumption; therefore larger sample sizes are
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needed to ensure the distribution assumption by Chi-squared test is correct. 
Therefore, the decision of whether to use a Fisher or Chi-squared test also depends 
on the observed numbers in the contingency table, but these numbers differ for 
each pathway.
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Figure 4.5. Three types of statistical tests frequently applied to define pathw
ay over-representation. Black points represent pathw
ays that have odds ratios <2 and red 
points represents pathw
ays w
ith odds ratios >2. The black dotted line represents an over-representation pathw
ay of <0.05.
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The odds ratio is suggested as a more appropriate scoring system to apply to define
which pathways are over-represented^ as the odds ratio does not have to make any 
assumptions as we are not testing anything ~ it is simply a statistic (like the mean, 
median or variance).
a*e
odds ratio =------
b*d
The odds ratio takes into account the proportion of differentially expressed genes in 
a pathway to the number of non-differentially expressed (background) genes in a 
pathway. Therefore, if an odds ratio is greater than 1 the proportion of differentially 
expressed genes in a pathway is greater than the proportion of background genes in 
a pathway. The components of the odds ratio are plotted in Figure 4.6A, when the 
numerator is greater than the denominator the pathway is classed as over­
represented and coloured red.
Looking back to the Chi Squared and Fisher tests in Figure 4.5, black pathways are 
pathways with odds ratios less than 2 and red pathways have odds ratios greater 
than 2. It is clear that there are differences between pathways classed as over­
represented, as defined using the different approaches. To try to explain this 
finding, the odds ratio equation needs to be broken-down; as 'e' is expected to be 
at least 3 times the size of'd', for an odds ratio of 1 or greater, 'a' would have to be 
greater or equal to b/3. Red dots with insignificant p-values are due to pathways 
with small numbers of background genes, therefore when 'b' is small (i.e. <3), V 
only has to be equal to 1 to have an odds ratio>l. Odds ratios are calculated for 
each pathway in the Reactome database (Figure 4.6B), to exclude noise all odds 
ratios >2 are classed as over-represented
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Figure 4.6. A) Odds ratio components, red pathways represent Reactome pathways with Odds ratios 
>1. B) Odds ratios for each pathway in the Reactome database. Dashed line represents an odds ratio 
threshold of 2.
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4.2.3.1.1 Similarities based on pathways
As discussed in the introduction the thought of pathways acting in isolation is 
physiologically unfeasible. Therefore the aim of this study was to identify groups of 
pathways, which are similar to one another, as they contain similar gene members. 
Identification of such sub-groups of related pathways is the first step in revealing 
groups of over-represented biological pathways, which share common components 
and represent areas of potential cross talk within the larger biological system. Initial 
hierarchal clustering analysis, of the pathway similarity analysis revealed an 
extremely complex dendrogram (Figure 4.7). As identification of pathway groups is 
impossible in this format, data was sub grouped using multi-dimensional scaling.
Figure 4.7. Resultant dendrogram from initial Hierarchal clustering analysis, similarities based on 
pathways. Presented to demonstrate the difficulty in identifying similar pathways without the 
identifaction of smaller subsets. Application of such an algorithm using small clusters identified using 
Multi-Dimensional Scaling would be informative.
As multi-dimensional scaling uses the matrix of dissimilarities, the pathways are 
plotted based on their dissimilarities to one another and the dissimilarities are 
represented by geometric distance. Multidimensional distances are plotted in four 
dimensions, the CAM vs. ANM dataset is shown as an example (Figure 4.9). 
Identification of pathways more similar to one another, in a 4-dimensional space, 
can be confusing. Therefore, pathways were generated as interactive 3-dimensional
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plots to aid subsequent analysis/visualization. For clarity, all datasets were 
visualised as 3D plots in which only over-represented pathways are visualised, a 
screen shot of the CAM vs. ANM normal 3D multi-dimensional plot is shown in 
Figure 4.8. Using these interactive 3D clusters plots, highly interconnected pathways 
were identified and highlighted for investigation in the correct 2-dimensional plane 
(Figure 4.10)
MD<;[sig, 1]
Figure 4.8. CAM vs. ANM dataset. Screen shot of an interactive 3D MDS plot, based on the similarity 
of pathways. Only over-represented pathways are displayed as red dots.
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Figure 4.9. Multi-dimensional scaling based on the similarity of pathways, visualised in four 
dimensions. Non-overrepresented pathways are represented by black points and overrepresented 
pathways (Odds Ratio>2) are represented by red points. MDS number as labelled on axis represents 
the dimensions visualised.
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Although this study is specifically focused on over-represented pathways, all
pathways need to be taken into account when calculating the multi-dimensional co­
ordinates, as excluding them could affect how dissimilar the over-represented 
pathways appear to one another. After calculation of co-ordinates with all pathways 
included, only over-represented pathways are visualised to helped distinguish 
dusters of over-represented pathways observed from the CAM vs. ANM {Figure 
4.10A&B), CAM vs. ATM (Figure 4.10C&D) and ATM vs. ANM (Figure 4.10E&F) 
datasets.
4.2.3.1.1.1 CAM vs. ANM
Six clusters of pathways were identified in the CAM vs. ANM dataset, all in the 1st 
and 3rd dimensions (Figure 4.10B). Pathways within each cluster are listed in 
Supplementary File 4.1. Cluster 5 is the large central cluster of pathways and 
therefore represents potentially the largest site of cross talk between over­
represented pathways, which was the aim of applying Multidimensional scaling and 
is therefore analysed in detail below. The other clusters represent areas of less 
dense clusters and therefore less potential cross-talk, therefore although these 
pathways are over-represented they provide less indication of the small numbers of 
differential regulation effecting large numbers of pathways/processes, a detailed 
analysis of such clusters have been analysed and provided as a resource in 
supplementary chapter 1, section 7.1.1.1.1.
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Figure 4.10. Multi-dimensional plots based on the similarity of pathways. CAM vs. ANM (A and B). 
CAM vs. ATM (C & D). ATM vs. ANM (E & F). Black dots indicate non-over-represented pathways and 
red dots indicate over-represented pathways with odds ratios >2. Clusters of pathways are 
identifiable by coloured boxes. MDS number as labelled on axis represents the dimensions 
visualised.
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Dense cluster 5 represents a range of diverse processes. A subset of over­
represented pathways include immune related processes, with a large proportion of 
differentially regulated genes being up-regulated in interferon signalling and 
interactions between lymphoid and non-lymphoid cells. Also, within this central 
cluster we found a clear group of over-represented pathways involved in energy 
metabolism, specifically beta-oxidation. All differentially regulated genes involved in 
these pathways were up regulated enzymes, suggesting an increase in energy 
generation, through fatty acid oxidation via the mitochondrial beta-oxidation 
pathway.
Interestingly, multiple pathways involved in the transport of energy metabolites 
across the cell membrane were also found to be differentially regulated. These 
include two over expressed facilitated glucose transporters; solute carrier family 2 
member 10 and solute carrier family 2 member 11. In cancer, high levels of cell 
proliferation requires large amounts of energy, therefore glucose is actively 
imported into the cell and glucose transporters are often up-regulated (Macheda et 
al., 2005). The differentially regulated proton-coupled monocarboxylate 
transporter, solute carrier family 16 member 3 was also found to be over­
expressed. This class of transporters are essential for the transport of 
monocarboxylates, such as pyruvate and lactate across the cell membrane (Morris 
and Felmlee, 2008). Finally, zinc and bile salt transporters were also up-regulated. 
Remaining pathways include those affecting cell life or death, such as the cell 
survival promoting nuclear kinase AKT pathway are negativity regulated, with AKT 
itself and CREB both being down-regulated. Pathways involving the regulation of
apoptosis are over-represented, two pro-apoptotic BH3 proteins BID and BAD are
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up regulated, whilst the anti-apoptotic protein BCL-2 is also increased (twice as 
much as BID and BAD) suggesting that on balance cell survival most probably 
remains stable, which agrees with levels of cell survival when cultured in vitro.
4.2.3.1.1.2 CAM vs. ATM
Six clusters of pathways were identified in the CAM vs. ATM dataset, all in the 2nd 
and 3rd dimensions (Figure 4.10D). Pathways within each cluster are shown in 
Supplementary File 4.2. As for the other datasets the dense cluster (cluster 2) is 
analysed in detail here and the other clusters are analysed and provided as a 
resource in Supplementary chapter 1, section 7.1.1.1.2.
Cluster 2 represents by far the largest cluster of connected pathways, including the 
unfolded protein response pathway, which contains the largest amount of 
differentially regulated genes, the pathway is a common cellular stress response 
pathway, triggered by the mis-folding or unfolding of proteins within the endoplasm 
reticulum. Pathways involved in interferon signalling are also over-represented. 
Interferons are released by host cells upon the detection of tumour cells, activating 
an immune response. Interferon's along with several antigen presenting proteins 
(HLA's) are up-reguiated within the myofibroblasts, suggesting increased 
inflammation and a heightened immune response. Genes involved in mTOR 
signalling are down regulated. mTOR up-regulation has been associated with cell 
proliferation, angiogenesis, inhibition of apoptosis and interestingly aerobic 
glycolysis (Sun et ai., 2011). Several other over-represented pathways are involved 
in LKB1 regulating AMPK and AMPK inhibiting mTOR, all differentially regulated 
genes in these over-represented pathways are down regulated. Generally, over-
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represented apoptotic pathways have many down regulated genes, including 
caspases suggested decreased programmed cell death.
Similar to the CAM vs. ATM dataset, pathways involved in fatty acid oxidation are 
also over-represented. The pathway; Activated AMPK stimulates fatty-acid 
oxidation in muscle is over-represented, activation of AMPK stimulates fatty acid 
oxidation and inhibits fatty acid synthesis, genes involved in this pathway are both 
up and down regulated. Enzymes involved in cholesterol biosynthesis are down- 
regulated, suggesting the end product of fatty acid (3-oxidation, acetyl co-A, enters 
the mitochondria to feed into the citric acid cycle, rather than being used to drive 
the biosynthesis of cholesterol. In addition, as seen in the CAM vs. ATM dataset, a 
number of solute carriers pathways are over-represented, the mono-carboxylate 
transporter SLC16A7 is under expressed, whilst SLC16A3 is over-expressed.
Genes involved in basigin (BSG) interactions are down-regulated. BSG is a matrix 
metalloproteinase inducer, which themselves degrade the extracellular matrix. The 
differentially expressed genes in this pathway have mixed expression, several solute 
carriers are over-expressed whist the integrin B1 is under-expressed. In many 
cancers, integrin expression is increased in cells with metastatic potential (Cooper 
et ai., 2002). Finally, differentially regulated genes involved in other cell- 
extracellular matrix interactions over-represented pathways involved in cell- 
extracellular matrix interactions are also down regulated.
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4.2,3.1.1.3 ATM vs. ANM
Five clusters of pathways were identified in the ATM vs. ANM dataset, all in the 1st 
and 3rd dimensions (Figure 4.10F). Pathways within each cluster are shown in 
Supplementary File 4.3. As for the other datasets the dense cluster (cluster 4) is 
analysed in detail here and the other clusters are analysed and provided as a 
resource in Supplementary chapter 1, section 7.1.1.1.3,
Within the dense cluster 4, there seems to be a selection of pathways that fall 
within metabolism of proteins, specifically translation, initiation, processing and 
termination. The majority of such differentially regulated genes are up regulated, 
indicating an increase in protein production. A range of pathways involving cell cycle 
checkpoints, including the activation of ATR in response to replication stress 
pathway. Normal activation of this pathway would inhibit DNA replication and 
initiate DNA repair, therefore the down regulation observed suggests initiation of 
DNA replication and inhibition of DNA repair, supporting other translation pathways 
which have increased expression of differentially regulated genes. All genes 
involved in E2F1 regulated gene expression, the inhibition of replication pathway 
and DNA glycosylases (enzymes involved in base excision repair) are decreased. 
E2F1 usually inhibits gene expression (Iglesias-Ara et al., 2010) and DNA 
glycosylases are enzymes, which are involved in DNA base excision repair, down 
regulation of pathways such as these suggest a lack of checkpoint control and of 
cellular proliferation.
All genes involved in metabolism of amino acids, carbohydrates and fatty acids are
increased. Specifically for the metabolism of carbohydrates, the pentose phosphate
pathway is over-represented and for the metabolism of fatty acids, the (3-oxidation
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pathway is over-represented. Remaining pathways include decreased cell junction 
organisation and cell-extracellular interactions and pathways involving the 
regulation of apoptosis are over-represented, both pro-apoptotic BH3 proteins BID 
and BAD are up regulated, suggesting an increase in apoptotic cell death but as 
mentioned previously these cells are not dying and therefore most probably 
opposing pathways are over-represented within alternative clusters.
4.2.3.1,1.4 Comparison of Dense Pathway Clusters Across 
Datasets.
A similar range of pathways are over-represented and present within the central 
dense clusters across datasets. Common pathways include metabolic pathways, 
those involved in fatty acid p oxidation, cholesterol synthesis and transport of 
metabolites across the cell membrane. All datasets show an increase in fatty -acid 
oxidation but cholesterol biosynthesis is only decreased in the CAM vs. ATM 
dataset, suggesting that it is specifically lost CAMs. Interferon signalling is increased 
in CAM vs. ANM and the CAM vs. ATM datasets, suggesting an increase in 
inflammation in the microenvironment of cancer but not ATM myofibroblasts.
4.2.3.1.2 Similarities based on genes
The aim of this part of the analysis was to identify groups of genes that are similar 
to one and other, due to the range of pathways in which they are members. 
Identifying genes that are present in many over-represented pathways is important, 
as they are the genes that represent sites of cross-talk between pathways. 
Therefore, if differentially expressed they have the potential to affect large numbers 
of processes. Identification of such promiscuous genes may therefore be important,
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as they may be responsible for producing the range of bioiogical processes that 
result in the cancer myofibroblast phenotype.
As for the similarity based on pathways, initial hierarchal clustering analysis, of gene 
similarity revealed an extremely un-clear dendrogram, as the dataset is far too large 
(data not shown). Identification of groups of similar genes was impossible and the 
data needed to be sub grouped using multi-dimensional scaling. Genes are plotted 
based on their dissimilarities to one another, the dissimilarities represented by 
geometric distance, genes are first visualised as interactive 3D plots enabling 
clusters to be identified within the correct 2-dimensions. For all three datasets, six 
clusters of genes were identified in the first three dimensions (Figure 4.11). When 
scrolling through the lists of genes differentially regulated in myofibroblasts derived 
from different regions, as the lists are so extensive a starting point is to look at 
genes which take part in a larger number of differentially regulated pathways, as 
they have the potential to cause most disruption if altered.
4.2.3.1.2.1 CAM vs. ANM
Six clusters of genes were identified in the CAM vs. ANM dataset, two in the 1st and 
2nd dimensions and four in the 1st and 3rd dimensions (Figure 4.11 A and B). Genes 
within each cluster are shown in supplementary excel file 4.4. Cluster 6 is the largest 
central cluster of genes, with genes present in the largest number of over­
represented pathways and therefore represents potentially the largest site of cross 
talk between pathways, which was the aim of applying multidimensional scaling and 
is therefore analysed in detail below. The other clusters represent areas of less 
dense clusters and therefore less potential cross-talk, therefore although these
genes are differentially regulated they provide less indication of the small numbers
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of differential regulated genes effecting large numbers of pathways/processes, a 
detailed analysis of such clusters have been analysed and provided as a resource in 
Supplementary Chapter 1, section 7.I.I.2.I. Cluster 6 represents the largest cluster 
of 296 significantly changed genes, 131 of which provide cross talk between 124 
over-represented pathways (OR<2). The majority of genes in multiple pathways are 
those involved in the DNA polymerase factors, elongation factors, DNA repair, DNA 
replication, cell cycle genes, pro-apoptotic genes, transcription factors and those 
involved in the MAPK/ERK pathway. The proliferating cell nuclear antigen (PCNA) is 
down-regulated and play a role in 25 different pathways, it is a clamp protein 
helping to hold DNA polymerase to the DNA.
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Figure 4.11. Multi-dimensional plots based on the similarity of genes A and B) CAM vs. ANM. C and 
D) CAM vs. ATM. E and F) ATM vs. ANM. Black dots indicate non-over-represented pathways and red 
dots indicate over-represented pathways with odds ratios >2. Clusters of pathways are identifiable 
by coloured boxes. MDS number as labelled on axis represents the dimensions visualised.
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4.2.3.1.2.2 CAM vs. ATM
Six clusters of genes were identified in the CAM vs. ATM dataset, two in the 1st and 
2nd dimensions and four in the 1st and 3rd dimensions (Figure4.11 C and D), Genes 
within each cluster are shown in Supplementary excel file 4.5. As for the other 
datasets, the dense cluster (cluster 6) is analysed in detail here and the other 
clusters are analysed and provided as a resource in Supplementary chapter 1, 
section 7.1.1.2.2.
Cluster 6 is by far the largest cluster, a group of 303 significantly changed genes, 149 
of which provide cross-talk between 110 over-represented pathways (OR<2). Top 
most promiscuous genes include, several types of integrin, both of which are down- 
regulated, a multitude of signalling cascade intermediates, and the fibroblast 
growth factor rector which is also down-regulated. Therefore, the majority of over­
represented pathways include signalling pathways, cell-cell and cell-extracellular 
interaction pathways, transmembrane transport of a wide selection of biological 
molecules and apoptosis
4.2.3.1.2.3 ATMvs.ANM
Six clusters of genes were identified in the ATM vs. ANM dataset, two in the 1st and 
2nd dimensions and four in the 1st and 3rd dimensions (Figure4.11 E and F). Genes 
within each cluster are shown in Supplementary excel file 4.6. As for the other 
datasets, the dense cluster (cluster 6) is analysed in detail here and the other 
clusters are analysed and provided as a resource in Supplementary chapter 1, 
section 7.I.I.2.3.
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Cluster 6 again represents by far the largest group of genes; with 374 significantly 
changed, of which 179 provide cross-talk between 131 over-represented pathways 
(OR<2). The top most promiscuous genes are involved in DIMA 
translation/regulation/repair, chromosome maintenance and multiple signalling 
pathways. In addition, there is a set of over-represented pathways involved in fatty 
acid metabolism, with all genes are up-regulated, and although they are by far not 
the most connected interconnected pathways, mitochondrial |3-oxidation enzymes 
show crosstalk between a maximum of 7 over-represented metabolic pathways.
4.2.4 Network Modularity - Netbox
The online resource Netbox (Cerami et al., 2010), was used to identify similar 
modules within the CAM and ATM myofibroblasts, at different stages of the disease, 
to distinguish driver from passenger genes. Differentially regulated genes were 
connected either directly or through a single linker node (an un-altered gene that 
directly connects two altered genes) to produce a network. Linker genes with 
p<0.05, are more highly connected than would be expected by random chance 
within the same network, and were therefore included in the network.
The CAM vs. ANM dataset generated a network of 711 differentially regulated 
genes and 325 linker genes, resulting in 142 modules (47 modules with >4 gene 
members). Details of all modules and linker genes are given in Supplementary File 
4.7. An observed local network modularity score of 0.615088 and a random local 
modularity score of 0.006481 resulted in a scaled network modularity score of 
307.876. Therefore, showing the CAM vs. ANM network demonstrates more local 
modularity than would be expected by random chance. Previous analysis in chapter
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3 shows that 818 differentially regulated CAM vs. ANM genes were unable to be 
mapped to pathways by any canonical pathway tool. Using this algorithm, 156/818 
are mapped onto modules using the Netbox software tool. A selection of the largest 
detected modules are shown in Figure 4.12, all of which contain genes which were 
unable to be mapped to canonical pathways. Biological processes relating to each 
module were retrieved using Cytoscapes BinGo plug-in. The biological processes of 
the CAM vs. ANM modules include; Response to stimulus/DNA damage; Regulation 
of metabolic processes; Nucleotide metabolic processes; Fatty- acid 
oxidation/energy metabolism; Apoptosis/cell death; DNA replication/DNA repair; 
Transcriptional regulation and Cell cycle/cell division, mitosis and M-phase. The 
two largest modules, relating to RNA processing and translation, are not shown, as 
their large size would affect the clarity of the figure and they did not incorporate 
any genes that were un-mapped to canonical pathways.
The ATM vs. ANM dataset generated a network of 835 differentially regulated genes 
and 189 linker genes, resulting in 245 modules 77 modules >4 gene members). 
Details of all modules and linker genes are given in Supplementary File 4.8. An 
observed local network modularity score of 0.611947 and a random local 
modularity score of 0.004807 resulted in a scaled network modularity score of 
290.317. Therefore, like the CAM vs. ANM dataset, the ATM vs. ANM network also 
demonstrates more local modularity than would be expected by random chance. 
200/1049 differentially regulated genes, which were unable to be mapped to 
canonical pathways, are included in modules using this Netbox software tool. The 6 
largest modules containing genes that were un-mapped to canonical pathway are
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shown in Figure 4.13. The ATM vs. ANM modules biological processes include; 
Signal transduction, Response to stimulus/DNA damage; DIMA replication/DNA 
repair; Transcriptional regulation; Cell cycle/cell division/mitosis and M-phase 
cellular organelle organisation. Importantly, clusters of modules in the CAM vs. 
ANM and ATM vs. ANM datasets reveal real biological processes, demonstrating 
that modules detected within the network are not just an artefact of biological 
networks, as suggested previously (Hallinan, 2004). Comparison of modules 
detected in both datasets also reveals modules involved in similar biological 
processes. The CAM vs. ATM dataset generated a network of 648 differentially 
regulated genes and 102 linker genes. However, the modules were surprisingly 
weak, only 4 modules came through, with the largest containing over 400 genes. 
Details of all modules and linker genes are given in Supplementary File 4.9. Upon 
analysis, this large module contained a range of very different biological pathways, 
from transcription, chromosomal maintenance to fatty acid metabolism. This 
dataset was not processed further.
We were interested to see if the Netbox tool could be used to identify patient 
specific modules, according to patient prognosis scores, and then look at module 
conservation across all samples. Therefore, CAM vs. ANM good and CAM vs. ANM 
bad differentially regulated genes were analysed to reveal common and unique 
modules. The good patient prognosis network consisted of 80 genes with no 
statistically enriched linkers (p<0.05), which resulted in 15 modules (8 modules >4 
gene members) (Figure 4.14A). The bad patient prognosis network consisted of 72 
genes with 36 linkers (p<0.05), resulting in 10 modules (8 modules >4 gene 
members) (Figure 4.14B).
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There are 11 genes that are commonly mapped to modules within both the 'good' 
and 'bad' CAM vs. ANM patient prognosis groups, which are represented by large 
network nodes (Figure 14A and B). The common differentially regulated genes 
include; CBL, COX4I1, KIF5B, KPNB1, KRAS, MAPSK2, NRIP1, PRPF4, SF3B1, SHC1 and 
TPR. This list includes several proto-oncogenes and genes involved in common 
signalling transduction pathways, such as CBL, KRAS, SHC1 (Thien and Langdon, 
2001). A couple of genes are connected to energy metabolism including COX4I1 and 
NRIP1. COX4I1 is the terminal mitochondrial respiratory chain enzyme, producing 
ATP from the citric acid cycle, fatty acid metabolism and amino acid oxidation. It is 
interesting to note that NRIP is down regulated, as RIP proteins are nuclear receptor 
interacting proteins, which bind to and inhibit nuclear receptors regulating energy 
metabolism enzymes (Rosell et al., 2011). The remaining genes are involved in 
nuclear export, pre-mRNA processing and splicing. Notably, all of these genes 
change in the same direction in good and bad prognosis datasets, with around half 
displaying progressive trends in bad prognosis patients. These commonly 
differentially regulated genes, may represent possible 'driver genes', who's change 
in expression could control a large number of biological processes and be causative 
of the gastric cancer phenotype.
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As differentially regulated genes differ between fgood' and 'bad' prognosis, 
common genes will link to different differentially regulated genes, resulting in 
modules clustering differently and the assigned biological process may changing 
slightly. Both prognosis groups have similar signalling and energy metabolism 
modules, the good patient prognosis groups other modules tend to be translation 
and transcription related, whilst the bad patient prognosis group modules tends to 
be mitosis, cytoskeleton organisation, chromatin remodelling and gene silencing via 
mRNA and epigenetics. Larger differentially regulated gene sets, as for the general 
CAM vs. ANM and ATM vs. ANM datasets, may be required to reduce the amount of 
variation in module biological process assignment.
The two modules labelled with a blue star (Figure 4.14) represent modules were no 
statistically relevant biological process could be assigned, these relate to module 1 
in the good patient prognosis set and module 0 in the bad patient prognosis 
module. Comparing modules between the two datasets, the gene expression 
direction of change is mixed within most modules. Across the good patient 
prognosis set, genes involved in transcription and regulation of signalling pathways 
are universally down regulated. Within the energy metabolism/fatty acid oxidation 
module, all genes involved in are up-regulated in the bad patient prognosis group, 
and 3/4 of genes are up-regulated in the good patient prognosis group.
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Figure 4.14. A) Good Netbox prognosis module network B) Bad Netbox prognosis module network. 
Modules are densely connected sets of differentially regulated genes (p<0.05), as shown by nodes, 
green representing down-regulated genes and red representing up-regulated genes. Large nodes are 
common differentially regulated genes within the good and bad patient prognosis datasets. Linker 
genes as shown by pink triangles are not differentially expressed but are statistically enriched within 
the network (p<0.05). The statistically relevant (p<0.05) biological process relating to modules was 
defined using the Cytoscape plugin BinGo, blue stars represent modules were no statistically 
relevant biological process could be assigned.
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4.3 Discussion
Preliminary network analysis revealed a high level of connectivity between 
differentially regulated genes within the interactome. The large amount of 
connectivity visualised between genes, which are members of different pathways 
demonstrates that although we tend to think of pathways as having linear order, 
they obviously do not work in isolation. They are highly connected processes that 
share components; therefore, disruption of shared components can potentially 
have dramatic effects on multiple pathways. Genes that were unable to be assigned 
to Metacore, DAVID, Ingenuity or Reactome canonical pathway tools were also 
highly connected within the interactome and directly interact with canonical 
pathway members. Therefore, we have demonstrated that integration of pathway 
enrichment methods with large-scale interactome networks may provide additional 
data relating to the potential global influence of differentially expressed proteins 
that link multiple biological processes or proteins that although not currently 
assigned to defined biological pathways are found to interact with one or more core 
pathway component. Therefore, may exert influence over one or more differentially 
regulated pathways. In order to analyse this phenomenon further it is necessary to 
extract details of all components assigned to each of the differentially regulated 
pathway so that this gene list can then be imported into an interactome network. 
However, it is extremely difficult to extract this information for multiple pathways 
using commercial tools such as Metacore, as the software does not allow large- 
scale export.
In contrast, the open access database, Reactome does allow pathway information
to be freely downloaded. Therefore, with the help of a collaborating statistician we
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exported all human biological pathways from the Reactome database using 
Bioconductor. Hierarchical clustering analysis and multi-dimensional scaling were 
then used to form groups within the data, and reveal either: pathways that contain 
similar gene members, or genes that occur in similar pathways. From this analysis 
we aimed to provide insight into differentially expressed genes that had the 
potential to exert maximal impact on the system by virtue of involvement in 
multiple biological processes and the spectrum of processes that may be effected 
by key differentially regulated genes in cancer derived or adjacent myofibroblasts.
It became apparent that analysing the datasets separately as 'similarities based on 
genes' and 'similarities based on pathways' was difficult. The limitation with this 
multi-dimensional scaling technique was the ability to compare clusters resulting 
from the two types of analysis. Therefore, upon identification of interesting clusters 
of over-represented pathways, identifying the relating duster of significantly 
changed gene was impossible. A conclusion was reached that pathways and genes 
needed to be plotted simultaneously, using a multidimensional scaling technique 
called correspondence analysis (Chapter 5, section 1.6). For this reason, dense 
central clusters of genes and pathways were analysed in detail within this chapter, 
but details of other over-represented pathways and significantly changed genes are 
provided within Supplementary Chapter 1. As the purpose of this analysis was to 
reveal pathways and genes that have the potential to affect a large number of 
processes, dense clusters were analysed in detail. Although an over-view of 
potentially important pathways and genes included within all clusters, including 
those identified within Supplementary Chapter 1 are discussed below.
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Primarily, plotting the pathways and genes as interactive 3-dimensional plots 
dramatically aids the identification of real clusters within the dataset in comparison 
to previous results obtained by canonical pathway tools (Chapter 3). Applying this 
approach across all three datasets, revealed that processes involved in DNA and 
chromosomal maintenance and repair, were over-represented with the 
overwhelming majority of differentially regulated genes being down regulated. As 
were pathways and genes involved in DNA synthesis/replication and replication 
stress. One such re-occurring over-represented process was the Fanconi Anemia 
pathway, which works to maintain genomic stability. Individuals displaying the 
autosomal recessive disorder have increased susceptibility to cancer, although the 
number of cases detected in gastric cancer are low (Pavithran et al., 2002). Again, 
the overwhelming majority of differentially regulated genes in these pathways were 
down-regulated. Finally apoptosis appeared increased across all datasets.
In the CAM vs. ANM and CAM vs. ATM datasets, there are clusters of pathways and 
groups of genes, representing immune related processes. With large proportions of 
differentially regulated genes up regulated in interferon signalling and interactions 
between lymphoid and non-lymphoid cells. Interferons are released by host cells 
upon detection of tumour cells, activating an immune response. Interferons along 
with several antigen-presenting proteins (HLA's) have been up regulated within 
these myofibroblasts, suggesting a heightened immune response in cancer 
associated myofibroblasts.
There are very striking re-occurring clusters of pathways and genes involved in 
energy metabolism over-represented within all datasets, specifically relating to
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mitochondrial p-oxidation pathways. All differentially regulated genes across all
datasets are up regulated metabolic enzymes, suggesting an increase in energy 
generation. Within the CAM vs. ATM dataset, the related pathway 'Activated AMPK 
stimulates fatty-acid oxidation' is over-represented. Activation of AMPK stimulates 
fatty acid oxidation and inhibits fatty acid synthesis; genes involved in this pathway 
are both up and down regulated. Also in the CAM vs. ATM dataset, enzymes 
involved in cholesterol biosynthesis are down-regulated, suggesting the end 
product of fatty acid (3-oxidation, acetyl co-A, enters the mitochondria for the citric 
acid cycle rather than for the biosynthesis of cholesterol. Within the ATM dataset 
an additional pathway, specifically involved in the metabolism of carbohydrates 'the 
pentose phosphate pathway' is over-represented.
At first glance, I was surprised with the large proportion of metabolic pathways, 
with such strong up-regulation of differentially regulated gene members. This 
pattern of changes would be consistent with the basic principles described in the 
'Reverse Warburg effect'. Warburg initially introduced the idea of cancer cells using 
aerobic glycolysis. He suggested that in cancer cells, cellular respiration is 
irreversibly damaged, which leads to an increase of energy production by 
fermentation to replace the lost energy (Warburg, 1956). It has since been proven 
that the mitochondrial function within cancer cells themselves is not defective 
(Fantin et al., 2006). That cancer cells use aerobic glycolysis as a selective growth 
advantage (Heiden et al., 2009) and may be induced by the hypoxia-inducible factor 
1-alpha (HIF-la) (Robey et al., 2005). The 'Reverse Warburg effect', was first 
suggested in 2009, as extension to Warburg's original observation (Pavlides et al., 
2009a). It is suggested that cancer cells induce cells within the cancer stroma to
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become activated, to initiate aerobic glycolysis in neighbouring fibroblasts, causing 
them to secrete lactate and pyruvate in order to 'feed' neighbouring cancer cells. 
Cancer cells take up these high energy metabolites (pyruvate and lactate) and feed 
them into their own TCA cycle generating large amounts of ATP for cell 
proliferation. Therefore, it is possible that the 'Reverse Warburg effect' will explain 
the observed up-regulation of fatty acid synthesis detected in cancer-associated 
fibroblasts in this study. It is possible that cancer associated myofibroblasts may 
utilize ketones as a second rate energy source for themselves, and convert the p- 
oxidation product acetyl-co-A into pyruvate to feed the cancer cells. This issue is 
discussed further in Chapter 5.
In addition, the 'Reverse Warburg effect' would also explain the observed increase 
in the expression of trans-membrane energy metabolite transporters, which was 
detected in all three datasets. Specifically, in the CAM vs. ANM dataset, which has 
the largest number of up regulated transporters, including the differentially 
regulated proton-coupled monocarboxylate transporter, solute carrier family 16 
member 3. Monocarboxylate transporters are essential for the transport of 
pyruvate and lactate across the cell membrane (Morris and Felmlee, 2008). In 
addition, two facilitated glucose transporters were also found to be over-expressed; 
solute carrier family 2 member 10 and solute carrier family 2 member 11. In cancer 
cells, high levels of cell proliferation requires large amounts of energy, therefore 
glucose is actively imported into the ceil and glucose transporters are often up- 
regulated (Macheda et al., 2005). Within the other two datasets, only SLC16A3 is 
also over-expressed in the CAM vs. ATM dataset, and SLC2A11 is over-represented 
in the ATM vs. ANM dataset.
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A further trend, which appeared in all datasets was the fact that signalling pathways 
seem to be most centrally located within multidimensional scaling plots. With a 
number of signalling cascade genes, displaying bottleneck properties, playing roles 
in very large numbers (20+) of signalling pathways. As these genes play roles in large 
numbers of over-represented pathways, they are potential therapeutic targets, if 
the processes they control appear causative of the cancer phenotype. The majority 
of signalling pathways are down regulated in all three datasets. Other main cross- 
talking genes across all datasets include several types of integrin, ubiquitin, and 
ribosomal protein subunits. The set of over-represented pathways involved in fatty 
acid metabolism and metabolite transport although striking, they are by far not the 
most connected interconnected pathways, mitochondrial (3-oxidation enzymes 
show crosstalk between a maximum of seven over-represented metabolic 
pathways.
We wanted to deduce using Netbox (Cerami et al., 2010) whether our networks of
differentially regulated genes were modular. Identification of modules within
networks provides invaluable information about the topology of the dataset. It has
been suggested that functional modules are a key level of cellular organisation, with
functional module separation being due to their molecular/chemical specificity or
cellular localisation. The very structure of modules, gives them very distinct
characteristics. Changes within a module would be possible without affecting the
entire network architecture. Similarly, changes in connections between modules
enable un-related functions to affect one another. It is suggested that modular
structures may facilitate evolution, as if molecules where un-structured or not
modular then it would be difficult to change a gene as it would affect all proteins in
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the cell, the positive alteration of the changed gene may be a disadvantage to 
others. The advantage of modules in evolution is that changing a gene within a 
module may predominantly affect other genes within that module, or neighbouring 
modules which are connected by linker genes. This therefore makes it easier to 
modify, add or delete genes, changing the way in which modules evolve and adapt 
to new changes (Hartwell et al., 1999). Identification of modules within our datasets 
may provide greater insight into of the genes affected upon differential regulation 
of a specific gene, and the biological processes directly linked. Importantly, clusters 
of modules in the CAM vs. ANM and ATM vs. ANM datasets reveal real biological 
processes, demonstrating that modules detected within the network are not just an 
artefact of biological networks, as suggested previously (Hallinan, 2004).
In glioblastoma the p53 pathway is altered but in the different cancers, different 
members controlling this pathway are altered (Cerami et al., 2010). Therefore, it has 
been stated that modules are universal but the genetics within and controlling the 
modules may vary, and this is exactly what we found. We have identified key 
modules occurring within both the CAM and ATM myofibroblasts, and highlighted 
the different gene members altered, based on the severity of the cancer.
The CAM vs. ANM and ATM vs. ANM datasets generated high-scaled network 
modularity scores, demonstrating more local modularity than would be expected by 
random chance and were able to incorporate redundant canonical pathway genes 
into biological modules. The biological processes common within CAM and ATM 
myofibroblasts included: response to stimulus/DNA damage; DNA replication/DNA 
repair; transcriptional regulation; ceil cycle/cell division mitosis and M-phase
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cellular organelle organisation. The cancer unique modules include; regulation of
metabolic processes, nucleotide metabolic processes, fatty- acid oxidation/energy 
metabolism and apoptosis. Whereas, there was only one unique module within 
ATMs; signal transduction. It is very interesting that metabolic modules are unique 
within cancer myofibroblasts, due to the earlier identification of genes related to 
the Warburg effect, suggesting this process may define CAMs from ATMs and give 
them the ability to support and promote tumour progression. Although ATMs 
displayed a larger number of differentially regulated genes than corresponding 
cancer derived myofibroblasts Netbox analysis showed that CAMs actually have a 
different network topology with a wider range of highly connected modules than 
observed in ATMs.
In addition, Netbox was also used to identify modules relating to particular patient 
prognosis scores. When comparing 'good' and 'bad' patient datasets, genes that are 
differentially regulated in both 'good' and 'bad' cancer sets appear to fall within 
similar (but not identical) modules. Both prognosis groups have similar signalling 
and energy metabolism modules, however, good prognosis patient groups also have 
other modules relating to translation and transcription, whilst the bad patient 
prognosis group also have modules relating to mitosis, cytoskeletal organisation, 
chromatin remodelling and gene silencing via mRNA and epigenetics.
However, although there are similarities between the 'good' and 'bad' prognosis 
datasets, the number and type of genes that are differentially regulated within each 
module clearly differ. Several genes are commonly mapped including several proto­
oncogenes, genes involved in common signalling transduction pathways, and a
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couple of genes related to energy metabolism. Notably, all of these genes change 
in the same direction in good and bad prognosis datasets, with around half 
displaying progressive trends in bad prognosis patients. These common 
differentially regulated genes, may represent possible 'driver genes', who's change 
in expression could control a large number of biological processes and be causative 
of the cancer phenotype.
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Chapter Five: Refined analysis of comparative gene expression 
profiles
5 Introduction
With the need for personalised medicine in the future, patient prognosis scores 
have been used to try to predict the stage and type of cancer, in order to administer 
the appropriate treatment. Previously we have used individual patient prognosis 
scores to determine which patients fall within 'good' and 'bad' patient prognosis 
groups. Recently we have been supplied with additional patient survival scores. The 
appropriateness of these survival scores to be able to predict patient prognosis 
needs to be assessed. Within this chapter, two different types of analysis will be 
carried out. Firstly, to compare the molecular and cellular characteristics of cancer 
myofibroblast to adjacent myofibroblasts, in order to understand the biological 
processes and transcription factors which potentially drive tumour related 
phenotypes. As myofibroblasts derived from the site of tumours have been shown 
to grow faster, with increased angiogenic potential and resistance to therapeutic 
drugs {Barclay et al., 2005). This process of non-cancerous cells conditioning was 
initially referred to as 'field cancerisation' (Slaughter et al., 1953).
In this study isolated populations of cancer associated myofibroblasts (CAM), 
matched adjacent (ATM) and absolute normal (ATM) myofibroblasts were used to 
compare the molecular changes that occur in myofibroblasts derived from patients 
with early ('good') or late stage ('bad') gastric tumours.
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5.1 Data analysis
5.1.1 Patient survival and prognosis
Analysis of patient survival and histopathology data (Table 5.1) shows that in several 
cases the patient prognosis scores do not directly correlate with patient survival 
period, in this study prognosis scores < 9 were classified as less advanced tumours, 
representing the 'good' patient sub-group, whilst scores >9 represent advanced or 
metastatic tumours, representing the 'bad' patient sub-group. In terms of survival 
data, patients who survived longer than 24 months were initially classified as having 
good' survival, whilst those patients who lived less than 24 months were classed as 
having 'bad' survival. However, this criterion was ultimately refined to reflect 
positive or negative lymph node status. Significantly this did not change the 
allocation of patients into 'good' or 'bad' sub-groups. Although patients with more 
advanced tumours may be expected to live for shorter periods this was not always 
the case as patients 4, 5, 9 and 13, (samples szl92, szl94, sz271 and szl87 
respectively) have conflicting prognosis and survival scores.
Patient 9 (sz271) and patient 13 (szl87) have very 'bad' histopathology scores, yet 
are still alive, current survival scores are >34 months and >43 months respectively. 
In addition, although patient 4 (szl92) and patient 5 (szl94) do not have conflicting 
histopathology and survival scores, they are both borderline between 'good' and 
'bad' patient sub-groupings. For example. Patient 4 has a relatively 'bad' 
histopathology score (11), yet has lived for 22 months, whilst patient 5 has a very 
'good' histopathology score (4), yet died after 25 months.
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represent 'good' patient survival. C
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Patient prognosis groups were reclassified, in light of newly available patient 
records (Table 5.2). The Patient 14 sample (szl97) was not included in the 'good' 
patient sub-group, as no matched adjacent sample was available for this patient. To 
detect changes in the 'good' cancer subset vs. absolute normal and the 'bad' cancer 
sub-set vs. absolute normal datasets, the data was processed as explained in 
methods chapter 2, section 2.1.1.1; In brief: background oligonucleotide IDs are 
detected and statistically significant oligonucleotide IDs were defined using un­
paired T-Tests and p-values corrected using the Benjamin! Hochberg FDR 
calculation. Finally, oligonucleotide probe IDs were converted into Entrez gene IDs 
using Metacore™.
'Good' patient prognosis groups
1-CAM
All Absolute normal samples
7-CAM
10-CAM
15-CAM
'Bad' patient prognosis group
2-CAM
All Absolute normal samples
3-CAM
8-CAM
11-CAM
12-CAM
Table 5.2. New revised, 'good' and 'bad' patient prognosis groups.
As work on this project progressed further patient information became available 
(Table 5.3), including data on primary tumour invasion, lymph node metastasis and 
distant metastasis. It appeared from this data that lymph node metastasis was a 
'good' predictive measure of cancer severity and relates well to patient survival 
scores (C.Holmberg et a I, 2012). The utility of this method to distinguish 'good' and 
'bad' patient sub-groups was further assessed in this study.
185
Table 5.3. Prim
ary tum
our, regional lym
ph node m
etastasis and distant m
etastasis inform
ation. A
) Scores relating to individual patients B) K
ey providing 
description of prim
ary tum
our, regional lym
ph node and distant m
etastasis scores assigned.
h-* 13
Ln
12 11 01 00 'vj -t* CO NJ
Patient Label
pT2N
0M
0
pT4N
2M
0
PT3N
1M
0
pTIN
BM
O
pT3N
2M
0
pT3N
0M
0
PT3N
1M
0
PT4N
2M
0
pT2aN
0M
0
pTIN
O
M
O
PT3N
1M
0
pT4N
4M
l
pT4N
2M
0
pTIN
O
M
O
Tum
our Staging
o u> NJ t-k o
5.1.2 Refined Principal Component Analysis
PCA analysis of CAM vs. ANM patient samples B \ ATM vs. ANM samples, before 
and after batch correction (also discussed in Chapter 3) are shown in Figure 5.1 
shows. This analysis shows that global gene expression profiles for CAMs and ATMs 
are distinct from ANM gene expression profiles. Although global gene expression 
profiles of cancer and adjacent samples are very similar (Figure 5.2A&B), patient 
pairs correction does improve separation of the two sample types (Figure 5.2C&D).
2IKj Dimension
Figure 5.1. Principal component analysis. A) Un-corrected cancer (red) and absolute normal (green) 
patient samples. B) Batch corrected cancer and absolute normal samples C) Un-corrected adjacent 
(blue) and absolute normal (green) samples D) Batch corrected adjacent and absolute normal 
samples.
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Figure 5.2. Principal component analysis of CAM (red) and ATM (blue) patient samples. Panels A and 
B show un-corrected data while panels C and D show patient-pair corrected data. Cages represent 
ellipsoids, which depicts the spread of the data based on the centre of origin.
Lists of statistically significantly changed genes from each dataset were generated in 
Parteks® agglomerative hierarchical clustering method with Euclidean distance and 
average linkage. The hierarchal clustering analysis was used to cluster patients 
based on the similarity of their gene expression profiles. This clustering analysis was 
carried out using varying fold-change thresholds to generate hierarchical cluster
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plots to determine the minimum fold-change threshold that effectively segregated 
myofibroblast subgroups, whilst retaining the highest number of genes possible. As 
shown in Figure 5.3, the samples within the CAM vs. ANM and ATM vs. ANM 
datasets correctly segregate into two distinct groups at any fold-change cut-off 
between 1 and 2. Thus demonstrating that a p-value significance threshold of <0.05 
alone, without an imposed fold-change cut-off is sufficient to define the expression 
profiles that differentiate CAM or ATM samples from ANM samples. All the samples 
used in this study were from Hungarian patients, apart from one English patient 
(28AN/AV53). Interestingly, within the ATM vs. ANM dataset, the English patient 
sample was the first to un-cluster at a 2.2 fold change threshold (data not shown).
A
Samples
gj 3l5'
Figure 5.3 Hierarchal clustering analysis of differentially regulated genes (p<0.05, no fold change cut­
off). (A) CAM vs. ANM samples, (B) ATM vs. ANM samples. Trees represent the similarity between 
individual CAM (red), ATM (blue) and ANM samples (green).
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Data for the CAM/ATM comparison does not separate well on p values alone (Figure 
5.4A) for the CAM vs. ATM dataset. Therefore, for this data set it was important to 
define the optimal fold-change cut-off to apply, whilst retaining the maximum 
number of genes. Although the samples separate perfectly when applying a 2-fold 
change cut-off, a 1.6 fold change cut-off also provides separation of most CAM and 
ATM samples (Figure 5.4 B and C), and this threshold is often selected as an 
arbitrary cut-off in many microarray studies. To establish an appropriate fold- 
change cut-off, for use in this study gene lists obtained using a 1.6 or 2 fold-change 
were used to compare pathway over-representation profiles using Metacore™. 
Metacore™ pathway analysis revealed that the application of a 2 fold change cut-off 
resulted in such a small gene list, that mapping genes to over-represented pathways 
proved difficult, with a maximum number of 3 differentially regulated genes being 
mapped to the most significantly enriched pathway, therefore a 1.6 fold change cut­
off was deemed acceptable for pathway analysis (Section 5.3.3).
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Figure 5.4. Hierarchal clustering analysis of differentially regulated genes (p<0.05) CAM vs. ATM (A) 
No fold change cut-off. (B) 1.6 fold change cut-off. (C) 2 fold change cut-off. Trees represent 
similarity between individual CAM (red) and ATM samples (blue).
5.1.3 Correlation analysis
5.1.3.1 Relationship between prognosis score and gene 
expression profiles.
All studies described in this chapter were performed after removal of ATM sample 
Sz45/22 and ANM sample Sz41/2. All three datasets, CAM vs. ANM, CAM vs. ATM 
and ATM vs. ANM were analysed to determine which genes exhibit expression 
trends that correlate with patient prognosis scores (Table 5.1). An example of the 
type of plot obtained by this method is shown in Figure 5.5A. Genes with scores
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es
approaching 1 or -1 have a high positive or negative correlation between expression 
level and tumour classification score for each patient sample. The optimal 
correlation threshold level was independently defined for each dataset by 
establishing the minimal level of correlation at which 'good' and 'bad' patient 
subgroups remained fully resolved. The resulting, subsets of differentially expressed 
genes represent a trend which upon exploration with bigger cohorts, may provide 
potential insights into stage-specific gene expression signatures, which may in turn 
indicate the biological processes that are selectively changed in 'good' and 'bad' 
prognosis cohorts. Expression profiles for genes with positive correlation scores 
>0.78 with prognosis scores in CAM vs. ANM myofibroblasts were clustered using 
the complete linkage algorithm, calculating Euclidean distances to generate a 
hierarchical clustered heat-map (Figure 5.5B). For this analysis, a correlation 
threshold of 0.78 was found to be the minima! level at which 'good' and 'bad' 
patient subgroups were resolved, resulting in a set of 9 genes whose expression 
profiles reflect the stage of tumour progression. In this analysis, no genes were 
found to exhibit negatively correlation with prognosis scores (data not shown).
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Figure 5.5. Spearmans correlation analysis score calculated for each gene. B) ATM vs. AN, genes 
positively correlated (>0.77) with prognosis score. C) CAM vs. AN, genes positively correlated (>0.78) 
with prognosis. D) CAM vs. ATM, genes correlated with prognosis, >0.79. Patient sample numbers 
are represented on the horizontal axis and Entrez gene Ids are represented on the vertical axis. 
Yellow represents up regulation. Red represents down regulation.
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The nine genes, which show strong correlation with tumour classification scores, 
indicate trends that may provide insights into tumour development within 
myofibroblasts derived from the cancer region. Three of these genes have large 
positive fold changes in patients with prognosis scores >9 ('bad'), compared to 
patients with prognosis scores <9 ('good') these are: PCCA (Entrez ID 5095) 
propionyl CoA carboxylase, TBK1 (Entrez ID 29110) TANK-binding kinase 1 and 
NSUN5 (Entrez id 55695) NOP2/Sun domain family member 5. Whilst the other 6 
have large negative fold changes in 'bad' compared to 'good' patient derived 
myofibroblasts; DNMBP (Entrez ID 9682) dynamin binding protein, KDM4A (Entrez 
ID 9682) lysine (K)-specific demethylase 4A, NSF (Entrez id 4905) N-ethylmaleimide- 
sensitive factor, GLRX3 (Entrez ID 10539) glutaredoxin 3, KLF2 (Entrez ID 10365) 
KruppeMike factor 2 and E2F7 (Entrez ID 144455) E2F transcription factor 7.
Patient samples 4 and 13 both have relatively 'bad' prognosis scores of 11, 
however, both were labelled as 'conflicting' (Table 5.1), as these patients both lived 
longer than may have been expected. Within the correlation analysis, sample 4 
clusters with 'good' patients, whereas sample 13 clusters with 'bad' patients. Data 
from patients' samples 4 and 13 were re-moved and the correlation analysis was 
repeated, to see if hierarchical clustering of the restricted cohort would generate 
better segregation of 'good' or 'bad' patient sub-groups. However, removal of these 
patients failed to improve clustering following correlation analysis (data not shown).
Following correlation analysis of the ATM vs. ANM dataset (Figure 5.5C) a 
correlation score threshold of 0.77 was found to be optimal. The 'good'/'bad' 
separation was not as clear as displayed within the CAM vs. ANM dataset but 'bad'
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patients displaying two distinct types of 'bad' patient subgroups. No genes showed 
strong negative correlation with prognosis scores (data not shown).
With respect to CAM vs. ATM correlation analysis, 36 genes that show a strong 
positive correlation with tumour classification stage score were defined using an 
optimised correlation threshold of 0.79 (Figure 5.5D). In total 36 genes were found 
to have larger fold changes in cancer samples from patients with worse prognosis 
scores (Supplementary table 5.1). The 'good' and 'bad' patient sub-groups separate, 
with the 'good' patients clustering centrally with two distinct 'bad' patient sub­
groups segregating on either side. This separation is much more distinct than the 
sub-groups identified within the ATM vs. ANM and therefore sub-groups are 
defined as: 'bad' sub-group A [patients 2(sz45), 3(szl90) and 9(sz271)], and 'bad' 
sub-group B [patients 4 (szl92), 8(sz265), ll(sz305) and 12(308)]. Interestingly, this 
data confirms results obtained in the CAM vs. ANM correlation analysis, regarding 
the clustering of inconclusive patients. In particular, 'inconclusive' patient 4, was 
now found to be clustered with the 'bad' patient group. As 'inconclusive' patient 
13 does not have an associated ATM sample this was not included in the analysis. 
To understand why such 'bad' patient cohorts may exist, and to try and correctly 
place sample 4 within a definite myofibroblast subgroup, patients H.pylori status 
was investigated. Interestingly all patients within 'bad' subgroup A were not 
infected by H.pylori, whereas all patients within 'bad' subgroup B were infected, 
with the majority being the cagA positive strain, which is known to be associated 
with gastric cancer. Therefore, it appears that comparison to paired ATM samples is 
needed to correctly define inconclusive patients within 'good' or 'bad' patient
cohorts. It is worth noting that no obvious bias in terms of age and sex was
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identified in relation to either 'bad' subgroups. Also; neither 'good1 nor 'bad' 
subgroups show any correlation with batch processing dates. Interestingly, all three 
of the correlation heat-maps show that fold expression changes for genes with high 
correlation scores in 'bad' patient sub-groups were noticeably larger than those 
observed for genes showing correlation to prognosis scores in 'good' patient sub­
groups.
5.1.3.2 Variance of gene fold changes
To investigate the apparent trends in gene expression observed in correlation 
analysis heat maps, the variances of genes fold changes for patients within 'good' 
and 'bad' sub-groups were calculated. Results from this analysis clearly show that 
'bad' patients have much larger fold changes in gene expression than 'good' 
patients (Figure 5.6).
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Figure 5.6. Box plots representing the variance in Log Fold change of genes for all individual patients. 
(A) CAM vs. ANM. (B) CAM vs. ATM. (C) ATM vs. ANM. Patient sample Ids and associated patient 
prognosis category are represented on the x axis, patient prognosis scores<9 are classified as 'Good' 
and patient prognosis scores >9 are classified as 'Bad'.
As boxplots use log fold changes for all genes, they allow an un-bias way of 
assessing 'inconclusive' patients. For the case of inconclusive patient 13 ('bad' 
prognosis score but 'good' survival score), the correlation analysis based on tumour 
classification score clusters sample 13 with 'bad' patients, in direct contrast to its 
survival scores (>43 months). Significantly, boxplots of all genes fold-change 
variances, provide a clear distinction, with sample 13 displaying a large variance.
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Since small variances in fold change is associated with 'good' patient tumour 
classification scores, while large variances in fold change is associated with 'bad' 
patient tumour classification scores. It is clear that patient samples can be 
accurately assigned to either 'good' or 'bad' prognosis score sub-groups simply by 
defining the relative degree of variance in gene expression levels, where 'bad' 
patient sub-groups exhibit large variance in gene expression profiles while 'good' 
patient sub-groups show significantly less variance in gene expression.
Inconclusive sample 4 (prognosis score 11 and survival score 22 months) was 
classified within the correlation analysis as 'good' upon comparison to absolute 
normal samples and 'bad' when compared to adjacent samples. Boxplots clarify 
this, as fold-change variances, are small within the CAM vs. ANM dataset and large 
within the CAM vs. ATM dataset. Placing this patient in alternative prognosis groups 
depending on the comparative dataset. As stated earlier, upon relation to patients 
H.pylori status patient 4 is infected with the cagA positive H.Pyori strain along with 
all other patients identified within 'Bad' patient prognosis group B. Thus suggesting 
that the comparison of cancer samples to adjacent samples may be a more accurate 
method of predicting patient prognosis.
Survival scores generated may not be accurate enough to use alongside gene 
expression data to predict prognosis due to other factors influencing the longevity 
of the patients, such as the ability of an individual's immune system to impair 
growth of cancer cells (Bhardwaj, 2007). Further to the earlier statement regarding 
patients with 'bad' prognosis scores having larger fold-changes in gene expression 
patterns. When log fold changes genes are plotted against prognosis scores for each
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patient, for the CAM vs. ANM and the CAM vs. ATM datasets (Figure 5.7), patient 
samples with worse prognosis scores can be seen to have larger variance of all gene 
log fold changes. In addition, it is clear that patients with worse prognosis scores 
have a larger variance of log fold changes of the highly correlated genes. By 
representing the data in this format it allows genes that have large fold changes and 
highly correlation with prognosis scores to be identified (represented by dashed 
circles in Figure 5.7B).
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Figure 5.7. Individual genes log fold changes plotted against patient prognosis scores. (A) CAM vs. 
ANM, red points represent genes with optimum correlation scores >0.78. (B) CAM vs. ATM, red 
points represent genes with optimum correlation scores >0.77. (C) ATM vs. ANM, red points 
represent genes with optimum correlation scores >0.77. Genes with fold changes < 1.6 are not 
displayed.
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Subsequently, for the CAM vs. ANM and the CAM vs. ATM datasets, genes that 
show high correlation to tumour classification score and have log fold changes >1.6 
or a 2-fold change were identified. Genes with fold changes above a 2-fold change 
have a better potential of being confirmed using qPCR. Three genes are identified in 
the CAM vs. ANM dataset as being highly correlated (0.78) and having greater than 
2 fold changes (Table 5.4). E2F7 is shown to be highly down regulated in 10/14 
patients, having small fold changes {<2 fold) in 4 patients with the best prognosis 
scores and is increasingly down regulated in patients with poor tumour 
classification scores. Patient 9 has a tumour classification score of 12 and E2F7 is 
most highly down regulated in this patient (by 9.6 fold). E2F7 is a transcription 
factor, specifically a transcriptional repressor that is believed to have negative 
effects on the regulation of the cell cycle and cellular proliferation (de et al., 2003). 
The kruppel-like factor KLF2 is a transcription factor down regulated in five patients 
with the worst prognosis scores. KLF2 is down regulated in many cancers and is 
seen as a potential tumour suppressor, due to its roles in inhibiting proliferation and 
migration, and initiating apoptosis and senescence (Black et al., 2001). One 
particular KLF2 is known to be epigenetically silenced in cancer cells by EZH2 
(Taniguchi et al., 2011). DNMBP is a scaffold protein that links dynamin with actin 
and is thought to be involved in membrane trafficking. Interestingly, DNMBP is only 
down regulated by >2 fold in CAMs derived from patient 3, which is the patient with 
the worst tumour classification score of 13, showing >2 fold changes in all three 
genes (KLF2, DNMBP and E2F7). Mitochondrial enzyme Propionyl-CoA carboxylase 
(PCCA) was the only highly correlated gene that was added when the fold change
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threshold was lowered to 1.6 PCCA was over-expressed in two patients with the 
worst tumour classification scores, 1.8 fold in patient sample 3 and 1.66 fold in 
patient sample 9.
Patient Prognosis KLF2 DNMBP E2F7
Sample 1 ProgS 'good' Entrez Entrez -2.14711Entrez
Sample 2 Progll 'bad' -5.22738
Sample 3 ProglB 'bad' -2.6884 -2.82622 -3.5363
Sample 4 Progll inc -2.60948
Sample 5 Prog4 inc
Sample 7 Prog7 'good'
Samples Progll 'bad' -2.36734
Sample 9 Progl2 inc -4.56794 -9.65032
Sample 10 Prog? 'good' -2.58598
Sample 11 Progl2 'bad' -3.51655 -6.0506
Sample 12 Progl2 'bad' -2.14483 -3.90297
Sample 13 Progll inc -2.45251 -4.45644
Sample 14 Prog6 'good'
Sample 15 ProgS 'good'
Table 5.4. CAM vs. ANM, genes highly correlated with prognosis (0.78) and expression > 2 fold 
change. Fold change in individual patients and associated patient prognosis score.
In general, more genes showing high correlation with prognosis scores and >1.6 fold 
changes were identified in the CAM vs. ATM dataset when a 0.79 correlation 
threshold was applied (Supplementary excel file 5.2). Increasing the stringency, 12 
genes were found to have fold changes >2 in at least one patient and have the 
potential to be confirmed using qPCR (Table 5.5). In particular, patient 3 has the 
highest tumour classification score (13) and the largest number (11/12) of highly 
correlated genes with +/- fold changes >2.
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1075 1535 2627 3710 3915 5327
Sample CTSC CYBA GATA6 ITPR3 LAMC1 PLAT
1 Prog5 (G)
2 Progll(B) 2.241117 -2.12066
3 Progl3(B) 2.633758 2.137527 -27.2294 -2.37362 -4.57122 3.376451
4 Progll (1) -2.18877
5 Prog4 (1)
7 Prog7 (G)
8 Progll (B) 2.949478
9 Progl2 (1) 2.019918 -12.0161 2.019528
10 Prog7 (G)
11 Progl2(B) 4.273957
12 Progl2(B) 2.419692
15 ProgS (G)
8519 51678 63898 79090 150864 100128893
Sample
Ifitml MPP6 SH2D4A TRAPPC6A famll7b
LOG
100128893
1 Prog5 (G)
2 Progll(B) -2.60606 3.876139 -4.60362
3 Progl3(B) 6.179804 -2.45994 -8.46253 2.613945 -9.88329
4 Progll (1) -2.42006
5 Prog4 (1)
7 Prog7 (G)
8 Progll (B) -2.06323
9 Progl2 (1) -2.07144 2.365152 -4.03056
10 Prog7 (G)
11 Progl2 (B) 2.459117 2.05854 2.55737 2.35559
12 Progl2 (B)
15 ProgS (G)
Table 5.5. CAM vs. ATM, genes highly correlated with prognosis (0.79) and expression greater than 2 
fold change. Fold change given for individual patients and associated patient prognosis score. 
Prognosis categories abbreviated as G= 'good', B= 'bad' and I = inconclusive.
The transcription factor GATA6 (2627) is expressed differently in the two 'bad' 
patient subgroups, it is particularly down regulated in patients 3 and 9 from 'bad' 
subgroup A, with the worst patient tumour classification score but is up-regulated 
in 'bad' subgroup B containing patient samples 8, 11 and 12. GATA6 is amplified in 
pancreatic cancer, contributing to the oncogenic phenotype (Kwei et al., 2008). In 
colon cancer, GATA6 was also shown to be up-regulated, causing an indirect 
decrease in apoptosis. Increased expression of GATA6 causes a decrease in the LOX- 
1 protein, which in turn decreases Fas induced apoptosis (Shureiqi et al., 2007).
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Cathepsin C (CYSC) is a cysteine proteinase up-regulated in two 'bad7 patients from 
subgroup A. Cathepsin C is able to activate other cysteine proteinases, together 
they cleave proteins, degrade the extracellular matrix and increase inflammation, 
and are known to be up-reguiated in many cancers (Mohamed and Sloane, 2006). 
Interestingly, the expression of plasminogen activator PLAT is increased in 'bad' 
subgroup A, patients 3 and 9. PLAT is a tissue type plasminogen activator, a 
secreted serine protease, which converts the pro-enzyme plasminogen to plasmin. 
Plasmin is a protease which may increase cell migration and remodelling and is 
known to be up-regulated in a range of tumours, including, glioma (Sandstrom et 
al., 1999), melanoma (Meissauer et al., 1991), pancreatic (Paciucci et al., 1998) and 
breast cancer {Chernicky et al., 2005). MPP6, a membrane associated kinase, 
involved in tumour suppression {Tseng et al., 2001) is decreased in patient sample 3 
with the worst prognosis score. Inositol 1,4,5-trisphosphate receptor (ITPR3) is 
responsible for the release of calcium from intracellular stores, and is up-regulated 
in two patients from 'bad' subgroup A. SH2D4A is a member of the SH-2 signalling 
protein family and has been suggested as a possible anti-cancer drug, as it binds 
directly to the oestrogen receptor, inhibiting oestrogen-induced cell proliferation (Li 
et al., 2009). In keeping with these findings, SH2D4A has been down regulated in all 
patients within subgroup A.
Additional patient information became available {Table 5.3) during the course of 
this study, as a result it was suggested that lymph node metastasis may accurately 
predicts patient prognosis scores. Therefore, in addition to using patient prognosis 
scores, correlation analysis was conducted to identify genes whose expression
profiles correlate with lymph node metastasis. Firstly, for both datasets, CAM vs.
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ANM and ATM vs. ANM, no clear separation was shown to differentiate patients 
with little or extensive lymph node metastasis, when correlation analysis was 
conducted comparing lymph node metastasis to gene expression (data not shown). 
Previously, correlating patient Prognosis scores to gene expression profiles for the 
CAM vs. ATM myofibroblast dataset revealed two distinct 'bad' patient subgroups. 
We were therefore interested to determine if the same trend was observed when 
correlating lymph node metastasis to gene expression, in agreement with previous 
correlation analysis, patients with worse lymph node metastasis exhibited more 
extreme changes in gene expression profiles (Figure 5.8A). Each gene was plotted 
against its correlation score, which ranges between -1 and +1 (Figure 5.8B). A 
correlation threshold of 0.70 was found to be the optimum positive correlation 
threshold to apply, resulting in 280 genes (Supplementary excel file 5,3) having 
larger fold changes in patients with increased lymph node metastasis (Figure 5.8C). 
Of those positively correlating, 109 had gene expression profiles > 2 fold change in 
at least one patient (Supplementary excel file 5.4). Genes did not negatively 
correlate with prognosis (data not shown).
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Genes that were found to be positively correlated with lymph node metastasis were
then compared to genes that show positive correlation with patient prognosis 
scores. 28 genes were found to positively correlate with both prognosis score and 
lymph node metastasis (Table 5.6), of those genes 9 had fold changes >2. Therefore, 
only 3 genes which positively correlated with patient prognosis scores and had fold 
changes >2 were not shown to also correlate with lymph node metastasis.
Entrez Gene ID Gene name Entrez Gene ID Gene name
51 ACOX1 23641 LDOC1
166 AES 51082 POLR1D
1075 CTSC 51647 FAM96B
1535 CYBA 51678 MPP6
1635 DCTD 51759 C9orf78
2627 GATA6 56927 GPR108
3915 LAMC1 63898 SH2D4A
4677 NARS 79090 TRAPPC6A
5327 PLAT 79180 EFHD2
6223 RPS19 84056 KATNAL1
8666 EIF3G 114818 KLHL29
10581 IFITM2 127281 Clorf93
11153 FICD 389541 C7orf59
23107 MRPS27 100128893 LOC100128893
Table 5.6. Genes whose expression is positively correlated with both patient prognosis and lymph 
node metastasis. Genes highlight in grey, have fold changes >2 in at least one patient.
5.1.4 Metacore analysis 
5.1.4.1 Data processing
After removal of outlying patient samples identified during principal component 
analysis (Section 5.3.1.1) and re-grouping of 'good' and 'bad' patients, lists of 
background detected gene lists and significantly changed genes are displayed in 
Table5.7.
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Dataset Background 
gene list
Significantly changed 
Genes (p<0.05)
CAM vs. ANM 10,618 2,298
ATM vs. ANM 10,818 3,881
CAM vs. ATM 10,678 1,892
'good' CAM vs. ANM 10,632 313
'bad' CAM vs. ANM 10,568 1415
Table 5.7 Numbers of background detected gene lists and significantly changed genes (p<0.05) for 
each dataset.
The p-values of all significantly changed gene lists (apart from the CAM vs. ATM 
dataset) were corrected using the Benjamini-Hochberg false discovery rate (FDR) 
algorithm. In the CAM vs. ATM dataset no genes passed a FDR <0.05 and the gene 
list passing, an un-corrected p-value <0.05 was much smaller than the other two 
datasets. This is most likely due to the high degree of similarity in gene expression 
profiles expected for samples taken from the same tissue of the same individual, as 
highlighted by principal component analysis (Figure 5.2). Of the 1,892 genes found 
to be significantly changed in the CAM vs. ATM dataset, 132 have a fold change 
greater than 1.6, and 49 have a fold change greater than 2, Metacore™ analysis 
below will be used to select the optimum threshold to apply. The number of genes 
classed as statistically changed in the 'bad' patient sub-set is far higher than that 
observed in the 'good' patient sub-set, suggesting that samples derived from 'bad' 
sub-group patients are consistently more altered when compared to normal 
samples than those derived from patients with 'good' prognosis scores. Metacore™ 
GeneGo analysis was performed on five different datasets; CAM vs. ANM; ATM vs. 
ANM; CAM vs. ATM and 'good' or 'bad' CAM vs. ANM datasets. Twenty eight 
pathways were found to be over-represented (p<0.05) in the CAM vs. ANM dataset
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in comparison to 35 pathways that were over-represented (p<0.05) in the ATM vs.
ANM dataset
Within the CAM vs. ANM dataset a large proportion of over-represented pathways 
(10/28); are involved in regulation of the cell-cycle; of which all differentially 
regulated genes are down-regulated; suggesting a decrease in cell proliferation. Cell 
cycle dependent kinases, genes required for spindle-chromatin attachment, the APC 
complex, which induces exit from mitosis and are all down-regulated throughout, 
suggesting a decrease in progression through the cell cycle stages and an overall 
decrease in proliferation. Genes involved in DNA damage induced apoptosis and 
DNA damage checkpoint arrest are down-regulated, leading to loss of internal 
safety controls upon potentially dangerous DNA damage. Down-regulated DNA 
damage caretaker proteins, include Brcal and Brca2. Brcal and Brca2 were both 
linked to breast cancer in 1994 (Hall et al., 1990; Wooster et al., 1994) and since 
then have been shown to be important caretaker genes, repairing DNA, remodelling 
chromosomes and orchestrating DNA damage signalling (Duncan et al., 1998; 
Durant and Nickoloff, 2005). The over-representation of ketone body synthesis 
pathway is associated with increased expression of key enzymes regulating the 
conversion of acetyl-CoA into the soluble ketone body, acetoacetate (Williamson et 
al., 1971).
Within the ATM vs. ANM dataset, interestingly the top pathway hit was cholesterol 
biosynthesis, with all of the differentially regulated genes up-regulated. As for 
ketone body synthesis (over-represented in the CAM vs. ANM dataset), cholesterol 
biosynthesis can also be synthesised from acetyl Co-A. This apparent difference in
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the metabolism of acetyl-coA within CAMs and ATMs is interesting and will be 
investigated further. A smaller number of cell cycle pathways (6/35) are over­
represented within the ATM vs. ANM dataset, compared to the CAM vs. ANM 
dataset. Although the trend is the same, with all differentially regulated genes 
hitting the pathway down regulated, suggesting an over-all decrease in cell 
proliferation. Another similar trend to the CAM vs. ANM dataset, is the large 
number of genes that are down-regulated in response to DNA damage, usually 
involved in cell cycle arrest, such as Brcal. Unique pathways coming through within 
the ATM vs. ANM dataset include an increase in the expression of genes controlling 
smooth muscle contraction, which seems appropriate for the myofibroblast cell 
type and an overall increase in the expression of genes involved in a range of amino 
acid metabolism pathways.
To establish an appropriate fold change cut-off to define a statistically significant 
CAM vs. ATM gene list, Metacore™ analysis was carried out using both a 1.6 and 2 
fold change cut-off. Table 5.8 displays statistically over-represented (p<0.05) 
pathways, after applying a 0, 1.6 or 2-fold change cut-off. As expected, the more 
stringent the fold change cut-off applied the smaller the resulting gene list and 
fewer pathways were found to be statistically over-represented. Nearly half of the 
pathways statistically over-represented (p<0.05) in the 2 fold change gene list were 
also over-represented (p<0.05) in the 1.6 fold change gene list, indicating that 
completing a 1.6 fold change cut-off wouldn't impair pathway enrichment analysis.
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Upon closer assessment, due to the smaller differentially regulated 2 fold cut-off
gene list, very few genes are mapped to the over-represented pathways, with only 1 
gene being mapped in some cases. This makes it difficult to assess pathway 
assignment accurately; therefore the 2 fold over-represented pathways alone was 
deemed uninformative. It may be sensible to complete pathway analysis with both 
gene lists, using the over-represented pathways from the 2 fold cut-off as the high 
confidence set and the over-represented pathways from the 1.6 fold cut-off list to 
provide larger numbers of differentially regulated genes mapped to pathways. The 
red highlighted pathway, the development TGF-beta-dependent induction of EMT 
via MARK, is common in all three-fold change cut-off pathway lists. Transforming 
growth factor itself is increased but only one other member of the pathway is 
differentially regulated, therefore its role is unclear. Although TGF-P is known to 
stimulate differentiation of a fibroblast into the activated myofibroblast phenotype 
therefore it is interesting that this pathway has appeared statistically enriched in 
CAMs compared to the ATMs. In addition, EMT takes place within the cancer cells, 
therefore this pathway would not be expected to take place in the myofibroblast 
themselves. The fact that TGF-p expression is increased in CAMs compared to ATMs 
suggests that CAMs may stimulate EMT though increased secretion of TGF-(3.
Understanding the unique pathways over-represented in the 'good' and 'bad' 
prognosis sub-groups may help us to understand the biological processes that 
contribute to patient prognosis. Whilst understanding the common pathways over­
represented in the 'good' and 'bad' prognosis groups may help us to understand the 
biological processes that are inherently changed throughout the different stages of
tumour development. Firstly, 30 pathways are over-represented in the 'bad'
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prognosis score, CAM vs. ANM dataset, which is far more than the 12 pathways
over-represented in the 'good' prognosis score, CAM vs. ANM dataset. This increase 
in the number of statistically significantly over-represented pathways could be due 
to the larger number of significant changed genes found in the 'bad' prognosis 
group. Twenty six pathways are uniquely over-represented in the 'bad' dataset 
(Table 5.9), there is a general down regulation in all genes involved in the four over­
represented cell-cycle pathways, suggesting an overall decrease in cell proliferation, 
consistent with the overall datasets. Interestingly, three separate over-represented 
pathways are involved in DNA damage detection and down-regulation of caretaker 
genes, such as Brcal. No such signature arises within the 'good' prognosis dataset, 
and may suggest a genetic difference, which causes a more aggressive tumour. As 
also shown in the CAM vs. ANM dataset, mitochondrial ketone body biosynthesis is 
over-represented. With enzymes converting acetyl-CoA into the soluble ketone, 
acetoacetate, displaying increased expression.
Twelve pathways are uniquely over-represented in the 'good' dataset (Table 5.10). 
With the top four unique pathways are involved in the cell cycle, Cell cycle_Start of 
DNA replication in early S phase passes a FDR corrected p-value of 0.05, displaying 
four genes with reduced expression, and in fact, genes within all the unique cell 
cycle pathways are down regulated. In addition, the genes differentially regulated 
throughout the majority of the unique 'good' Metacore™ pathways seem to be 
either CDKs or the transcription factor E2F1. However the 'Translation_(L)- 
seienoaminoacids incorporation in proteins during translation' pathway identifies 
the increased expression of a range of anti-oxidant enzymes, whose increase in 
expression is often in response to oxidative stress. This increase in expression of
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protective anti-oxidant enzymes within patients with 'good' prognosis scores could 
be a protective mechanism, decreasing the aggressiveness of the tumour. Within 
the G-protein signalling K-RAS regulation pathway, K-RAS is down regulated, 
suggesting a decreased propagation signal from growth factors within 'good' 
patient subgroups.
Ceil cycle Start of DNA replication in early S phase
Cytoskeleton remodeling_Role of PKA in cytoskeleton reorganisation
Cell cycle Transition and termination of DNA replication
DNA damage ATM/ATR regulation of Gl/S checkpoint
Fatty Acid Omega Oxidation
Nicotine signaling in dopaminergic neurons, Pt. 2 - axon terminal
Transport„ACM3 in salivary glands
Leucine, isoleucine and valine metabolism/ Rodent version
Leucine, isoleucine and valine metabolism.p.2
DNA damage DNA-damage-induced responses
Serotonin modulation of dopamine release in nicotine addiction
Cardiac Hypertrophy Ca(2+)-dependent NF-ATsignaling in Cardiac Hypertrophy
Cell adhesion Cadherin-mediated cell adhesion
Vitamin E (alfa-tocopherol) metabolism
DNA damage Role of Brcal and Brca2 in DNA repair
Neurophysiological process Glutamate regulation of Dopamine D1A receptor signaling
Cytoskeleton remodeling ACM3 and ACM4 in keratinocyte migration
Mitochondrial ketone bodies biosynthesis and metabolism
Apoptosis and survivaLDNA-damage-induced apoptosis
Apoptosis and survival Granzyme A signaling
Cell cycle_Sister chromatid cohesion
Immune response^Antigen presentation by MHC class I
G-protein signaling Regulation of CAMP levels by ACM
Leukotriene 4 biosynthesis and metabolism
Cytoskeleton remodeling Alpha-lA adrenergic receptor-dependent inhibition of PI3K
Cholesterol and Sphingolipids transport / Recycling to plasma membrane in lung (normal and CF)
Table 5.9. Uniquely over-represented Metacore pathways in the 'bad' tumour classification set.
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Cell cycle Cell cycle (generic schema)
DNA damagejnhibition of telomerase activity and cellular senescence
Cell cycle Regulation of Gl/S transition (part 2)
Cell cycle ESRl regulation of Gl/S transition
Translation(L)-selenoaminoacids incorporation in proteins during translation
G-protein signaling K-RAS regulation pathway
Cell cyclejnfluence of Ras and Rho proteins on Gl/S Transition
Translation Regulation of translation initiation
Polyamine metabolism
HETE and HPETE biosynthesis and metabolism
Signal transductionJNK pathway
Signal transduction_ERKl/2 signaling pathway
Table 5.10 Uniquely over-represented Metacore pathways in the 'good' tumour classification set.
Four pathways are commonly over-represented within both the 'bad' and 'good' 
dataset. Differentially regulated genes involved in apoptosis and survival Granzyme 
A signalling, are down regulated, suggesting a decrease in apoptosis across patients 
with varying degrees of tumour progression.
'bad' p-value 'good' p-value
Gamma-secretase proteolytic targets 0.000524 1.612E-07
Gamma-Secretase regulation of neuronal cell development and
function 0.000259 0.00009861
Proteolysis Putative ubiquitin pathway 0.03357 0.03753
Regulation of lipid metabolism Stimulation of Arachidonic acid
production by ACM receptors 0.01317 0.01808
Table 5.11. Common over-represented Metacore pathways within the 'good' and 'bad' tumour 
classification set. Red p-values represent the most significant over-representation result between 
the 'good' and 'bad' prognosis groups.
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5.1.4.2 Transcription factor analysis
The Metacore™ one click analysis function was used to identify transcription factors 
that were statistically changed (p-values<0.05) within the CAM vs. ANM, ATM vs. 
ANM and CAM vs. ATM datasets. Differentially expressed (p<0.05) transcription 
factors identified in all three datasets are shown in Table 5.12. in total 51 
transcription factors were identified in the CAM vs. ANM dataset, 35 in the CAM vs. 
ATM and 95 in the ATM vs. ANM patients.
Numbers of differentially regulated transcription factors (p<0.05) common 
between: CAM vs. ANM; CAM vs. ATM and ATM vs. ANM, are shown in Figure 5.9. 
Lists of genes represented in each segment are given in Supplementary excel file 5.5
CAM vs. ANM CAM vs. ATM ATM vs. ANM
ETV3 STAT1 ETV3 TFE3
ETS1 GTF2I XBP1 TWISTI
YY1 EGR1 EPAS1 FUBP1
RXRA RELA EGR1 CTCFL
HCFC1 SOX9 YY1 SMAD3
ATF3 BCL6 CBFB MAFB
E2F1 ETV5 RXRA ZNF350
FUBP1 PURA HCFC1 KLF2
HES1 MZF1 CTCF ZNF83
ZNF263 HHEX ATF3 ETV1
ZNF217 SMAD5 E2F1 MYEF2
IRF9 SMAD3 RFX5 PPARA
CREB1 F0XD1 ARNT2 SP1
F0SL1 ILFS BCL6 ETS1
CLOCK MEF2C IRF2 F0X03
MTF1 RUNX1 ZNF148 TEAD1
GLI2 DDIT3 ETV5 NFAT5
NFATC3 CREB3 HES1 SMAD5
TFAM C2orf3 SATB1 KLF13
PA2G4 KLF6 ZNF263 GTF2A1
HMGB2 PBX1 F0XJ2 CEBPG
KLF6 MEF2A ZNF217 CREB1
TCF3 KLF3 NR1H3 STAT2
MEF2C ATF1 GABPB1 TFDP2
MAX GMEB2 NR2C1 AR
DDIT3 ZRANB2 TCF21 FOXK2
DBP ETS1 CLOCK ZBTB33
TCF4 NFAT5 PRDM2 ATF6
NFE2L1 NFATC3 P0U6F1 MTF1
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TEADl FOSL2 CNBP E2F7
CTCFL GLI2 GLI2 TWIST2
ILF3 MXD1 RBPJ SIX4
E4F1 RUNX2 PA2G4 NFIA
KLF2 SREBF2 HMGB2 ARNT
F0X03 TAF9 KLF6 GMEB1
NFAT5 NR2F2 NFATC4
STAT2 TCF3 ELK4
TFDP2 MEF2C ZFHX3
F0XK2 KLF5 GTF2A2
ZBTB33 MAX ZNF224
ATF6 MAF THRA
LRRFIP1 DDIT3 NPAS2
EGR1 TEAD3 TEAD4
E2F7 NR2F1 SREBF2
SIX4 DBP NFATC1
ETV5 MZF1 MAZ
SMAD5 NFATC3 TCF4
ELK4 GTF2I
THRA
MZF1
SREBF2
Table 5.72. Differentially expressed transcription factors identified in, CAM vs. ANM (FDRp<0.05), 
CAM vs. ATM (p<0.05) and ATM vs. ANM (FDR p<0.05) datasets. No fold change cut-off was applied 
in this analysis.
CRN VS. ABS (51) CRN VS. RDJ (35)
RDJ VS. RBS (95)
Figure 5.9. Venn diagram displaying the over-lap of differentially regulated transcription factors 
(p<0.05) in the CAM vs. ANM, CAM vs. ATM and ATM vs. ANM datasets.
216
Gene expression profiles of the differentially regulated transcription factors were 
visualised in Partek® using hierarchal clustering analysis. The CAM vs. ANM dataset 
(Figure 5.10) shows the gene expression profiles of differentially regulated 
transcription factors at p<0.05 (Figure 5.10A) or p<0.05 and 1.6 fold change (Figure 
5.10B), which separates the cancer samples (red) and absolute normal samples 
(green) perfectly. Transcription factors are also separated into two clear groups, 5 
transcription factors are down regulated in the cancer-derived samples compared 
to the normal and 9 transcription factors are up regulated in the cancer samples 
compared to the normal. These two facts together, result in a clear four quadrant 
hierarchical clustering plot.
Comparable analysis of the ATM vs. ANM dataset (Figure 5.11) revealed very similar 
findings to the CAM vs. ANM dataset, in that, the gene expression of differentially 
regulated transcription factors separate ATM and ANM samples perfectly and also 
segregate transcription factors into two groups; those that are up regulated in 
ATMs and those that are down regulated in ATMs. When no-fold change cut-off is 
applied, the numbers of transcription factors that are over and under regulated in 
adjacent samples is approximately equal. Raising the fold change cut-off to 1.6 
results in similar findings as seen in the CAM vs. ANM dataset, with the majority of 
transcription factors being down regulated in adjacent samples. For the CAM vs. 
ATM dataset (Figure 5.12), hierarchical clustering analysis of differentially regulated 
transcription factors, does not reveal clear separation of cancer and adjacent 
samples. A 1.4 fold change resulted in a slightly better, but not perfect, separation 
of samples, highlighted by the lack of clear red and blue quadrants. Transcription 
factors with the highest fold changes, between 1.4 -1.55 fold-change include;
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DDIT3, S0X9, RUNX1, KLF6 and SMAD3. Overall, upon application of a range of fold
change cut-offs it has become apparent that transcription factor gene expression 
fold changes are not large across any of the datasets.
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Figure 5.10. Transcription factors identified in the CAM vs. ANM differentially regulated gene lists. 
(A) Statistically significant transcription factors FDR p<0.05. (B) Statistically significant transcription 
factors FDR p<0.05 and >1.6 fold change. Individual patients on the x-axis and transcription factors 
on the y-axis. Red patients represent cancer samples, whilst green patients represent absolute 
normal samples.
218
^
G
en
e'
s 
G
en
e'
s
Samples
Tn mn iTn 11 irmn
Samples
ff hfl .I£l. ME
W
Figure 5.11. Transcription factors identified in the ATM vs. ANM differentially regulated gene lists. 
(A) Statistically significant transcription factors FDR p<0.05. (B) Statistically significant transcription 
factors FDR p<0.05 and >1.6 fold change.
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Figure 5.12. Transcription factors identified in the CAM vs. ATM differentially regulated gene lists. (A) 
Statistically significant transcription factors p<0.05. (B) Statistically significant transcription factors 
p<0.05 and >1.4 fold change.
As the differentially regulated transcription factors hierarchal clustering analysis 
failed to separate CAM vs. ATM samples clearly, it seemed sensible to compare 
transcription factors in just the CAM vs. ANM and ATM vs. ANM datasets, as the
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gene expression of these transcription factors gave clear separation of sample 
types. Figure 5.13 shows the similarity of transcription factors with fold changes 
>1.6 that are differentially regulated in CAM and ATM samples. Of those 16 
transcription factors, 13 have larger negative fold changes in the ATM than the 
CAM.
CAM ATM
(24) (36)
Cancer Common Adjacent
DDIT3 DBP TCF21
ETS1 STAT2 MAF
NFAT5 PA2G4 NFIA
TFAM ELK4 MAFB
ILF3 E2F1 EPAS1
GLI2 ETV3 ZNF224
LRRFIP1 CLOCK TWIST1
MEF2C TCF4 NFATC4
HMGB2 NR1H3
KLF2 NR2F1
KLF6 GTF2A2
ETV5 MAX
EGR1 SATB1
E2F7 BCL6
ATF3 CTCFL
HES1 MAI
ZFHX3
MYEF2
KLF5
ETV1
Figure 5.13. The intersection of differentially regulated (p<0.05 and 1.6 fold change) transcription 
factors in cancer and adjacent samples.
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5.1.4.2.1 Transcription factors expressed in 'good' and 'bad'
patient subsets
Transcription factors that were significantly changed (p<0.05) within the 'good' and 
'bad' patient prognosis sub-sets, CAM vs. ANM datasets. Transcription factors were 
identified using the Metacore 'one click analysis' transcription factor tool. Thirty- 
three transcription factors were changed in the 'bad' prognosis dataset, far more 
than the 7 changed in the 'good' patient prognosis set. Transcription factors 
differentially regulated in the 'good' patient prognosis group included RBL1, E2F1, 
CLOCK, MTF1, PA2G4, STAT2 and SMAD5, all of which, apart from STAT2 were down 
regulated. Transcription factors differentially regulated in the 'bad' patient 
prognosis group are listed in Table 5.13
'Bad' patient prognosis transcription factors
RBL1 MTF1
HINT1 BPTF
SCP2 PDIA3
EGR1 PA2G4
RXRA MEF2C
E2F1 MAX
FUBP1 TCF4
ETV5 CTCFL
FOXJ2 KLF6
NF1 F0X03
FOSL1 NFAT5
BRCA1 STAT2
NFE2L3 UHRF1
CLOCK TFDP2
E2F7 ATF6
ARNT NACC1
NFATC4
Table 5.13. Differentially regulated (p<0.05) transcription factors in the cancer vs. absolute 'bad' 
patient prognosis group.
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Comparison of differentially regulated transcription factors in the 'good' and 'bad' 
patient prognosis groups would be interesting to identify transcription factors that 
could potentially regulate the range of significantly regulated genes associated with 
particular prognosis scores. A direct comparison of transcription factors identified in 
each group is shown in Figure 5.14.
Good (7) Bad (33)
Figure 5.14. Intersection of differentially regulated (p<0.05) transcription factors in the CAM vs. AN 
'good' and 'bad' patient prognosis groups. Numbers outside of the circles represent total numbers of 
differentially regulated genes.
Of the six common differentially expressed transcription factors in both the 'good' 
and 'bad' prognosis sub-groups, all but STAT2 were down regulated and 4/6 had a 
more extreme log fold changes in the 'bad' patient prognosis set. The transcription 
factors displaying this progressive change include, E2F1, PA2G4, RBL1 and STAT2. 
E2F1 promotes the expression of cell-cycle and tumour suppressor genes. 
Expression of pro-apoptotic genes, are regulated by E2F1 directly or through E2F1 
transcriptional regulation of P53 (Polager and Ginsberg, 2009). Progressive down- 
regulation of E2F1 within 'bad' patient subgroups suggests a lack of cell-death 
signals within cancer-associated myofibroblasts, thus able to support tumour
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growth in un-desirable environments. PA2G4 dependent on the isoform expressed 
is either an oncogene or a tumour repressor (Liu et aL, 2006). The longer, nuclear 
form inhibits apoptosis whilst the shorter cytoplasmic form inhibits cell 
proliferation. In view of this, progressive down regulation in the 'bad' patient group 
suggests expression of the shorter cytoplasmic isoform.
RBL1 binds to the E2F transcription factor family and inhibits their ability to activate 
cell cycle genes, thus is thought to have roles in tumour suppression by preventing 
progression through the cell cycle (Munger and Howley, 2002). In addition, RBL1 
acts epigenetically as a transcriptional repressor by recruiting chromatin- 
modification enzymes to the promoter (Lai et al., 1999). STAT2 signal transducer 
and activator of transcription, upon activation STAT2 enters the nucleus and binds 
with IFN regulatory factor family protein p48 [ISGF3G), activating transcription 
(Martinez-Moczygemba et al., 1997). Overall decreased expression of these genes 
involved in transcriptional regulation, across patients with worsening prognosis 
scores is in keeping with previous findings, with relation to their roles in supporting 
tumour progression
5.1.5 Epigenetics
Epigenetics is known to play a key role in the differential expression of genes during 
carcinogenesis, yet the role of epigenetic regulation in cancer-associated 
myofibroblasts remains poorly characterised. The fact that cancer-associated 
myofibroblasts seem to retain their ability to confer cancer cell proliferation and 
migration when isolated as purified primary cultures suggests that they have in 
some way been re-programmed. Recent evidence suggests that cancer associated
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myofibroblasts do not accumulate significant chromosomal abnormalities or
mutations as observed for most tumour cells. This raises the possibility that induced 
changes may be conferred by epigenetics. Therefore, we were interested to see to 
what extent expression of proteins involved epigenetic regulation may be changed 
in cancer derived myofibroblasts gene expression, potentially leading to 
oncogenesis. The prefix-epi stands for on top or in addition to, therefore 
epigenetics relates to anything other than information provided by the genetic code 
(Sandoval and Esteller, 2012) . Genes involved in epigenetic regulation can be split 
into two types, epigenetic chromatin modification enzymes and epigenetic 
chromatin remodelling factors. Epigenetic chromatin modification enzymes modify 
the DNA and histones by methylation, de-methyiation, phosphorylation, 
acetlyation, deacetylation and ubiquitination. Although the epigenetic code is 
complex and combinatorial, epigenetic chromatin-remodelling factors recognise the 
modified histones or DNA and remodel chromatin to allow accessibility to DNA gene 
expression. We compiled a list of 164 epigenetic genes, consisting of 83 epigenetic 
chromatin modification enzymes and 81 epigenetic chromatin-remodelling factors 
(Supplementary excel file 5.6 as stated on the Quagen PCA arrays and papers stated 
in methods chapter 2, section 2.9. The 'good' and 'bad' patient prognosis, CAM vs. 
ANM datasets were analysed for differentially regulated epigenetic genes (Table 
5.14). Shared differentially regulated epigenetic genes within the 'good' and 'bad' 
patient prognosis groups include PBRM1 and CHD1, which both show decreased 
expression. PBRM1 acts as a negative regulator of cell proliferation, with 
knockdowns shown to lead to renal cancer (Varela et al., 2011); therefore, its 
reduced expression across patients with varying degrees of tumour severity, and
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increased reduced expression in 'bad' patient subgroups suggests it as a possible 
general epigenetic therapeutic target. The chromatin modification organiser CHD1 
alters the structure of the chromatin on DNA, to control the accessibility of the DNA 
by transcriptional factors. CHD1 generally works to maintain an open chromatin 
structure.
Entrez Gene ID Gene name 'Bad' CAM vs. ANM log FC 'Good' CAM vs. ANM log FC
23468 CBX5 -0.955037952
80854 setd7 -0.864601896
2186 BPTF -0.796579836
54556 Ing3 -0.758565437
23476 brd4 -0.745729218
1108 CHD4 -0.698922229
55193 pbrml -0.691598035 -0.566572281
6597 SMARCA4 -0.69070869
84444 Dotll -0.679232763
1105 CHD1 -0.506866988 -0.333428964
5253 Phf2 -0.245098803
3275 PRMT2 0.358612005
4152 mbdl 0.628257285
23492 CBX7 0.709790185
10783 Nek6 0.864250001
1488 CTBP2 0.435127622
8726 BED -0.447436142
Table 5.14. Differentially regulated epigenetic genes (p<0.05), identified within the 'bad' and 'good' 
patient prognosis, CAM vs. ANM datasets. Green shading represents down-regulated genes and red 
shading represents up-regulated genes.
A larger number of epigenetic genes were differentially regulated within the 'bad' 
patient subgroups, indicating that epigenetic regulation may be more pronounced
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in more aggressive or later stages of cancer progression. Histone methytransferase 
by SETD7, is an important pre-initiation step, which epigeneticaly activates insulin 
and collegenase gene expression (Kwon et alv 2003; Martens et al., 2003), 
coilagenases breakdown collagen within the extracellular matrix. MBD1 binds to 
methylated DNA, inhibiting gene transcription, its down-regulation in 'bad' patients, 
suggests a release of negative control on a subset of genes (Ng et al., 2000). ING3 is 
a member of the inhibitor of growth protein family, the tumour suppressor acts 
through binding to methylated histones, inducing cellular senescence. Reduced 
expression of ING5 has been demonstrated in many cancers (Ludwig et al., 2011). 
Here ING5 is uniquely reduced within the 'bad' patient prognosis group, and 
reduced mRNA expression of an alternative ING family member has previously been 
shown to directly relate to poor prognosis in head and neck cancers (Gunduz et al., 
2008; Ludwig et al., 2011). SMARCA4 has an ATP dependent nucleosome- 
remodelling complex, and many inactivating mutations within this have been shown 
in cancers (Medina et al., 2008; Sudarsanam and Winston, 2000). Therefore, 
SMARCA4 is often referred to as a tumour repressor; acting to repress ZEB1, which 
itself increases E-cadherin expression and initiates epithelial mesenchymal 
transition (EMT) (Sanchez-Tillo et al., 2010).
As numbers of differentially regulated genes given epigenetic roles are relatively 
low, 15/1415 within the 'bad' patient subgroup and 4/313 within the 'good' patient 
subgroup, a 164 gene epigenetic network was generated within the human protein- 
protein interactome. The mapping of such an epigenetic network on to the human 
interactome provides us with essential protein-protein interaction information of
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epigenetics first neighbours. Differentially regulated genes which are not 
characterised as epigenetic genes but directly interact with them can be identified 
within one step networks. Complete lists of differentially regulated interacting 
partners are provided in Supplementary excel file 5.7. The 'bad' patient prognosis 
CAM vs. ANM network identifies 153 differentially regulated genes that directly 
interact with epigenetic genes (Figure 5.15A).
The 'good' patient prognosis CAM vs. ANM network identifies 38 differentially 
regulated genes, which directly interact with epigenetic genes (Figure 5.15B). In 
combination, utilizing the interactome provides a list of around 190 differentially 
regulated genes that directly interact with genes involved epigenetics regulation.
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Yellow nodes are un-differentially regulated epigenetic genes.
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5.1.6 Statistically different gene expression between prognosis 
groups
As a result of correlation analysis described above it became clear that gene 
expression patterns of patients with 'bad' and 'good' prognosis scores were 
different. The 'bad' patients often displayed larger changes in gene expression than 
patients with 'good' prognosis scores. Therefore, a T-test was applied to identify 
genes with significantly different gene expression between the 'good' and 'bad' 
prognosis sub-groups.
Figure 5.16 displays genes with statistically significant difference in log fold-change 
between 'good' and 'bad' patient sets, at three different thresholds, p<0.05, p<0.01 
and p<0.005. At the p < 0.05 level, 191 genes are classified as having statistically 
significant different gene expression between 'good' and 'bad' prognosis patients 
(data supplied in Supplementary excel file 5.8). Seventy-three of which have 
increased expression in 'bad' prognosis patients and 113 have increased expression 
in the 'good' prognosis patients. At the p < 0.01 level, 33 genes are classified as 
having statistically significant different gene expression between 'good' and 'bad' 
prognosis patients (Table 5.16). Only nine of which have increased expression in 
'bad' prognosis patients and 24 have increased expression in the 'good' patient sub­
groups. At the p < 0.005 level, 16 genes are classified as having significantly 
different gene expression between 'good' and 'bad' prognosis patients (Table 5.15). 
Four genes have increased expression in 'bad' prognosis patients and 14 have 
increased expression in the 'good' prognosis patients.
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AFigure 5.16. Genes with statistically significant difference in log fold change between 'good' and 
'bad' patient sets. (A) Genes statistically significant p<0.05. (B) Genes statistically significant p<0.01 
(C) Genes statistically significant p<0.005. Yellow colouring represents under-expression and red 
colouring represents over-expression. Patient labels represent patient prognosis score followed by 
associated 'Good' or 'Bad' prognosis category.
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Statistically different (p^O.Ol) Statistically different (p^O.OOS)
Gene name Direction of change Gene name Direction of change
C15orf44 up in 'good' CDC42BPB up in 'bad'
RWDD4A up in 'bad' KIAA1539 up in 'bad'
MAK16 up in 'bad' SNRNP70 up in 'bad'
SM67 up in 'bad' Hsdl 7bl up in 'bad'
CDC42BPB up in 'bad' bpntl up in 'good'
RBM15B up in 'bad' ZNF816A up in 'good'
KIAA1539 up in 'bad' Tafia up in 'good'
SNRNP70 up in 'bad' ST7L up in 'good'
ZNF407 up in 'bad' CUL5 up in 'good'
Hsdl 7bl up in 'bad' MTERFD1 up in 'good'
Tmeml78 up in 'good' Slc46al up in 'good'
BANK1 up in 'good' CCBL1 up in 'good'
bpntl up in 'good' LOC100130320 up in 'good'
Tuftl up in 'good' lyrml up in 'good'
ZNF816A up in 'good' FAM120C up in 'good'
Tafia up in 'good' BANK1 up in 'good'
ST7L up in 'good'
CUorfS up in 'good'
CUL5 up in 'good'
MTERFD1 up in 'good'
FTSJD1 up in 'good'
FARS2 up in 'good'
RCHY1 up in 'good'
Slc46al up in 'good'
CCBL1 up in 'good'
Rnfl 70 up in 'good'
Tmeml67b up in 'good'
DNAJC27 up in 'good'
LOC100130320 up in 'good'
Arpml up in 'good'
lyrml up in 'good'
FAM120C up in 'good'
ARMCX3 up in 'good'
Table 5.85. Genes with statistically different gene expression (p<0.01 and p<0.005) in 'good' and 
'bad' patient prognosis sets, CAM vs. AN.
Previously in section 5.3.3, a statistical analysis was performed on the 'good' CAM 
vs. ANM dataset and the 'bad' CAM vs. ANM dataset to define which genes were 
differentially regulated in CAMs compared to ANMs, for 'good' and the 'bad' patient
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sub-groups. In theory, genes significantly changed in the 'good' CAM sub-group vs. 
ANMs may also be statistically different between 'good' and 'bad' patients in the 
gene lists above. However, this may not always be the case, as small consistent 
changes may occur and therefore be classed as statistically significant in the 'good' 
CAM vs. ANM dataset. However, if the same consistent values are seen in the 'bad' 
CAM vs. ANM dataset, they will not be detected in the analysis of differences 
between gene expression in 'good' and 'bad' patient subgroups (Figure 5.17).
The number of genes classed as statistically changed in the 'bad' patient prognosis 
sub-set is far more than those in the 'good' patient prognosis set. Therefore, as 
expected far more genes, 46 (3.5%) compared to 12 (4%), are statistically changed 
in the 'bad' CAM vs. ANM dataset and have statistically different gene expression 
profiles compared to the 'good' patient sub-group.
191 Genes statistically 
different between 
'Good' and 'Bad' patients
1415 Genes statistically changed 
'Bad' cancer v/s absolute 
normal
313 Genes statistically changed 
'Good' cancer v/s absolute 
normal
Figure 5.17. Venn diagram representing the crossover of genes identified as statistically significant 
(p<0.05) in the 'good' and 'bad' patient CAM vs. ANM datasets to those identified as having 
statistically different gene expressions (p<0.05) between the 'good' and 'bad' patient prognosis 
groups. Numbers of genes outside the circles represent total numbers within each category.
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5.1.7 Correspondence analysis
Previously in chapter 4, section 4.3.2.1 multidimensional scaling was used to plot 
the genes and pathways within 3 dimensional plots based on either their similarities 
of genes or similarities of pathways. It became apparent that linking clusters of 
genes within one plot to the associated clusters of pathways within another plot 
was difficult. Odds ratios were calculated to define pathways that were over­
represented in each dataset, using all Reactome™ pathways. Although this has been 
carried out on all datasets, only the CAM vs. ANM dataset is shown as an example 
(Figure 5.18). Odds ratios greater than 2 were considered over-represented in all 
subsequent correspondence analysis.
—i------------------------1-------------------------- 1---------- --------------1------------------------- 1-------------------------1-------------------------
0 200 400 600 800 1000 1200
Pathway index
Figure 5.18. Odds ratio's for each individual pathway in the Reactome™ database. Red dotted line 
represents an odds ratio of 2.
Here, using correspondence analysis, clusters of genes and clusters of pathways are 
plotted together on a single 3 dimensional plot, allowing the easy interpretation of 
genes affecting pathways and vice versa, as shown below; genes are represented by 
red dots and pathways are represented by blue dots:
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4an.abs Ard$ord$li[sig.can abs, 2] 
0
ab^efd$ord$li[sig.can.abs, 3]
abs.ord$ord$li[sig.can.abs, 1]
CAM vs. ANM, correspondence analysis of all significantly changed genes and all 
over-represented pathways are displayed in Figure 5.19. As the positioning of points 
on the plot represents similarity of pathways and gene membership, those 
clustered close together must have high similarity. Using the three different 
dimensions together allows the identification of a dense cluster of pathways and 
genes, identified by the turquoise box. Similar solitary dense clusters were 
identified in CAM vs. ATM (Figure 5.20) and ATM vs. ANM (Figure 5.21) datasets. 
Genes and pathways within dense clusters from the CAM vs. ANM dataset are 
provided in Supplementary excel file 5.9, CAM vs. ATM dataset provided in 
Supplementary excel file 5.10 and ATM vs. ANM dataset provided in Supplementary 
excel file 5.11.
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5.1.7,1 CAM vs. AN
Interferons are glycoproteins that are presented at the cell surface upon the 
detection of a virus, infection or tumour cells, subsequently triggering an immune 
response. Specifically, interferon signalling and interferon gamma signalling have 
many shared genes. Rather than there being a lot of crosstalk between these 
pathways, the large number of shared genes appears to be because interferon 
signalling is a parent pathway of interferon gamma signalling. Interferon gamma is 
released from macrophages and its receptor is present on most cells in the human 
body, within this dataset the receptor IFNGR2 is up-regulated, along with the 
majority of differentially regulated genes within the pathways, suggesting a 
stimulation of interferon genes and an anti-viral state. This increase in interferon 
activity could be related to interferon's known relation to increased inflammation 
(Billiau, 1987) as inflammation is known to be precede gastric cancer (Lu et al., 
2006).
Many different pathways involving AKT and CREB have been over represented; 
within the dataset AKT2 itself is up regulated, whilst AKT1 and CREB are down 
regulated. In general, AKT phosphorylates many different targets in the nucleus, 
including CREB, the phosphorylation of CREB leads to its activation and the 
increased transcription of genes regulating cell survival including the proto­
oncogene c-fos {Du and Montminy, 1998; Ponti et al., 2002). Over-represented 
pathways containing these genes include downstream immune signalling, and 
CAMK iV-mediated phosphorylation of CREB. In addition, PTEN, which is up 
regulated, negatively regulates the AKT pathway. The CAMK IV-mediated
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phosphorylation of CREB pathway members is a process that occurs in a large range
of signalling pathways, such as FGF and PDGF signalling and therefore differential 
regulation of its related genes allows for a wide range of downstream targets (Tan 
et al., 1996; Wang et al., 2011). The differentially regulated gene list within this 
dataset are all down regulated.
Three genes involved in RAF activation, including the oncogene KRAS and RAF itself 
are shown to be down regulated. In its active form, the GTPase KRAS converts GTP 
to GDP, simultaneously activating c-RAF (Zhang et al., 1993). This pathway is a 
downstream component of many signalling pathways, which when differentially 
regulated, as shown by the many activating mutations of KRAS found in cancers, 
can have a range of detrimental effects on the cell (Poulogiannis et al., 2012). 
Within cancers, a mutation of KRAS leads to its constant activation, leading to a 
down-stream propagation signal of constant growth factor stimulation.
The dissociation of glucokinase from its regulatory protein appears to be down 
regulated, as glucokinase phosphorylates glucose, converting it into glucose-6- 
phosphate, thus suggests a decrease in glucose catabolism (lynedjian, 2009). 
Conversely however, a pathway involving the transport of glucose molecules across 
the cell membrane is over-represented with two isoforms of the solute 
transporters, SLC2A11 and SLC2A10 being up regulated.
5.1.7.2 CAM vs. ATM
As in the CAM vs. ANM dataset, Interferon signalling and interferon gamma 
signalling pathways are over-represented, yet this time the just over half of the 
differentially regulated genes are down-regulated within these pathways. This lack
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of distinctive increase or decrease of interferon signalling within cancer cells
compared to adjacent cells may represent the similar level of inflammation induced 
within the cancer and adjacent environment.
Two pathways involving the regulation of apoptosis are over-represented, with pro­
survival BCL2 family members being down regulated and pro-apoptotic proteins 
being up regulated, overall this should result in an increase in apoptotic cell death. 
The RAF activation pathway, the RAF phosphorylating MEK pathway and MEK 
activation pathway are all over-represented, with KRAS and NRAS over-expressed in 
ail three. These processes take place in a large number of different signalling 
cascades suggesting KRAS and NRAS as possible bottlenecks, where by their 
differential expression could affect a large number of processes. The increase in 
expression of KRAS and NRAS suggest an increase in activity of their target RAF, 
which in turn phosphorylates and activates MEK, which relates to increased cell 
growth and division.
5.1.7.3 ATM vs. ANM
Thirty-seven genes are differentially regulated in the innate immune system, with 
the majority up-regulated, suggesting an increase in immune response, possibly 
inflicting inflammation and a cancer initiation supportive environment. It is 
interesting that this is such a largely over-represented pathway with many 
differentially regulated genes, are occurring in ATMs myofibroblast and 
inflammation is an early cancer event.
There are 27 genes differentially regulated, in the over-represented 'transmission 
across chemical synapses' pathway. Ten increased expression and 17 with
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decreased expression. As transmission across chemical synapses only occur in
neurons, this pathway is not applicable to the myofibroblast, yet interestingly the 
connection between the cancer microenvironment and neuronal pathways has 
been made previously. In relation to our previous findings in chapter 4, section 
4.2.3.1, we detected differential regulation of a range of metabolic pathways 
similar to the previously described 'Reverse Warburg effect', whereby fibroblasts 
carry out aerobic glycolysis to produce lactate, to feed the cancer cells (Pavlides et 
al., 2009b). Pavlides et al, went on to state that the 'Reverse Warburg effect' and 
'neuron-glia metabolic coupling' are analogous biological processes (Magistretti, 
2009; Pavlides et al., 2010b).
The over-represented L1CAM interactions pathway contains, 24 differentially 
regulated genes, three isoforms of Laminin itself, LAMA1, LAMB1 and LAMC1, are 
over-expressed. Laminins are extracellular glycoproteins which make up part of the 
basement membrane (Yurchenco, 2011) and interestingly in breast cancer, laminin 
has been shown to be increased in fibroblasts from the tumour margin, but not in 
fibroblasts directly from the cancer region (Broes et al., 1988). Thus the difference 
in laminin expression between fibroblasts from different regions could represent 
the ability of the cancer to metastasise through the basement membrane.
Overall, interesting over-represented pathways and promiscuous genes identified 
within the dense clusters for each dataset represent potential points of therapeutic 
intervention. The alteration of a few or even a single gene will have effects on a 
large number of over-represented pathways. Using this technique it is possible to
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carefully select a gene, by understanding the range of pathways it is involved in and 
those believed be causative of the cancer or adjacent phenotype.
5.1.8 Metabolic signature
As described in the previous chapter the 'Reverse Warburg effect' has been 
described as a mechanism of metabolic interaction between cancer cells and cells 
within the cancer microenvironment. To investigate if evidence for similar process 
could be identified in our data, a targeted analysis was performed to identify 
changes in metabolic pathways in each dataset. For this study, the Reactome 
dataset was used without the application of correspondence filters and metabolic 
pathways were identified as over-represented based on an odds ratio score >2 
(Table 5.17).
Within the CAM vs. ANM and the CAM vs. ATM dataset, 3 cycles of the fatty acid p- 
Oxidation pathway were found to be over-represented. This signature was found to 
be reduced in ATM vs. ANM dataset, with only one cycle of the B-oxidation pathway 
being over-represented. Overall, CAM vs. ANM dataset reveals the largest number 
of differentially regulated genes relating to the largest selection of fatty acid B- 
oxidation pathways. Significantly, the expression of genes within these pathways 
was generally found to be up in the cancer and adjacent compared to normal 
samples, however as cancer-associated fibroblasts have a slightly lower up- 
regulation than the adjacent fibroblasts, the associated genes appear reduced 
when comparing CAM vs. ATM.
For saturated fatty acids, there are seven cycles through p-oxidation with each cycle 
of oxidation requiring four individual enzymatic steps. HADHA and HADHB are
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differentially expressed in all three datasets, these subunits form the tri-functional
protein; hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA 
hydralase, which is involved in the three last enzymatic steps of p-Oxidation. The 
enzyme required for the first enzymatic step is not so uniformly expressed, with 
different members of the acyl-CoA dehydrogenase (ACAD) family being 
differentially expressed within the different datasets. The different ACAD members 
have not been annotated within the Reactome pathways and so had to be 
identified within the differentially regulated gene sets. For the CAM vs. ANM ACAD9 
was differentially regulated, for the ATM vs. ANM dataset ACAD9 and ACAD11 were 
differentially regulated and for the CAM vs. ATM dataset ACADM member was 
differentially regulated. Each cycle of {3-oxidation produces one molecule of acetyi- 
CoA and an extra acetyl-CoA generated from the last cycle, with the number of 
cycles needed for a single fatty acid being represented by (C2n) n - 1 oxidations, 
therefore for palmitate (Ci6, n = 8)a maximum of seven passes is required.
The classical 'Warburg effect' describes a process whereby surrounding fibroblasts 
upon activation by cancer cells carry out aerobic glycolysis, producing lactate and 
pyruvate which can then be transported back into nearby cancer cells, via 
membrane transporters, before entering the TCA cycle to drive for oxidative 
phosphorylation (Pavlides et al., 2010b; Pavlides et al., 2009b). However here we 
have not identified an alteration in such glycolytic pathways that would result in an 
end product of pyruvate or lactate but have identified an increase in fatty acid 13- 
oxidation and production of acetyl coA. Acetyl CoA is a high energy source, with 
each molecule of acetyl CoA producing 10 molecules of ATP, when fed into the
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citric acid cycle. Whilst acety! CoA itself cannot be transported between cells, it can
be converted into ketone bodies such as acetoacetate or 3-hydroxybutrate, which 
are known to 'fuel7 tumour cell metabolism when converted from pyruvate 
(Pavlides et al.; 2010a).
Studies have shown that the MCT4 transporter is up regulated in cancer-associated 
fibroblasts displaying the 'Reverse Warburg' phenotype (Pavlides et al., 2009b). As 
this transporter can also transport ketone bodies out of the cell datasets were 
screened for differential regulation of related transporters (Table 5.16). In this 
study, the same transporter SLC1A3 (MCT4) was found to be progressively up- 
regulated based on the proximity of the fibroblasts to the cancer cells, being up- 
regulated 5.5 fold in CAMs and 3.5 fold in ATMs.
In addition, 4 glucose transporters that are alternative transporters to those shown 
to be involved in the 'Reverse Warburg effect' in breast cancer (Pavlides et al., 
2009b), which were; Slc2a6 solute carrier family 2 (GLUTS), Slc2a5 solute carrier 
family 2 (GLUTS), Slc2a3 solute carrier family 2 (GLUT3) and Slc2a8 solute carrier 
family 2 (GLUTS) were all found to be up-regulated in this study.
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CAM vs. ANM
Genename Over-represented pathway Fold change
HADHA Beta oxidation of palmitoyl-CoA to myristoyl-CoA 1.435057531
HADHB Beta oxidation of palmitoyl-CoA to myristoyl-CoA 1.245247808
HADHA Beta oxidation of lauroyl-CoA to decanoyl-CoA-CoA 1.435057531
HADHB Beta oxidation of lauroyl-CoA to decanoyl-CoA-CoA 1.245247808
HADHA Beta oxidation of hexanoyl-CoA to butanoyl-CoA 1.435057531
HADHB Beta oxidation of hexanoyl-CoA to butanoyl-CoA 1.245247808
CRAT Beta-oxidation of very long chain fatty acids 1.440261377
ACOX1 Beta-oxidation of very long chain fatty acids 1.354181826
ACAA1 Beta-oxidation of very long chain fatty acids 1.260756855
HADHA mitochondrial fatty acid beta-oxidation of unsaturated fatty acids 1.435057531
DECR1 mitochondrial fatty acid beta-oxidation of unsaturated fatty acids 1.26565037
HADHB mitochondrial fatty acid beta-oxidation of unsaturated fatty acids 1.245247808
CAM vs. ATM
Genename Over-represented pathway Fold change
HADH Beta oxidation of hexanoyl-CoA to butanoyl-CoA -1.237411811
HADHA Beta oxidation of hexanoyl-CoA to butanoyl-CoA -1.14483521
HADH Beta oxidation of lauroyl-CoA to decanoyl-CoA-CoA -1.237411811
HADHA Beta oxidation of lauroyl-CoA to decanoyl-CoA-CoA -1.14483521
HADHA Beta oxidation of palmitoyl-CoA to myristoyl-CoA -1.14483521
HADHA mitochondrial fatty acid beta-oxidation of unsaturated fatty acids -1.14483521
ACADM mitochondrial fatty acid beta-oxidation of unsaturated fatty acids 1.147683425
ATM vs. ANM
Genename Over-represented pathway Fold change
HADHB Beta oxidation of myristoyl-CoA to lauroyl-CoA 1.248679319
HADHA Beta oxidation of myristoyl-CoA to lauroyl-CoA 1.514652933
ACAA1 Beta-oxidation of very long chain fatty acids 1.348725926
CRAT Beta-oxidation of very long chain fatty acids 1.572007723
SC5DL Cholesterol biosynthesis 1.344902646
NSDHL Cholesterol biosynthesis 1.464412774
DHCR24 Cholesterol biosynthesis 1.491199752
SQLE Cholesterol biosynthesis 1.497376826
POPS Cholesterol biosynthesis 1.518657587
HMGCR Cholesterol biosynthesis 1.643579611
CYP51A1 Cholesterol biosynthesis 1.713404237
FDFT1 Cholesterol biosynthesis 1.713556629
SC4MOL Cholesterol biosynthesis 2.027605686
DHCR7 Cholesterol biosynthesis 2.086732666
IDI1 Cholesterol biosynthesis 2.145916269
TM7SF2 Cholesterol biosynthesis 2.416819435
HMGCS1 Cholesterol biosynthesis 4.403840803
LSS Cholesterol biosynthesis 6.094901379
AG PATS Triglyceride Biosynthesis -1.700541207
ACSL1 Triglyceride Biosynthesis 1.186610321
ACSL3 Triglyceride Biosynthesis 1.214242907
HSD17B12 Triglyceride Biosynthesis 1.231835938
ELOVL5 Triglyceride Biosynthesis 1.291191624
AG PAT3 Triglyceride Biosynthesis 1.431333726
AGPAT2 Triglyceride Biosynthesis 1.437392973
LPIN1 Triglyceride Biosynthesis 2.79518078
Table 5.96. Reactome metabolic changes, over-represented fatty acid pathways (odds ratio >2) and 
differentially regulated genes (p<0.05), for the CAM vs. ANM, CAM vs. ATM and ATM vs. ANM 
datasets.
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Interestingly the fatty acid transporter, SCL27A1 was also found to be up-regulated 
in CAMs vs. ANMs and the CAM vs. ATM fibroblasts, but not in ATM vs. ANM 
fibroblasts, which supports our earlier findings of an over-representation of fatty 
acid-oxidation pathways within cancer associated fibroblasts.
CAM vs. ANM
Genename Over-represented pathway Fold change
SLC2A11 Facilitative Na+-independent glucose transporters 1.756220546
SLC2A10 Facilitative Na+-independent glucose transporters 1.418203451
SLC16A3 Bile salt and organic anion SLC transporters 5.435000361
SLC16A7 Bile salt and organic anion SLC transporters -1.498706699
SLC27A1 Transport of fatty acids 1.414045494
CAM vs. ATM
Genename Over-represented pathway Fold change
SLC16A7 Bile salt and organic anion SLC transporters -1.149752179
SLC16A3 Bile salt and organic anion SLC transporters 1.527248631
SLC27A4 Transport of fatty acids 1.31118933
ATM vs. ANM
Genename Over-represented pathway Fold change
SLC16A1 Bile salt and organic anion SLC transporters -1.488331374
SLC16A3 Bile salt and organic anion SLC transporters 3.591340078
Table 5.17. Over-represented transporter pathways (odds ratios >2) identified within the Reactome 
database and associated with differentially regulated transporters (p<0.05), for the CAM vs. ANM, 
CAM vs. ATM and ATM vs. ANM datasets.
Cholesterol and triglyceride biosynthesis was also found to be up-regulated in ATM 
(Table 5.17), which was confirmed within Metacores™ GeneGo pathways (Figure 
5.22). Principal component analysis revealed a 1.6 fold change cut-off to be 
optimum to reveal changes in the CAM vs. ATM dataset, and was therefore applied 
throughout this chapter. However, it is interesting to mention that removing this 
fold change cut-off, yet retaining a p-value <0.05 and subsequent Metacore 
GeneGo pathway analysis reveals cholesterol biosynthesis as a significantly over­
represented pathway (Figure 5.22). No change in cholesterol biosynthesis is
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detected upon comparison of CAM vs. ANM, within the ATM vs. ANM dataset, 
differentially regulated genes are up regulated and within the CAM vs. ANM dataset 
differentially regulated genes are down-regulated. These findings are summarised 
in the diagram below:
No change between 
ca n ce rafrcTfrejfm af
Up in adjacent\\ 
compared to normal
Down in cancer
compared 
to adjacent
Cholesterol biosynthesis is an alternative route for acetyl-CoA production, and this 
apparent increase in fatty acid storage as opposed to energy metabolism may 
indicate an important difference between cancer-associated fibroblasts and 
adjacent fibroblasts.
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Figure 5.22. Metacore Cholesterol Biosynthesis GeneGo pathway. Differentially regulated genes are 
represented by numbered thermometers within the (1) CAM vs. ATM or (2) ATM vs. ANM datasets. 
Red thermometers represent up-regulated genes and blue thermometers represent down-regulated 
genes, with the relative amounts of red/blue colouring representing the size of the change. Orange 
shapes represent generic enzymes, grey rectangles are reactions and purple hexagons are 
compounds.
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The final data required to support this hypothesis, was evidence of the conversion 
of acetyl-CoA into a transportable ketone body, such as acetoacetate or 3- 
Hydroxybutrate. Metacore™ GeneGo pathway analysis revealed the over­
represented pathway, 'ketone body biosynthesis in the CAM vs. ANM dataset 
(Figure 5.23). Importantly the two enzymes involved in important steps leading to 
the production of acetoacetate are up-regulated within cancer associated 
fibroblasts.
Figure 5.23. Metacore Ketone Body synthesis GeneGo pathway. Differentially regulated genes are 
represented by numbered thermometers within the 1) CAM vs. ANM dataset. Red thermometers 
represent up-regulated genes and blue thermometers represent down-regulated genes, with the 
relative amounts of red/blue colouring representing the size of the change. Orange shapes represent 
generic enzymes, grey rectangles are reactions and purple hexagons are compounds.
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5.2 Discussion
PCA analysis alone revealed little difference between CAMs and ATMs, however by 
applying more stringent thresholds than those needed for CAM vs. ANM or ATM vs. 
ANM comparisons the two myofibroblast populations could be resolved. However, 
the challenge remained, to establish an appropriate fold change cut-off to apply, 
whilst retaining the maximum number of genes to allow meaningful pathway 
enrichment and correspondence analyses. A 1.6 fold change cut-off provided a 
reasonable segregation of samples and a useable size gene list for further analysis. 
To be cautious, a 2-fold change gene list pathway analysis, was also performed to 
provide confidence in 1.6-fold change pathway findings.
Availability of new survival scores during the course of these studies, demonstrated 
that prognostic scores and survival scores do not always correlate, therefore a 
decision needed to be made of the most appropriate scoring system to apply to 
categorise changes related to different stages of tumour development. Plotting the 
variance of the individual patients fold changes revealed an interesting trend, the 
larger the variance of the data the worse the tumour classification score. Patients 
with contradicting prognosis and survival scores, whose outcome is potentially hard 
to predict, displayed variances, which directly correlated with prognosis, based on 
tumour stage score and not with survival.
Prognosis (Tumour stage) scores were then used to perform a correlation analysis, 
comparing individual gene fold changes to prognostic scores. The correlation 
analysis successfully differentiated those patients with conflicting prognosis and 
survival scores. Two lists of highly correlated genes, which distinguish between
251
'good' and 'bad' patient sub-groups show interesting trends, which may provide 
insights into the processes which operate at different stages of tumour 
development. Verification of the observed differences is now being performed by 
rtPCR and/or western blotting.
Throughout this study, several different approaches have been used to provide new 
insight into the molecular processes that are altered and therefore contribute to 
the different phenotypic properties of CAMs and ATMs relative to ANMs.
Biological pathways found to be important in CAMs include a large number of cell- 
cycle regulation pathways, of which all differentially regulated genes are down- 
regulated, suggesting a decrease in cell cycle progression and cell proliferation. This 
same trend was observed in ATMs, although fewer pathway members were 
affected in these cells. Another similar trend in CAMs and ATMs includes DIMA 
damage induced apoptosis or cell cycle checkpoint arrest, involving important 
caretaker genes, such as BRCA1, which was down regulated in both CAMs and 
ATMs. Ketone body synthesis was up-regulated in CAMs, whilst in ATMs, the top 
Metacore™ pathway was cholesterol biosynthesis, with all of the differentially 
regulated genes being over-expressed. As both pathways utilise acetyl-CoA, this 
apparent difference within CAMs and ATMs was interesting and was investigated 
further.
These pathways represent the novel differences between CAMs and ATMs, in all 
stages of cancer, whereas Metacore™ GeneGo pathway analysis of 'good' and 'bad' 
patient prognosis CAM vs. ANM represents over-represented biological processes 
or pathways seen in cancer myofibroblasts at different stages of the disease. This
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may be an interesting resource, which could be used as a starting point, to highlight 
a range of pathways that are differentially active in CAMs and ATMs in different 
patients.
Biological pathways important in 'bad' patient prognosis CAMs include cell-cycle 
pathways, suggesting an overall decrease in cell proliferation. Interestingly, three 
separate over-represented pathways are involved in DNA damage detection and 
down-reguiation of caretaker genes, such as BRCA1. Significantly, this signature is 
not detectable in 'good' prognosis dataset. As also shown in the CAM vs. ANM 
dataset, mitochondrial ketone body biosynthesis is over-represented. With 
enzymes converting acetyl co-A into the soluble ketone, acetoacetate, displaying 
increased expression. In 'good' patient prognosis cancer myofibroblasts, the top 
pathways include cell cycle related pathways with many down-regulated genes, and 
increased expression of a range of anti-oxidant enzymes, whose increase in 
expression is often indicative of exposure to oxidative stress. Patients with this 
antioxidant signature would possibly be more resistant to the oxidative stress, 
which is known to be created by rapidly growing tumours.
Overall, changes in transcription factor gene expression were not large across any 
of the datasets, but differentially regulated transcription factors did include BRCA1, 
which was is down-regulated in both CAMs and ATMs. Transcription factors 
displaying this progressive change include, E2F1, PA2G4, RBL1 and STAT2. In breast 
cancer low E2F levels are associated with a 'good' outcome (Vuaroqueaux et al., 
2007). The only transcription factors displaying this progressive change, with over­
representation is STAT2, which is known to contribute to cancer progression
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(Gamero et alv 2010). The 27 transcription factors differentially regulated, solely in 
patients with 'bad' prognosis scores, are currently being investigated by rtPCR may 
be potentially interesting. In future it would be interesting to investigate if genes 
regulated by differentially expressed transcription factor are components of 
pathways which are predicted to contribute to CAM or ATM related phenotypes.
Interestingly we observed that a larger number of genes involved in epigenetic 
regulation were found to be differentially regulated in the 'bad', compared to the 
'good' patient prognosis group, therefore suggesting that epigenetic changes may 
be more extensive in later stages of gastric cancer. Interestingly ING3 and SMARCA4 
were found to be differentially regulated in our study, INGS's family members have 
previously been linked to poor patient cancer prognosis, and as ING3 is uniquely 
differentially regulated within the 'bad' patient prognosis cancer associated 
myofibroblasts this observation merits further investigation. Equally, SMARCA4 has 
been linked to cancer progression, through effects on the extracellular matrix, 
suggesting that these changes may contribute to the known role of CAMs in 
modifying the stromal extracellular matrix.
Within the previous results chapter the idea of the 'Reverse Warburg effect' was 
introduced it was speculated that a similar process could be taking place within 
gastric CAMs. Interestingly it seems that gastric CAMs may operate a variation on 
this process. The classical 'Reverse Warburg effect' describes a mechanism whereby 
surrounding fibroblasts are programed to carry out aerobic gylcolysis, producing 
lactate and pyruvate, which can then be transported to nearby cancer cells, via
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membrane transporters, entering the TCA cycle for oxidative phosphorylation 
(Pavlides et al., 2010b; Pavlides et al., 2009b).
In this study we have not identified any alterations in glycolytic pathways that 
would result in an end product of pyruvate or lactate. However, gastric CAMs have 
increased expression of the fatty acid transporter SCL27A1 and fatty acid [3- 
Oxidation pathways, with the fatty acid transporter un-differentially expressed and 
the fatty acid f3-Oxidation pathway signature present but much reduced within the 
ATM vs. ANM dataset. Cycles of (3-oxidation produce high energy molecules of 
acetyl Co-A, with each molecule of acetyl CoA producing 10 molecules of ATP, when 
feed into the citric acid cycle.
Cholesterol and triglyceride biosynthesis was also found to be up-regulated in 
ATMs. However, in this case it appears that this may be diverted to drive an 
increase in fatty acid storage, as opposed to energy metabolism. This may 
represent an important and novel difference between CAMs and ATMs. As 
mentioned later cancer cells are thought to induce oxidative stress in surrounding 
fibroblasts, causing them to become 'activated' and to change their metabolic 
behaviour.
In comparison, CAMs exhibit changes, which indicate that in these cells acetyl-CoA 
is converted into a transportable ketone body, acetoacetate, which has been shown 
to has been shown to 'fuel' tumour cell metabolism (Pavlides et al., 2010a). 
Bonuccelli (2010) showed that the end products of glycolysis, 3-hydroxy-butyrate 
and L-lactate stimulate tumour growth. In addition, they show that mitochondrial 
respiration in increased in cancer cells relative to adjacent stroma cells (Bonuccelli
255
et al., 2010a). Overall, addition of energy metabolites, ketones and lactate 
increased cell 'stemnesss' and are shown to correlate with poor clinical outcome, 
specifically metastasis and re-occurrence. In addition to the well-known role of 
acetyl-CoA in driving the TCA cycle, acetyl-CoA and ketone bodies have also been 
shown to increase histone acetylation and drive epigenetic changes (Martinez- 
Outschoorn et al., 2011). Again it would be interesting to see if increased levels of 
acetyl-CoA and ketone bodies could drive epigenetic changes in CAMs or ATMs, 
which in anyway contribute to their altered phenotypes relative to ANMs.
The MCT4 transporter is known to be up regulated in cancer-associated fibroblasts 
displaying the 'Reverse Warburg' phenotype (Pavlides et al., 2009b); In breast 
cancer, increased MCT4 is observed in cancer associated fibroblasts with 'bad' 
patient survival scores and therefore MCT inhibitors were suggested as possible 
anti-cancer therapies (Bonuccelli et al., 2010a). Due to its strong links with the 
'Reverse Warburg effect', we looked into the MCT4 transporter family and found 
they can also transport ketone bodies out of the cell. Significantly MCT4 appears to 
be progressively up-regulated in gastric myofibroblasts (CAM>ATM>ANM), being 
up-regulated 5.5 fold in CAMs and 3.5 fold in ATMs. A model of gastric 
myofibroblast metabolic remodelling is presented in chapter 6, Figure 6.1.
Finally, we were interested to know if hypoxia or oxidative stress may contribute to 
the 'metabolic reprogramming' of gastric myofibroblasts. There is a growing body 
of evidence relating cancer cell induced 'aerobic glycolysis' and mitophagy. Hypoxia 
is thought to be caused by the cancer cells, increasing or activating the transcription 
factor HIF within the cancer associated fibroblasts. HIF binding to hypoxia response
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element (HRE) sites within the MCT4 promoter region, directly causes an increase in 
MCT4 expression. The abolishment of HiF or use of an oxidative stress inhibitor 
removed hypoxia induced promotion of MCT4 (Robey et al., 2005; Ullah et a!., 
2006; Whitaker-Menezes et al., 2011). The deletion of the oxidative defence gene, 
Jun D, in cancer stroma of mice resulted in an increased activated cancer associated 
fibroblast and increased metastasis and angiogenesis (Toullec et al., 2010). in light 
of these observations it will be important to investigate if oxidative stress can 
trigger the observed increase in 'fatty acid metabolism' in gastric myofibroblasts, or 
drive ATMs towards a more dangerous CAM phenotype. As ketone bodies produce 
more energy than lactate and also use less oxygen (Cahill, Jr. and Veech, 2003) they 
are a more powerful metabolite for cancer cells. These finding suggest that 
diabetics high ketonic diets may need to be re-thought to improve prognosis in 
these patients (Bonuccelli et al., 2010b). Work in now underway to verify the 
predicted changes in metabolic status and expression of transport channels in all 
available CAM and ATM cell lines.
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6 Chapter 6 Concluding summary
There is now strong evidence that tumours do not simply grow independently in 
tissues. The growth, proliferation and spread of cancer cells is intimately linked to 
the microenvironment that surrounds the growing tumour. Fragmented evidence is 
emerging to show that normal tissue stroma can be inhibitory for the growth and 
proliferation of cancer cells (lacopino et al., 2012), however, under conditions of 
oxidative stress or chronic inflammation, stromal cells become reprogrammed to 
provide signals and nutrients which aid tissue repair processes. In these, conditions, 
cells that would normally work to maintain normal tissue function actually aid 
tumour growth. This process sets up a self-perpetuating cycle of paracrine 
communication in which cancer cells reprogram stromal cells to produce growth 
factors, metalo-proteases {MMPs), and nutrients, which together drive further 
tumour growth, and induce cancer cell migration. The stroma that surrounds a 
developing tumour may vary in different tissues, or different stages of tumour 
development. However, there is strong evidence that myofibroblasts for a key part 
of the tumour stroma in several tissues. To date, most work in this area has been 
focused on breast, prostate & colon cancers (Barron and Rowley, 2012; Untergasser 
et al., 2005; Yazhou et al., 2004). From these studies it has become clear that 
myofibroblasts within the tumour stroma play an important role in all aspects of 
tumour growth including proliferation and metastasis. However, many of the 
details relating to the origins of myofibroblasts, the ways in which they become 
reprogrammed still remain unclear. In addition, it is also not clear to what extent 
processes observed in one type of tumour niche operate in other tissues, or if
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common affects are elicited by the same molecular changes in different tumours, or 
in different individuals. For example, different components of the same pathway 
may be changed in different situations resulting in the same net effect. In terms of 
gastric cancer very few of these questions have been addressed.
In this study we aimed to analyses the global gene expression profiles of a series of 
primary human gastric myofibroblasts, purified from tissue samples isolated either 
from the site of a tumour, from matched tissue adjacent to the tumour (from the 
same patient), or from normal gastric tissues derived from organ downers. 
Purification of myofibroblast cells and processing of samples for microarray was 
performed in the lab of Professor. Andrea Varro (University of Liverpool). At this 
stage data was provided as Mass normalised data, which had been subject to in- 
house quality control. At the time these studies were performed Mas5 was a more 
widely used form of data normalisation and a method that had been used in many 
published studies. In a retrospective analysis of this data (described in Chapter 3) 
we used the AQM package to re-assess overall data quality and provide insight into 
the possible effects that batch processing may have had on data quality or 
interpretation. In addition, we also performed a second retrospective study to 
assess the possible limitations of using the Mas5 normalisation method, as opposed 
to the now more commonly used RMA method. Reassuringly the AQM analysis of 
data quality showed that most arrays were of acceptable quality and despite the 
high number of batch processing dates used in the study, only two arrays were 
found to be significant outliers, when compared to all other arrays. Also, these two 
arrays did not appear as outliers, after batch or patient correction was performed.
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With respect to the comparisons of using RMA or Mass methods to normalise
primary data; Relatively small differences in gene numbers or altered processes 
were detected when using identical stringent thresholds (p<0.005, with a £2 fold 
change threshold), similar to those used in our initial analysis (Chapters 3 and 5). 
However, the potential value of the RMA method does become apparent when 
using less stringent thresholds, where far more changed genes are represented. In 
light of this observation it is reasonable to conclude that RMA normalised data may 
provide a greater range of information than the Mas5 data used in our initial 
studies. This may be particularly true for the types of multivariate/correspondence 
analyses described in Chapters 4 & 5. In light of this data we have now initiated 
further studies to assess the benefits of using RMA normalised data in these 
approaches. Despite the fact that Mas5 normalisation methods may limit the 
amount of information available for analysis there is no reason to believe that 
robust signatures that were identified from this data are not real or significant. 
Indeed, several of the predicted signatures and functional predictions made from 
this data have since been verified in the Sanderson lab, including the differential 
expression of surface transport channels, the altered metabolic status of CAMs and 
most significantly the fact that myofibroblasts from different prognostic patient 
subgroups (identified in Chapter 5) actually induce subgroup specific changes in 
gene expression profiles when AGS gastric cancer cells are conditioned with media 
derived from CAMs from different prognostic sub-groups. Most significantly, this 
also applied to detectable differences between the two different 'bad7 CAM 
subgroups. Due to the relatively small number of available primary myofibroblast 
cell lines available for use in this study, we cannot say with certainty that these are
260
generic trends that would be seen in all patients with similar stage tumours, or that 
the gene expression signatures that define these subgroups would be effective 
biomarkers. However, these are nevertheless very interesting observations, which 
are supported by our more recent experimental studies. As such, data generated in 
this project should provide useful insights, which can be used to guide future 
studies into the relevance of these trends in larger patient cohorts, or to guide 
further experimental work into the correlation between CMA or ATM 
reprogramming, tumour development and patient prognosis.
Considering results from our study in light of information emerging from the study 
of cancer microenvironment interactions in other tissues, several similarities and 
novel observations have emerged. Firstly, our data has provided the first 
information, to suggest that both gastric CAMs and ATMs undergo metabolic 
reprogramming relative to gastric ANMs. Our finding generally support the principle 
of the reverse Warburg effect, proposed by Lisanti et al from work performed on 
Breast tumours (Pavlides et al., 2009b).
The classical 'Reverse Warburg effect' describes a process whereby 'activated' 
cancer associated fibroblasts carry out aerobic gylcolysis, producing lactate and 
pyruvate, which is then transported to nearby cancer cells, via membrane 
transporters (MCT4 & MCT1), where they then feed into the TCA cycle for oxidative 
phosphorylation (Pavlides et al., 2010b; Pavlides et al., 2009b). In comparison to 
this model, we did not identify any alterations in glycolytic pathways that would 
result in an end product of pyruvate or lactate. However, we found that CAMs have 
increase expression of the fatty acid transporter SCL27A1 and up-regulation of fatty
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acid (3-Oxidation pathways. In comparison the SCL27A1 transporter was not up 
regulated in ATM and fatty acid (3-Oxidation appeared reduced within ATM vs. ANM 
data. In addition, gastric CAMs showed evidence of the conversion of acetyl-CoA 
into transportable ketone bodies, such as acetoacetate, which has been shown to 
'fuel7 tumour cell metabolism in other studies {Pavlides et al., 2010a). Also, the 
ketone body 3-hydroxy-butyrate is known to increased cancer cell growth and act 
as a chemo-attractant, which increases cancer cell migration (Bonuccelli et al., 
2010a). Our observations on the changes seen in gastric CAMs are also consistent 
with recent evidence that mitochondrial respiration in increased in cancer cells 
relative to adjacent stromal cells (Bonuccelli et al., 2010a). Overall, increased 
production of ketone bodies and lactate are shown to correlate with poor clinical 
outcome. As increases in acetyl-CoA and ketone bodies have both been reported to 
enhance epigenetic remodelling, leading to changes in gene expression (Martinez- 
Outschoorn et al., 2011) it would be interesting to investigate the effects that 
elevated lactate and ketone body levels may have on gene expression in gastric 
CAMs, ATMs or AN Ms.
The MCT4 transporter is up regulated in breast cancer-associated fibroblasts 
displaying the 'Reverse Warburg' phenotype (Pavlides et al., 2009b); In this case, 
increased MCT4 expression is observed in CAMs with 'bad' patient survival scores. 
Therefore, MCT inhibitors were suggested as possible anti-cancer therapies 
(Bonuccelli et al., 2010a). Due to its strong links with the 'Reverse Warburg effect', 
we looked into the MCT4 transporter family and found they can also transport 
ketone bodies out of the cell. In our studies we find that in gastric myofibroblasts
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MCT4 is progressively up-regulated (CAMs >ATMs>ANMs) based on proximity to 
the site of the tumour (increased 5.5 fold in CAMs and 3.5 fold in ATMs).
Metabolic signature of cancer-associated 
and pre-neoplastic fibroblasts
Predicted metabolic effects 
on cancer cell
Cancer-associated fibroblast
t SCL27A1 Cancer Cell
^ Fatty acids n.
| Fatty acid metabolism 
| Cholesterol metabolism 
| Ketone biosynthesis
Acetyl Co-A
Acetoa relate
f MCT4
Pre-neoplastic fibroblast
| Fatty acid metabolism 
| Cholesterol metabolism,
Figure 6.1 Model of metabolic signature observed in gastric CAMs and ATMs. IN this 
alternative 'reverse Warburg effect' gastric cancer myofibroblasts up regulate fatty acid 
metabolism resulting in increased production of ketone bodies, which are then transported 
to 'fuel' the cancer cell. ATMs (pre-neoplastic fibroblasts) do not exhibit this phenotype. 
This may be due to reduced exposure to cancer cell induced 'metabolic reprogramming'. 
Cholesterol and fatty acid metabolism are also up-regulated in ATMs, however in this case 
cholesterol biosynthesis appears to be routed into increased fatty acid storage as opposed 
to energy metabolism as observed in CAMs.
Our next aim is to understand whether hypoxia or oxidative stress contributes to 
'metabolic reprogramming' of CAMs or ATMs. Several studies have shown that 
hypoxia is caused by cancer cells activating the transcription factor HIF within 
cancer-associated fibroblasts. HIF binding to hypoxia response element (HRE) sites 
within the MCT4 promoter region directly causes an increase in MCT4 expression.
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The abolishment of HIF or use of an oxidative stress inhibitor prevents hypoxia- 
induced production of MCT4 (Robey et al., 2005; UNah et al., 2006; Whitaker- 
Menezes et al., 2011). Also, deletion of the oxidative defence gene, Jun D, in cancer 
stroma of mice resulted in an increased activation of cancer associated fibroblasts 
and increased metastasis and angiogenesis (Toullec et al., 2010). MCT4 is directly 
related to 'aerobic glycolysis' and links in with other studies showing that cancer 
cells induce oxidative stress in fibroblasts by inducing aerobic glycolysis (Martinez- 
Outschoorn et al., 2010). In terms of our studies on gastric myofibroblasts we now 
need to investigate whether oxidative stress can trigger the increase in 'fatty acid 
metabolism' observed in our study.
Overall, our data provides increased insight into the specificity and range of 
molecular changes that are altered in gastric CAMs and starts to reveal mechanisms 
by which these phenotypes may occur. It is also important to note that most of the 
work performed on the breast tumour microenvironment (which led to the 
development of the reverse Warburg effect, cancer induced pseudo-hypoxia and 
cancer induced mitophagy) were performed on fibroblast cell lines, not activated 
tumour-conditioned myofibroblasts. As such, there may be significant differences in 
the way that these cells respond to the effects of tumour cell conditioning in 
comparison to the tumour-conditioned CAMs and ATMs used in our studies.
Our preliminary studies focused on identifying the differences between 
myofibroblasts derived from different regions of the tumour, in all stages of cancer, 
however in our later studies (chapter 4 and 5) an attempt was made to reveal
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differences occurring between myofibroblasts isolated from 'good' and 'bad' 
patient prognosis groups.
Biological pathways that appear to be important in 'bad' patient prognosis CAMs 
include cell-cycle pathways, suggesting an overall decrease in CAM proliferation. 
Interestingly, three separate over-represented pathways are involved in DNA 
damage detection and down-regulation of caretaker genes, such as Brcal. No such 
signature arises within the 'good' tumour classification dataset. Also, mitochondrial 
ketone body biosynthesis is over-represented in CAMs derived from bad prognosis 
patients. In 'good' prognosis CAMs, we observed increased expression of a range of 
anti-oxidant enzymes, which could represent a protective mechanism, to retard 
tumour development work is now on-going to assess the relative levels of these 
enzymes in all CAM and ATM cell lines.
In our studies we observed a strikingly clear trend in that the variance of gene 
expression profiles for myofibroblast cells derived from 'good' or 'bad' patient 
prognosis samples displayed very different patterns, in that variance of gene 
expression was found to be much larger in myofibroblasts derived from patients 
with 'bad' prognosis scores (based on the stage of tumour development). To our 
knowledge this is the first time that such simple criteria has been shown to resolve 
patients into subgroups that directly match tumour stage scoring. Following this 
observation, we wished to identify genes that had statistically different expression 
profiles between 'good' and 'bad' patients; as this analysis could in theory provide 
clues towards the reason of such differences. Whilst, gene signatures characteristic 
of each patient prognosis group were identified in our study this analysis is clearly
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underpowered, due to the low number of sample available from each prognostic 
group. However, these are the first indications that this may be possible for gastric 
cancer samples, and this information can be used to systematically test these 
trends in future larger studies, involving greater numbers of patient samples.
Having performed a retrospective analysis of different normalisation methods it is 
feasible that repeating this study on RMA normalised data could provide larger and 
more informative prognosis group specific signatures. As yet this information does 
not exist for CAMs derived from other tumour types. Finally, it is interesting to note 
that prognosis groups could not be identified by correlation analysis, using 
ATM/ANM profiles. This suggests that it is the type, or extent of reprogramming by 
cancer cells that confers prognosis related effects in myofibroblasts within the 
immediate vicinity of the tumour.
It is highly likely that cancer induced reprogramming of CAMs and ATMs is in part 
mediated by imposed epigenetic remodelling. Indeed, this is most probably why 
CAMs and ATMs retain programmed characteristics even when isolated from the 
tissue niche. With this in mind it is interesting to note that a larger number of 
genes involved in epigenetic regulation are differentially regulated in the 'bad' 
prognosis CAM sub-group in comparison to the 'good' prognosis CAM sub-group. 
Previous work in the field has shown that CAMs are more hypo-methylated that 
ANMs, however, no information currently exists to relate these changes to 
prognosis or the stage of tumour development. On-going work in the Sanderson lab 
has now shown that CAMs, ATMs and ANMs respond differently to drugs that 
modify epigenetic regulation. Also, it appears that exposure to different forms of
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oxidative stress induce different changes in epigenetic status, which is linked to the 
ability of CAMs or ATMs to induce cancer cell migration or proliferation. Again 
these observations demonstrate that predictions made from our microarray 
analysis can provide meaningful leads to drive future experimental research.
In conclusion, there are clear limitations to the observations and predictions 
reported in this study, which are largely due to the restricted number of samples 
available for analysis. However, several common trends identified in myofibroblasts 
studied in other tissues were also detected in our study, suggesting that our data is 
meaningful and informative. In addition, we were able to make new predictions as 
to the changes, which may contribute to the differential properties of gastric CAMs 
or ATMs. Finally, the true value of the data and predictions generated in this study 
will be to provide information to guide future experimental studies into the 
molecular mechanisms that drive the development of gastric tumours, and 
secondly, to suggest candidates, which could in future be explored as potential 
biomarkers. Given that no such markers or effective treatments exist for gastric 
cancer, we hope that this data will be a useful contribution to the field.
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